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ABSTRACT 
Jessica Ellis Wilcox: Acyl-CoA Synthetase Isoform 1 Deficiency Impairs Beta-Oxidation In 
Mouse Heart And Adipose Tissue 
(Under direction of Dr. Rosalind A. Coleman) 
 
The balance between fatty acid (FA) catabolism and anabolism plays a central role in 
obesity and obesity-related complications; and understanding derangements in metabolism 
that underlie disease will aid in setting strategies for treating disease. The activation of long 
chain FA for cellular metabolism requires the five mammalian long chain acyl-CoA 
synthetases (ACSL) that catalyze the conversion of long chain FA into their acyl-CoA 
derivatives. The reason mammals need five unique ACSL isoenzymes remains unknown.  
The purpose of this study was to determine the role of ACSL one (ACSL1) in FA metabolism 
in adipose tissue and heart.  To study ACSL1 in adipose, we generated an adipose-specific 
ACSL1 knockout mouse, the Acsl1A-/- mouse. ACSL1 in adipose was believed to be 
essential for the synthesis of triacylglycerol. However, in Acsl1A-/- white and brown 
adipocytes, the rate of TAG synthesis was similar to controls, whereas FA oxidation in 
isolated adipocytes and mitochondria was reduced 50-90%. Acsl1A-/- mice had increased fat 
mass and were severely cold intolerant. Their reduced adipose FA oxidation and marked 
cold intolerance indicate that normal activation of FA for oxidation in adipose tissue in vivo 
requires ACSL1.  To study ACSL1 in heart, we generated a multi-tissue temporally induced 
ACSL1 knockout mouse, Acsl1T-/-. Although cardiac ACSL1 is the most abundant of the 
ACSL isoenzymes, its role in cardiac FA metabolism had remained unclear.  In Acsl1T-/- 
mice, acyl-CoA synthetase activity was reduced ~90%, acyl-CoA content was reduced 65%, 
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and long-chain acyl-carnitine species and palmitate oxidation were 80-90% lower than in 
control hearts. Acsl1T-/- hearts developed hypertrophy, increased mitochondrial content, and 
had 5-fold greater phosphorylation of S6 kinase, a target of mTOR kinase. These data 
suggest that ACSL1 catalyzes the initial step in the pathway of heart FA oxidation and that 
without ACSL1, diminished FA oxidative capacity leads to mTOR activation and results in 
cardiac hypertrophy and increased mitochondria.  Together, these data suggest that ACSL1 
has a specific function in directing the metabolic partitioning of FA towards β-oxidation in 
both adipose tissue and heart. This dissertation has elucidated the novel role for ACSL1 as 
the first and required step for the oxidation of FA.  
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CHAPTER I  
INTRODUCTION 
 
 The current epidemic of obesity, diabetes, cardiovascular disease, and dyslipidemia 
is characterized by an imbalance of lipid metabolism.  The ability of white adipose to both 
store fat as triacylglycerol and to oxidize fat for energy are critical factors of obesity and 
obesity-related complications such as diabetes and heart disease. In heart disease, such as 
diabetic cardiomyopathy, triacylglycerol (TAG) accumulates because fatty acid (FA) uptake 
is increased and FA oxidation is decreased.  In cardiac hypertrophy, FA oxidation is reduced 
and the risk of cardiomyopathy and cardiovascular complications is increased.  While the 
mechanisms that regulate the cellular uptake, activation, and metabolism of fatty acids are 
not fully understood, it is known that for nearly every biochemical pathway the conversion of 
FA to acyl-CoA is critical for metabolism.  Acyl-CoAs have multiple fates including their 
incorporation into complex lipids, use in lipid remodeling, effects on signal mediation, 
regulation of transcription factors, and oxidation for energy. After cellular uptake of FA, long-
chain acyl-CoA synthetase (ACSL) isoenzymes convert FA to acyl-CoA to both trap the fatty 
acid within the cell and simultaneously activate it.  The activation of long chain FA by 
ACSL is the first and essential step for the cellular metabolism of fatty acids.    
 The five mammalian ACSL isoenzymes have unique coding region, tissue-
dependent expression pattern, intracellular location, and are under different regulatory 
mechanisms. The reason mammals need five unique isoenzymes of ACSL remains 
unknown. Our group focuses on the role ACSL isoenzymes play in lipid metabolism.  This 
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dissertation will focus on ACSL-isoenzyme-1 (ACSL1) which is the most abundantly 
expressed isoenzyme in human and rodent heart and adipose tissue.  Data suggest that the 
ACSL isoenzymes channel FA towards specific metabolic pathways in a tissue-dependent 
manner. The literature suggests that ACSL1 plays a role in channeling fatty acids toward 
TAG in white adipose because PPARγ upregulates Acsl1 in white adipose tissue, the 
overexpression of ACSL1 in adipocyte-precursor NIH-3T3 cells results in TAG accumulation, 
and Acsl1 mRNA expression increases 160-fold in differentiating 3T3L1 adipocytes 
concomitant with increased TAG formation [1-4]. However, in cardiac muscle ACSL1 is 
thought to channel FA toward oxidation because Acsl1 mRNA is upregulated by PPARα in 
cardiomyocytes and in the developing mouse heart Acsl1 mRNA increases X-fold 
concomitant with increases in FA oxidation rates [5, 6].   To determine if ACSL1 channels 
FA towards opposing metabolic pathways in heart and adipose tissue we have generated 
mice that lack ACSL1 specifically in adipose tissue or in heart, as well as a temporally-
induced multi-tissue knockout. In the ACSL1 adipose-specific knockout mouse, Acsl1A-/-, 
total ACSL activity for palmitate is reduced ~80% in white and brown adipose tissue.  In the 
Acsl1A-/-adipose tissue, mitochondrial FA oxidation is severely impaired, resulting in mice 
with increased adipose mass and marked cold intolerance.  In both the temporally-induced 
heart-specific knockout, Acsl1H-/- , and the multi-tissue knockout, Acsl1T-/-, total ACS activity 
in the heart is reduced by 90-97%, as is the rate of mitochondrial FA oxidation. The lack of 
ACSL1 in the heart results in pathological hypertrophy and increased mitochondrial 
biogenesis that our data suggest is mediated through the activation of mTOR.  Both the 
Acsl1T-/- and the Acsl1H-/- mice have enlarged hearts, confirming that the lack of ACSL1 
specifically in cardiomyocytes impairs FA oxidation and elicits hypertrophy.   
 With the current obesity epidemic it is critical to understand the mechanisms that 
underlie the cellular uptake and processing of lipids. ACSL1 is a key enzyme of fatty acid 
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metabolism in both adipose tissue and heart, and characterizing its influence on cellular lipid 
metabolism is critical for the evaluation of the metabolic processes underlying obesity and 
heart disease. This work provides convincing data that ACSL1 activates FA for oxidation, 
not TAG synthesis, in adipose and cardiac tissue.  
Specific Aims: 
1. Determine the role of ACSL1 in activating fatty acids for white adipose tissue 
using the adipose-specific ACSL1 knockout mice, Acsl1A-/-, and primary 
adipocyte cultures from Acsl1A-/- mice. 
2. Determine the role of ACSL1 in activating fatty acids in brown adipose tissue 
using the adipose-specific ACSL1 knockout mice, Acsl1A-/-, and primary 
adipocyte cultures from Acsl1A-/- mice. 
3. Determine the role of ACSL1 in activating fatty acids in the heart using the 
multi-tissue ACSL1 knockout mice, Acsl1T-/-, and the heart-specific ACSL1 
knockout mice Acsl1H-/-. 
 
 
 
 
 
 
 
CHAPTER II 
BACKGROUND 
 
 As the rates of obesity and heart disease rise around the globe, our knowledge of the 
physiological mechanisms underlying these disorders is expanding.  While the data 
continues to mount, connecting obesity to disorders such as diabetes and heart disease, our 
13understanding of lipid metabolism and its regulation in adipose tissue and heart remains 
unclear.  ACSL1 has been manipulated and studied in vitro but little data exists on ACSL1 in 
adipose in vivo.  I have used the Acsl1A-/- mice to study ACSL1 in adipose in vivo.  In 
contrast, heart research has focused heavily on heart function and the associated disease 
outcomes; however, the cardiomyocyte metabolism that underlies heart function and heart 
disease remains relatively unexplored.  I have used our Acsl1T-/- and Acsl1H-/- mice to study 
heart lipid metabolism in the absence of ACSL1 in a physiological system.   
 
Figure 2.1. Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had 
Diagnosed Diabetes in 1994, 2000, and 2008 [7]. The epidemic of obesity and related 
complications is illustrated by the center for disease controls (CDC) records of the rising 
incidence of obesity and diabetes in the United States over the past two decades. 
Obesity (BMI ≥30 kg/m2)
Diabetes
1994
1994
2000
2000
No Data         <14.0%         14.0-17.9%         18.0-21.9%          22.0-25.9%           >26.0%
No Data          <4.5%           4.5-5.9%             6.0-7.4%             7.5-8.9%               >9.0%
CDC’s Division of Diabetes Translation. National Diabetes Surveillance System available at 
http://www.cdc.gov/diabetes/statistics
2008
2008
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B.1. Acyl-CoA synthetase activates fatty acids and determines their metabolic fate.  
 Cellular fatty acids have many metabolic fates including storage as TAG, 
incorporation into phospholipids, and oxidization for ATP production. Nearly all FA metabolic 
pathways require the activation of FA to acyl-CoA.  This reaction is catalyzed by acyl-CoA 
synthetase (ACS) in an ATP-dependent manner.  
Fatty acid + ATP ? acyl-AMP + PPi 
Acyl-AMP + CoA ? acyl-CoA + AMP 
The ACS catalytic domain shares homology with the ANL superfamily, a family consisting of 
ACS, nonribosomal peptide synthetase, and luciferase (3). The homology between ACS and 
luciferase is so similar that mutation of a single residue (L345S) allows the Drosophilia 
melangaster ACS to gain luciferase activity (4). 
 
 
Figure 2.2: The schematic mechanism for the unidirectional ordered catalysis by ttLC-
FACS, figure from Hisanaga, Y. et al. J. Biol. Chem. 2004; 279:31717-31726. 
 
The structural conformation of ACS has been predicted from crystal structure analysis of a 
thermophilic bacterial long-chain acyl-CoA synthetase, schematic above [8].  After ATP 
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binds to ACS in the adenylate-forming conformation the C-terminus is rotated 140°, opening 
the gate to the fatty acid binding tunnel, and this rotation results in the thioester 
conformation. For long-chain ACS the C-terminal domain is predicted to remain closed 
throughout the entire ACS reaction so that the acyl-AMP intermediate is never released, 
which explains why the acyl-AMP intermediate has never been successfully isolated. Upon 
opening of the gate, a fatty acid enters the fatty acid-binding tunnel unidirectionally and 
travels toward the ATP binding site. A pyrophosphate is released when the fatty acyl-AMP 
complex is formed.   The CoA then attacks the fatty acyl-AMP to form the acyl-CoA. 
Formation of the acyl-CoA opens the C-terminus domain and the acyl-CoA and AMP 
products are released from the enzyme. In 2009, Kochan et al. reported the crystal structure 
of human ACSM2A [9].  Analysis of this mammalian ACS crystal structure revealed the 
following: 1) in the adenylate-forming conformation a conserved lysine, Mg2+, and the P-loop 
hold the pyrophosphate in the active site, 2) in the thioester conformation an Arg472-Glu365 
salt bridge sterically blocks ATP binding, and 3) switching of the adenylate-forming 
conformation to the thioesterase conformation requires the presence of pyrophosphate. The 
isolation of additional mammalian ACSL crystal structures would increase our understanding 
of the protein structure, mechanism, and regulation.  
 Humans are predicted to have 26 genes that encode acyl-CoA synthetase 
enzymes. ACSs are grouped into 5 families according to their substrate preference for fatty 
acids of varying chain lengths [10].  The 26 predicted human ACSs include 5 families 
consisting of 3 short-chain, 6 medium-chain, 5 long-chain, 6 very-long chain, and 2 
bubblegum isoenzymes, plus 4 additional likely acyl-CoA synthetase genes.  The prediction 
for the 26 ACS genes is based on conserved amino acid sequences of 5 distinct motifs: 
Motif I-V.  The predicted biochemical role for the five motifs are as follows: Motif I is the 
AMP-binding domain that helps to maintain AMP substrate in the proper orientation, Motif II 
is the linker motif that is thought to induce a conformational change to aid fatty acid and/or 
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CoA binding, Motif III is associated with substrate stabilization for the AMP-binding domain, 
Motif IV contains the gate-domain that allows fatty acid binding only after ATP binding-
induced conformational change, and lastly, Motif V contains a conserved lysine that is 
thought to participate in a conformational change to create the CoA binding pocket [10].  
The ACS amino acid sequences range from 438 to 739 amino acids including the five 
conserved motifs.  
 ACS post-translational regulation. Broad mass spectrometry surveys reveal a 
number of post-translational modifications to ACS enzymes, although the functional 
significance is generally unknown.  An exception is the regulation on Lys-609 located on the 
C-terminus of the Salmonella enterica ACS, for which lysine acetylation inhibits activity by 
preventing formation of the thioester [11].  Similar regulation occurs by the SIRT acetylases 
on Lys-661 and Lys-635 of acetyl-CoA synthetase-1 and acetyl-CoA synthetase-2, 
respectively, and human acetyl-CoA synthetase 2 is regulated on Lys-642 [12].  In response 
to a calorie restricted diet, acetylation of Lys-534 of ACSM1 and Lys-510 of acyl-CoA 
synthetase family member-2 (Q8VCW8) increased 2.75-fold and 2.3-fold, respectively [13].  
Dr. L.O. Li and Dr. J. Frahm of the Coleman lab have identified multiple ACSL1 acetylation 
sites (unpublished data). Additional research is required to connect the functional 
contribution of ACSL1 acetylation to its activity.  
 Mass spectrometry techniques used to identify post-translational modification in rat 
liver mitochondria showed acetylation at Lys-633 and phosphorylation at Tyr-85 of ACSL1 
protein [14]. The phosphorylation site of ACSL1 is a predicted insulin receptor consensus 
site; however, insulin effects on this phosphorylation site and the ensuing effect on ACSL1 
protein activity are unknown. Work by L.O. Li and J. Frahm of the Coleman lab have 
identified numerous phosphorylation sites by mass spectrometry for the ACSL1 protein, 
unpublished data.  L.O. Li is currently mutating the predicted phosphorylated amino acids to 
evaluate the effects of phosphorylation on enzyme activity. These acetylated and 
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phosphorylated regulatory sites of ACSL1 support the idea of complex and acute regulation 
on ACSL activity.  
 Role of ACS in regulating transcription.  ACSL can theoretically regulate 
transcription by modulating the intracellular content of FA and acyl-CoA, which are ligands 
for transcription factors.  FA, for example, are ligands for PPARα and β/δ and may suppress 
SREBP1c target genes, and acyl-CoA is a possible ligand for HNF4α [15].  The role of ACS 
in regulating transcription was addressed by a study that used siRNA to knock down the 
long-chain ACS isoenzymes that are expressed in liver, ACSL1, 3, 4, and 5 and FATP2, 4, 
and 5 [16].  In primary rat hepatocytes the siRNA that targeted ACSL3, the only siRNA that 
affected transcription, elevated intracellular FA 82% and diminished PPARγ expression, as 
well as reporter gene activity for PPARγ, carbohydrate-responsive element-binding protein, 
SREBP1c, and the liver X receptor-α, together with the expression of the target genes for 
these transcription factors.  Decreased use of [1-14C]acetate for de novo lipogenesis and 
complex lipid synthesis confirmed the effect of diminishing the expression of genes involved 
in lipid synthesis.  Although one might conclude that the knockdown of ACSL3 decreased 
transcriptional activities via an increase in a specific pool of FA ligand, Bu et al. argue that 
ACSL3 must control transcription in a ligand-independent manner because synthetic ligands 
did not normalize transcriptional activities of LXR and PPAR-γ [16].  
ACS for long-chain fatty acids (ACSL) is a family consisting of 5 known 
independent mammalian isoenzymes: ACSL1, ACSL3, ACSL4, ACSL5, and ACSL6 
[17].  Based on sequence homology, the ACSL isoenzymes consist of two subfamilies; 
ACSL1, -5, and -6 which share ~60% homology and ACSL3 and -4 which share ~70% 
homology and share ~30% with 1,5, and 6 [18].  The active sites of the ACSL proteins face 
the cytosol to produce an amphipathic acyl-CoA which could feasibly be partitioned either 
into the membrane compartment or the cytosolic compartment to provide a FA in a 
subcellular location optimal for a particular metabolic fate [19].  ACSL isoenzymes are 
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unique proteins that differ in their substrate preferences, enzyme kinetics, and tissue-specific 
expression [20-22], suggesting that each has a distinct function. ACSL proteins have been 
shown to interact with other ACS enzymes and binding proteins and it is predicted that these 
interactions may facilitate channeling of the acyl-CoA product [23]. 
  
 
Figure 2.3. Pathways of acyl-CoA metabolism, adapted [24] 
AA, arachidonic acid; ACSL,long-chain acyl-CoA synthetase; CL, cardiolipin; PC, 
phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, 
phosphatidylinositol.  
 
  FA channeling. ACSL isoenzymes activate fatty acids with chain lengths of 12 to 24  
carbons and ACSVL isoenzymes activate fatty acids with chain lengths of 16 to 24 carbons, 
yet the physiological roles of these enzymes remain unknown [25, 26].  We hypothesize that 
different ACS isoenzymes channel FA into specific downstream pathways and that the 
channeling could vary in a tissue-specific manner [27]. For example, ACSL1 liver-specific 
knockout primary hepatocytes, compared to controls, have 20% lower rates of FA 
incorporation into TAG and 4.5% reduced ASM production [28].  Whereas, ACSL1 adipose-
specific knockout primary brown adipocytes, compared to controls, have normal rates of FA 
incorporation into TAG and 90% reduced ASM production (this dissertation). The ACSL1 
adipose-specific knockout primary white adipocytes, compared to controls, have normal 
rates of FA incorporation into TAG and 50% reduced ASM production (this dissertation).  
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These data suggest that ACSL directs the metabolism of fatty acids similarly but to different 
degrees in adipose and liver. In Huh7 human hepatoma cells ACSL3 is found in lipid 
droplets and is important for vesicle secretion of ApoB-containing particles [29, 30].  A 
siRNA against ACSL3 expressed in Huh7 cells decreased oleate incorporation into PC, 
increased free cellular oleate, and inhibited vesicle secretion of ApoB-containing particles. 
However, siRNA against ACSL1 and ACSL4 in Huh7 did not change FA uptake or 
incorporation into complex lipids.  The knockdown of ACSL3 in primary rat hepatocytes, 
compared to vector control cells, suppresses de novo fatty acid synthesis by 40% [16].  
E.coli with absent FadD, a bacterial ACSL, has retarded cell growth, when grown on media 
containing FA as the sole energy substrate, that is rescued by ACSL5, but not by any other 
ACSL isoenzyme [31]. Together, these data suggest that ACSL isoenzymes impact cellular 
metabolism uniquely in different cell types, cell lines, and tissues, and that the isoenzymes 
are not able to compensate for one another.   
The formation of specific complex lipids, TAG and PL, from [3H]glycerol-3-phosphate 
is blocked by triacsin C, a fungal-derived competitive inhibitor of ACSL1,-4, and -3 activity, in 
fibroblasts, hepatocytes, and other cells [20, 32].  The incorporation of FA into TAG in 
hepatocytes is blocked by troglitazone, an inhibitor of ACSL4 [20].  The incorporation of 
[14C]oleate into DAG and PL increases while its incorporation into cholesterol esters 
decreases when ACSL1 is overexpressed in primary hepatocytes [33]. In contrast, the 
overexpression of ACSL5 in rat hepatoma cells increases [14C]oleate uptake and 
incorporation into TAG [34]. ACSL5 does not facilitate FA uptake when overexpressed in 
yeast, whereas the overexpression of ACSL1, 4, and 6 does [35].  Differential effects of 
individual ACSL isoenzymes support the notion that ACSL isoenzymes channel FA to 
distinct metabolic fates.   
Several overexpression studies are inconsistent with knockdown studies and provide 
strikingly contradictory interpretations of the role of ACSL isoenzymes.  For example, when 
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ACSL1 is overexpressed in rat primary hepatocytes, FA are incorporated into diacylglycerol 
and phospholipids, but not into cholesterol ester or secreted triacylglycerol [36], whereas 
ACSL1 knockout primary mouse hepatocytes have 20% reduced FA incorporation into TAG, 
but not DAG, CE, or PL. Overexpressed ACSL5 increased FA incorporation into 
diacylglycerol and triacylglycerol, but does not affect FA used for β-oxidation [34], whereas, 
overexpressing either human ACSL3 or rat ACSL5 in HepG2 cells increases palmitate 
oxidation [37].  Further, TAG content increased in NIH-3T3 fibroblasts when ACSL1/FATP1 
was overexpressed [38] and TAG content increased in insulin-stimulated 3T3-L1 adipocytes 
when ACSL1 was knocked down [39].   
We see two potential problems.  The first is that overexpression of an enzyme may 
overwhelm downstream pathways that cannot readily accommodate excess substrate; the 
second problem is that studies in 3T3-L1 adipocytes are not always translatable to primary 
white or brown adipocytes.  Proteomic analysis of mitochondria isolated from white adipose 
tissue, brown adipose tissues, and 3T3-L1 adipocytes reveals substantial differences [40].  
Compared to mitochondria from adipose tissue, many proteins are down regulated in 3T3-
L1 mitochondria.  Further, ACSM (medium-chain ACS) isoenzymes are more abundant than 
ACSL isoenzymes in white adipose tissue mitochondria, suggesting greater medium-chain 
FA oxidative metabolism.  ACSL1 and ACSL6 are particularly enriched in white adipose 
mitochondria, whereas ACSL5 is more abundant in mitochondria from brown adipose.  
Despite the high abundance of ACSL5 in brown adipose mitochondria, ACSL1 is required 
for adaptive thermogenesis and normal FA oxidation in brown adipose (shown in this 
dissertation).  Thus, the function of ACSL5 in BAT remains unknown.   
 FA channeling could occur via protein-protein interactions.  
Immunoprecipitation of endogenous FATP1 from 3T3-L1 adipocytes followed by mass 
spectrometry identified mitochondrial 2-oxoglutarate dehydrogenase (OGDH), a key enzyme 
in the tricarboxylic acid cycle [41].   FATP1 enhances OGDH activity in proteoliposomes and 
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in 3T3-L1 cells that overexpress FATP1.  FATP1 knockdown 3T3-L1 adipocytes showed 
decreased OGDH and TCA cycle activity.  Over-expressed FATP1 and CPT1 also co-
immunoprecipitate from L6E9 myotubes and rat skeletal muscle in vivo [42].  In 3T3-L1 
adipocytes and L6E9 myotubes, FATP1 overexpression enhances FA oxidation, 
independent of ACS activity, suggesting that protein-protein interactions of FATP1 facilitate 
activities of FA oxidation proteins.   Overexpressed ACSL1 and FATP1 co-
immunoprecipitate in 3T3-L1 adipocytes [23], but it is not known whether endogenous 
ACSL1 and FATP1 proteins interact.   
The data in this dissertation show that ACSL1 preferentially channels FA toward 
oxidation in several tissues. However, it remains unclear exactly how the ACSL1 enzyme 
could be shuttling its product towards a single metabolic pathway.  The acyl-CoA produced 
by the ACS reaction has the chemical properties that would allow it to move freely within 
membranes and/or bind to proteins such as acyl-CoA binding proteins, thus all acyl-CoAs 
should theoretically be free to enter any downstream metabolic pathway on the cytosolic 
face of all subcellular membranes. These pathways include TAG synthesis, CE synthesis, 
PL synthesis, PL re-acylation, elongation, desaturation, protein acylation, and sphingolipid 
synthesis. We predict that the different ACSL isoenzymes have protein-protein interactions 
that put the acyl-CoA synthetase in direct contact with proteins specific to metabolic 
pathways. For example, we hypothesize that in muscle tissues, ACSL1 likely interacts with 
proteins such as M-CPT1 that would use the acyl-CoA as substrate to form acyl-carnitines 
for the oxidative pathway. The proteins that ACSL1 and other ACSLs interact with likely vary 
by tissue/cell type. Experiments are required to show the protein-protein interactions of 
ACSL1 in different tissues/cell types and under different hormonal/physiological conditions.  
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Figure 2.4. Protein-protein interactions may mediate ACSL channeling. We 
hypothesize that ACSL isoenzymes interact with proteins that facilitate the channeling of the 
acyl-CoA product to downstream pathways.  
 
 The Coleman Lab, specifically Dr. Jennifer Frahm and Dr. Lei Li, have recently 
generated data using mass spectrometry technologies that show ACSL1interacting with 
several mitochondria-specific oxidative proteins.  More studies are required to explore how 
the protein-protein interactions of ACSL1 facilitate channeling, enzyme activity, and regulate 
metabolic flux. Such studies would include identifying the protein-interacting domains of 
ACSL1, mutating or truncating these domains, and assessing enzyme activity and rates of 
FA oxidation in the mutants.  
The subcellular locations of ACS enzymes (reviewed in [26]), may influence the 
downstream metabolism of the acyl-CoA product.   However, subcellular localization studies 
have yielded conflicting interpretations.  Most have examined subcellular fractions that are 
limited in purity.  Data from overexpression studies is also problematic because the location 
of overexpressed proteins may not mimic the endogenous condition.  In one such example, 
the subcellular locations of overexpressed compared to endogenous FATP4/ACSVL5 
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differed [43].  Confocal microscopy with tested isoenzyme-specific antibodies will be 
required to determine precise locations of the acyl-CoA synthetases. 
ACSL and cell growth. ACSL is required for complex lipid synthesis in rapidly 
growing cancerous cells, and the fungal metabolite triacsin C was initially reported to inhibit 
ACSL, diminish the synthesis of phospholipids, and decrease cell proliferation [44].  Triacsin 
C caused apoptosis of glioma cells, and, although it inhibits ACSL1, 3, and 4, but not 
ACSL5, overexpression of ACSL5 rescued the glioma cells [45, 46].  In this case, ACSL5 
appeared to compensate for the inhibited isoenzymes.  In a related publication, ACSVL3 
(FATP3) was elevated in human gliomas [47].  When ACSVL3 RNA was knocked down, 
glioma cell growth was inhibited and the cells became less tumorigenic.  Because these 
features were reversed when active myr-Akt was expressed, ACSVL3 was thought to 
maintain oncogenesis by regulating Akt function.  
 Effect of fatty acid activation on AMP-activated kinase. Because the synthesis of 
each acyl-CoA uses the equivalent of 2 ATP molecules and produces one AMP, it has been 
suggested that FA activation might increase cellular AMP/ATP ratios and activate AMP-
activated kinase (AMPK).  AMPK would then increase FA oxidation while blocking TAG 
synthesis.  It would be surprising, however, if the conversion of FA to acyl-CoA triggered the 
activity of an energy deficit indicator in settings of energy surplus when TAG synthesis is 
prominent.   
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FIGURE 2.5. Potential interactions between ACSL and AMPK, [48]. When exogenous 
fatty acids enter the cell, are synthesized de novo, or are hydrolyzed from intracellular 
triacylglycerol stores, they must first be activated by a long chain acyl-CoA synthetase 
(ACSL) to form fatty acyl-CoAs. They can then enter downstream metabolic pathways. 
Because ATP is a substrate for ACSL and AMP is a product, the increased AMP/ATP ratio, 
a signal of low cellular energy stores, could theoretically activate AMP activated kinase 
(AMPK). Activated AMPK inhibits triacylglycerol synthesis and acetyl-CoA carboxylase 
(ACC). The resulting decrease in malonyl-CoA levels diminishes fatty acid synthesis and 
also relieves the inhibition of carnitine palmitoyltransferase-1 (CPT1) by malonyl-CoA, 
allowing the fatty acyl-CoA to be converted to acyl-carnitine and enter the mitochondria for 
b-oxidation. Thus, activated AMPK would generate an increase in ATP production. A 
prolonged lipogenic stimulus [which activates hormone-sensitive lipase (HSL)], may also 
inactivate AMPK to modulate these effects. It seems unlikely, however, that ACSL would 
activate AMPK under physiological conditions that stimulate triacylglycerol synthesis.  
 
Studies in animals have not been performed to compare ACSL-mediated activation 
of AMPK under different physiological conditions, but metabolic adaptations to fasting and 
chronic caloric restriction in heart, muscle, and liver do not result in changes in AMPK 
activity [49], and when mice are placed in a cold environment, AMPK is not activated for 
several days despite a huge increase in ACSL-mediated FA activation [50]. Some 
experiments, however, support ACSL-mediated activation of AMPK.  In 3T3-L1 adipocytes, 
stimulation of lipolysis results in activated AMPK [51].  The authors suggested that activation 
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of AMPK during lipolysis would “restrain the energy depletion and oxidative stress”.  It might 
also permit use of released FA for β-oxidation within the adipocyte and conserve glucose 
during a “fast.”  In a situation more akin to “feeding,” AMPK activation increased in 3T3-L1 
adipocytes during insulin-stimulated palmitate uptake, although the AMP/ATP ratio changed 
minimally [52].   
Studies in heart [53] and skeletal muscle [54-56] suggest that AMPK may be 
sensitive to the "lipid status" of the cell and that activation may be influenced by intracellular 
FA availability, independent of cellular AMP levels, with FAs, themselves, activating  AMPK 
[57].  FA allosteric activation of AMPK increases the ability of LKB1 to phosphorylate the 
AMPK holoenzyme in vitro [58, 59]. It was postulated by Zhang et al, that elevated acyl-CoA 
levels in the liver and muscle of very long-chain acyl-CoA dehydrogenase, VLCAD, 
knockout mice lead to the activation of AMPK and increased FA oxidation [60]. FA added to 
L6 myotubes increases AMPK activity 40-50%, together with phosphorylation of AMPK 
Thr172 and acetyl-CoA carboxylase-β Ser218, and the rate of palmitate oxidation almost 
doubles [59].  Surprisingly, no increase was detected in cell AMP content, and LKB1 was 
not activated.  Because a dominant-negative AMPK adenovirus reduced basal FA oxidation 
and inhibited the stimulatory effects of FA pretreatment on FA oxidation, the authors 
suggested that FA might improve AMPK as a substrate for LKB1.  However, in assays with 
purified components, 10-50 µM long-chain acyl-CoA directly inhibited AMPKK (LKB1), and it 
was suggested that the rise in long-chain acyl-CoA content that occurs when FA synthesis is 
enhanced would negate the effect of potential increases in AMP and prevent simultaneous 
FA synthesis and FA oxidation [61].  Although the cellular concentration of long-chain acyl-
CoAs has been estimated at between 5-160 µM [62], acyl-CoAs are amphipathic and are 
probably bound either to cell membranes or to acyl-CoA binding protein; neither their free 
concentration nor their availability as substrates or inhibitors can be known with certainty. 
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ACS in Disease Mutations in ACS genes have been identified in large screening 
studies.  An Acsl5 single nucleotide polymorphism (SNP) (rs2419621; C>T) increased Acsl5 
mRNA abundance in skeletal muscle and was associated with improved weight loss.  This 
SNP increases the transcriptional rate of Acsl5 by enhancing activation of the gene by the 
myogenic-regulatory factor, MyoD [63].  This mutation also increases the differentiation of 
skeletal myoblast cells.  The data suggest that persons with this SNP in ACSL5 may have 
an advantageous ability to increase muscle mass and caloric expenditure with diet and 
exercise.   
High level of Acsl3 methylation in umbilical cord white blood cells were strongly 
correlated with levels of maternal polycyclic aromatic hydrocarbons and with the mRNA 
abundance of Acsl3 [64].  In a separate cohort, Acsl3 methylation was associated with 
polycystic aromatic hydrocarbon exposure and childhood asthma [64].  These data suggest 
that maternal environmental exposures may affect childhood asthma through the 
methylation of Acsl3.    
The knockdown of Acsl4 in neurites reduces dendritic spine formation, suggesting a 
role for ACSL4 in the maturation and remodeling of neurons, and provides a link to the X-
linked mental retardation associated with human mutations in ACSL4 [65].  In another study, 
a SNP (rs1324805) in the Acsl4 gene was more prevalent in patients with the metabolic 
syndrome [66].  A third study found an Acsl4 SNP (rs7887981) associated with increased 
liver fat or with increased circulating insulin and TAG in overweight subjects from two 
different cohorts [67].  It is not unknown how these SNPs affect the function of ACSL4, nor is 
it clear how the preference of ACSL4 for long-chain polyunsaturated FA may be involved.  
A mutation within the Fatp4 gene is associated with the ichthyosis prematurity 
syndrome (IPS), a disease characterized by severe skin abnormalities at birth [68].  
Fibroblasts from an IPS patient had reduced ACSVL activity and reduced incorporation rates 
of very-long chain FA into complex lipids.  These skin findings are like those of Fatp4 null 
18 
 
mice which die in early life because of hyperproliferative hyperkeratosis [69], and suggest 
that FATP4 specifically plays a role in early epidermal development and that a deficit in this 
enzyme cannot be compensated for by other ACS enzymes.  Data presented in this 
dissertation show that ACSL1 is critical for FA oxidation. The knockout of ACSL1 in mouse 
results in increased adipose mass and hypertrophy cardiomyopathy. Thus, SNPs in ACSL1 
may be correlated with obesity and idiopathic hypertrophies.  
 
B2. Acyl-CoA synthetase isoenzyme 1, ACSL1 
ACSL1 was cloned in 1990 [70] and has since been found to be highly 
expressed in white and brown adipose tissue, heart and liver. It was speculated that 
ACSL1 channels fatty acids towards TAG synthesis in white adipose because the 
overexpression of ACSL1 in an adipocyte cell line increases fatty acid uptake and 
incorporation into complex lipids [71].  We have now examined how adipose is affected in 
vivo by the loss of ACSL1 and find that ACSL1 is critical for activating FA for oxidation, not 
TAG synthesis, in adipose tissue.  
The role ACSL1 plays in the heart’s ability to synthesize TAG and to oxidize FA has 
also been unclear. ACSL1 is upregulated during the development of the adult heart, which 
correlates with a metabolic switch from the use of glucose to use of FA as the hearts 
preferred ATP-generating substrate. Therefore, the heart may require ACSL1 for the 
activation of FA for subsequent oxidation. However, the 11-fold overexpression of ACSL1 in 
heart results in an 11-fold increase in heart TAG suggesting a role for ACSL1 in TAG 
synthesis [72].  The work highlighted in this dissertation through the use of two mouse 
models that lack ACSL1 in heart, shows that ACSL1 provides activated FA for cardiac 
oxidation.   
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ACSL1 cellular location may dictate its role in FA channeling. ACSL isoenzymes 
are intrinsic membrane proteins present in various subcellular compartments in a tissue-
specific manner.  The subcellular location of ACSL1 may dictate the fate of its acyl-CoA 
product according to the metabolic function of the organelle.  For example, if ACSL1 is 
associated with the mitochondria or the endoplasmic reticulum in a given cell, then the acyl-
CoA product may be channeled towards oxidation or TAG synthesis, respectively. In 
epithelial-like ptk2 cells and kidney HeLa and Cos-7 cells, the overexpression of an epitope-
tagged ACSL1 shows co-localization with the mitochondrial marker OCT-GFP [73]. Mutation 
studies show that the N-terminus (66 amino acids) is sufficient to target ACSL1 to 
mitochondria [73]. In adipocytes, ACSL1 protein and mRNA are found in the subcellular 
fractions that contain endoplasmic reticulum and Golgi membranes that are associated with 
complex lipid synthesis [71, 74].  ACSL1 protein is also found in trace amounts in the 
plasma membrane and in nuclear fractions from adipocytes [71, 74]. ACSL1 protein was 
found in GLUT4-containing vesicles isolated from adipocytes, and its presence on the 
vesicles may be regulated by insulin [75]. Lipid droplets isolated by fractionation, and that 
may be contaminated with ER, from adipocytes contain ACSL1 and ACSL3 protein [74, 76].  
All studies that have assessed ACSL1 subcellular location have used either tagged-ACSL1 
overexpression models or fractionation methods. Both of these methods are flawed in that 
overexpression can result in artifactual localization that does not represent the native protein 
location, whereas fractionation methods are highly susceptible to incomplete isolation of 
membrane fractions and appropriate markers for complete fractionation are critical, but not 
always shown.    
Therefore, the subcellular location of ACSL1 in adipocytes remains unresolved. It is 
not known how the subcellular location of ACSL1 in adipose affects the function of the 
enzyme nor is it understood how the protein is directed to and from a particular membrane.  
In the heart, the intracellular location of ACSL1 has not been reported.  In this dissertation, 
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we show endogenous ACSL1 protein in mitochondrial fractions isolated from mouse heart 
and BAT.  
Table 2.1. Subcellular location of ACSL1  
Cell/tissue Method Mito ER/Golgi Nuclear PM GV cytosol LD reference 
Ptk2 OE-CM X       Milger et al, 
2006 
Cos-7 OE-CM X       Milger et al, 
2006 
Rat 
adipocytes 
Frac-
GV 
    X   Sleeman et 
al, 1998 
3T3-L1 Frac X X X X    Gargiulo, et 
al 1999 
HuH7 Frac-
LD 
      X  
3T3-L1 Frac-
LD 
      X Brasaemle, 
et al, 2004 
3T3-L1, 
WAT, BAT 
Frac- 
mito 
X       Forner et 
al, 2009 
BAT, heart Frac-
mito 
X       Ellis et al, 
2010 
Frac, fractionation; OE, overexpression; LD, lipid droplet; GV, Glut4-containing vesicles; CM, 
confocal microscopy; mito, mitochondria.  
 
 Manipulation of ACSL1 to understand function. To determine the function of 
ACSL1, numerous groups have manipulated its expression in various cell types. For 
example, both ACSL1 and 6, when overexpressed in PC12 neuronal cells, increase cellular 
uptake of fatty acids and their incorporation into complex lipids [3]. In contrast, the 
overexpression of ACSL1 in rat primary hepatocytes does not alter the rate of fatty acid 
uptake but increases FA incorporation into DAG and PL [33]. ACSL1 overexpression in 
human hepatoma HepG2 cells increases [14C]-oleate incorporation into complex lipids by 
40% [77]. Despite data obtained from hepatocytes in vitro, the ACSL1-liver specific knock 
out mouse, Acsl1L-/- does not exhibit changes in liver TAG or serum VLDL [78].   
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Table 2.2. ACSL1 manipulation in multiple tissues/cell types and outcome 
 
Cell Type/Organ ACSL1 FA Incorporation into lipids FA  uptake Oxidation 
NIH-3T3 OE  ↑  ↑ ? 
Rat 1° hepatocytes OE ↑ - - 
HepG2 OE ↑ ↑ - 
PC 12 OE ↑ ↑ ? 
Cos-7 OE - ↑ ? 
Heart OE ↑ TAG content ? ? 
Huh7 KD - ? ? 
3T3-L1 KD ↑ TAG content with insulin  - 
OE, overexpressed; KD, knock down; ?, not tested; -, no change observed 
 ACS and FA uptake. FA may enter cells via both concentration based flipping and 
protein-mediated transport [79].   It is likely that cellular retention depends on "vectorial 
acylation," the trapping of exogenous FA as an acyl-CoA within the cell and its subsequent 
use in downstream metabolic pathways [27].  Although FATP1 was discovered in a 
functional FA uptake screen [80], several FATP family members are not present on the 
plasma membrane [27], and so they are also called ACSVL to distinguish their ability to 
activate FA with chain lengths as long as 26 carbons [81]. The overexpression of ACSL1 
and/or FATP1/ACSL4 (a very long-chain acyl-CoA synthetase that is highly expressed in 
white adipose) in NIH 3T3-L1 adipocyte-precursor cells increased the rate of lipid 
incorporation into TAG [23], [38].  The overexpression of ACSL1 or FATP1 in NIH 3T3 cells 
increased fatty acid uptake 50% while the overexpression of both ACSL1 and FATP1 
increased fatty acid uptake 150% suggesting a synergistic relationship [71].  Overexpressed 
ACSL1 and FATP1 co-immunoprecipitated in 3T3-L1 adipocytes suggesting direct 
interaction [23], but it is not known whether endogenous ACSL1 and FATP1 proteins 
interact.  While overexpressed ACSL1 increases FA uptake in NIH fibroblasts [71] and COS 
cells [73], FA uptake was unaffected by overexpressing [36] or knocking out ACSL1 in 
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primary hepatocytes [78] or 3T3-L1 adipocytes [39]. It is likely that conflicting data 
concerning results of FA uptake by the same ACSL isoenzyme reflect differences in the 
techniques for measuring uptake [27], the artificial effect of overexpression, tissue-specific 
subcellular location, and tissue-specific interacting proteins. ACSL1 overexpression in 
kidney-derived Cos-7 cells also increased oleate uptake but did not increase oleate 
incorporation into specific lipids [73]. FATP4 overexpression increased FA uptake, however, 
an FATP4 mutant that ablates its ACS activity no longer increased FA uptake suggesting 
that ACS activity is the factor driving FA uptake [73].  FATP1 overexpression enhances 
adipocyte fatty acid uptake and TAG accumulation in vitro, however, the knockout of FATP1 
in mice did not alter adipose weight or size nor did microchip analysis show compensation 
by other FATP or ACSL isoenzymes [82].  Therefore, it has been unclear if ACSL1 affects 
the rate of FA uptake in adipose in vivo or whether the absence of ACSL1 would decrease 
fatty acid uptake.  
 Because all five ACSL isoenzymes have unique subcellular locations and tissue 
specific expression, we hypothesize that ACSL is regulated by multiple mechanisms 
including transcriptional activation and repression, post-transcriptional modification, post-
translational modification, allosteric modification, and phosphorylation.  If all of these 
mechanisms are in play to regulate the activity of ACSL isoenzymes in a precise manner, 
we predict that overexpression of ACSL in cell culture or in vivo may lead to artificial results 
due to loss of these regulatory mechanisms. Therefore, the interpretations derived from the 
overexpression or knock down of ACSL1 in cell culture may not reflect the enzyme’s true 
physiological role.  Furthermore, cell lines are often tumor-derived or made immortal.  Thus, 
cell lines in vitro often have metabolism different from the tissue from which they were 
derived and different cell lines have differing metabolic activities. We predict that studying 
the loss of ACSL1 in mice will provide a better model to study the physiological role of 
ACSL1.  
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B3. White adipose tissue Background  
The main function of white adipose tissue (WAT) is to store excess body fuel in the 
form of TAG and to regulate satiety, food intake, insulin sensitivity, pregnancy, and menses 
through its endocrine activity. Humans and rodent models with lipodystrophy and lipoatrophy 
usually have severe insulin resistant diabetes. Conversely, humans and rodent models with 
obesity or excessive WAT mass often suffer from severe insulin resistant diabetes together 
with multiple metabolic complications. Therefore, it is clear that an optimum range of WAT 
mass is required to maintain normal metabolism and prevent the onset of diabetes.  
 How is ACSL1 regulated in adipose? Acsl1 mRNA is the most abundantly 
expressed ACSL isoenzyme in rodent white adipose tissue in which the expression acsl3, -
4, and -5 is relatively minor  [83]. Because adipose is the major storage site for TAG, and 
ACSL1 is the major ACSL isoenzyme, we thought that ACSL1 may be critical in activating 
FA destined for TAG synthesis. ACSL1 in adipose is regulated by a variety of physiological 
conditions, nutritional components, and hormones. For instance, acsl1 transcription is 
upregulated in adipose/adipocytes by exposure to insulin, PPARγ agonists, and retinoic 
acids, all of which regulate lipid anabolism physiologically [2, 84-86]. Conversely, acsl1 
mRNA in adipose or adipocytes is down-regulated by corticosteroids, exercise training, 
adrenaline, and other activators of cyclic-AMP that are linked to lipid catabolism [84, 87, 88].  
However, the data conflict because not all PPARγ agonists or cAMP activators increase or 
decrease acsl1 mRNA.  
In vitro, ACSL activity increases 100-fold and acsl1 mRNA expression increases 
160-fold in differentiating 3T3L1 adipocytes [1, 3, 89].  Meanwhile, as 3T3L1 cells 
differentiate into adipocytes and accumulate TAG, the expression of the other ACSL 
isoenzymes remains unchanged [90].  Therefore, as adipocytes accumulate lipid in vitro, the 
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expression of ACSL1 is induced, suggesting the enzyme’s involvement in lipid anabolism.  
The typical adipocyte differentiation cocktail includes dexamethasone, 1-methyl-3-
isobutylxanthine (MIX), and insulin. Dexamethasone and MIX reduce acsl1 mRNA in 3T3L1 
adipocytes, whereas, insulin increases acsl1 mRNA. Insulin is required for insulin-like 
growth factor receptor (IGF-R) stimulation for mitotic clonal expansion that is essential for 
adipocyte differentiation in 3T3L1 cells. in contrast, mouse embryonic fibroblasts, MEFs or 
mesenchymal tissue containing preadipocytes, do not require mitotic clonal expansion or 
insulin for differentiation and lipogenesis [91].  It is unknown whether acsl1 mRNA is induced 
in the presence of lipogenesis but in the absence of insulin.  Perhaps insulin increases acsl1 
mRNA as a secondary effect of IGF-R stimulation, and ACSL1 may not serve a critical role 
in lipogenesis of differentiating 3T3-L1 cells.  Differentiating primary pre-adipocytes express 
l-cpt1 mRNA whereas mature adipose tissue expresses both L-CPT1 and M-CPT1 [92].  
The role that FA oxidation plays in WAT has not been extensively investigated [93]. Apart 
from the normal demands of cellular metabolism, adipocytes require energy both to 
synthesize FA de novo and for ACS-mediated activation of FA to acyl-CoAs for TAG 
synthesis. The potential importance of FA β-oxidation in WAT is supported by the 
observation that mitochondrial proteins increase 20- to 30-fold in WAT after treatment with a 
PPARγ agonist or during 3T3-L1 adipocyte differentiation [94, 95]. The physiological stimuli 
that increase the rate of FA oxidation in WAT are unknown, but treating 3T3-L1 cells with an 
adipocyte-differentiation cocktail plus rosiglitazone increases the content of both 
mitochondrial ACSL1 protein and proteins required for FA oxidation, suggesting coordinated 
regulation [96]. Whether the increase in ACSL1 during adipocyte differentiation is part of the 
mitochondrial biogenesis or the lipogenic program is unknown.  
Some research suggests that ACSL1 is not involved in lipid anabolism.  For 
example, in humans, researchers were surprised to find that Acsl1 mRNA in subcutaneous 
fat is inversely correlated with central obesity and insulin resistance in a small Swedish 
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cohort of healthy males [97]. In liver, heart and adipose tissue, Acsl1 mRNA is upregulated 
by PPARα, a transcription factor that increases the expression of genes involved in the 
oxidation of FA [6]. Therefore, the role of ACSL1 in TAG formation in adipose has remained 
unclear. Data presented in this dissertation shows that ACSL1 is not the critical activator of 
FA for TAG synthesis, but that ACSL1 is critical for FA oxidation in adipose.  
It is important to note that many studies do not specify the specific ACSL isoenzyme 
and therefore, interpretation of the specific role of the ACSL isoenzymes is difficult.  It is also 
important to consider that most adipose-related ACSL1 research has been conducted using 
3T3-L1 cells, an immortalized cell line that has undergone multiple passages and for which 
an artificial hormonal cocktail is used to induce the accumulation of lipid and therefore may 
not accurately represent the metabolism of an adipocyte in vivo.  By creating an adipose 
specific knockout mouse we have studied ACSL1 physiologically.  
Table 2.3. ACSL1 discrepancy in adipose 
ACSL1 Fast Refed 
mRNA - ↓ 
Protein ↓ ↑ 
Activity ↓ - 
The vast majority of research illustrates changes in ACSL1 in 
adipose tissue and adipocytes, supporting a role for ACSL1 in 
lipid anabolism. However, following a 48-hr fast, rat visceral 
white adipose has reduced total ACSL activity and reduced 
ACSL1 protein, but no change in acsl1 mRNA.  
Furthermore, fasting followed by refeeding for 24 hours normalizes ACSL total activity and 
increases ACSL1 protein, but reduces acsl1 mRNA levels [83].  The discrepancies between 
ACSL1 activity, protein, and mRNA levels, highlighted by Mashek et al, indicate that the 
ACSL isoenzymes are under complex regulatory mechanisms that are not well understood. 
Moreover, most research on ACSL1 is based on changes in protein or mRNA levels that 
may not necessarily correlate with the activity of the enzyme, suggesting that previous 
research may have misleading interpretations. The antibody used to quantify ACSL1 protein 
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reported by Mashek et al and others does not recognize ACSL1 specifically (Li and Ellis, 
unpublished data).  In order to ascertain the function of ACSL1 in adipose, we have 
specifically ablated the ACSL1 gene exclusively in adipose tissue in order to study the 
effects in a living system.  
B4. Brown Adipose Tissue 
 Brown adipose tissue (BAT) functions to provide heat for mammals in response to 
cold exposure. The role of brown adipose tissue and its metabolism have been extensively 
reviewed [98-100].  Brown adipose tissue is found in small mammals including rodents and 
in human newborns. However, recent evidence indicates that adult humans contain BAT 
depots [101].  Brown adipocytes contain multi-locular lipid droplets and a high abundance of 
mitochondria. The mitochondria of BAT contain large amount of uncoupling protein-1, 
UCP1.  UCP1 is located on the inner mitochondrial membrane where it uncouples the 
electron transport chain from ATP synthesis and is almost exclusively expressed in BAT 
[102].  The hydrogen ions pumped into the inner mitochondrial membrane space by the 
electron transport chain are pumped through the UCP1 protein, and not pumped through the 
ATP synthase complex, resulting in the production of heat instead of ATP.  The heat-
generating ability of UCP1 is thought to be an exclusive property of UCP1 and not of the 
related proteins UCP2, -3, -4, or -5.   
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histology and by the mRNA expression of the BAT-specific UCP1 protein. 
 
 Figure 2.8. BAT in adult humans by CT-PET. “Computed Tomographic (CT) and 
Positron-Emission Tomographic (PET) Images from the Neck and Upper Thoracic Region, 
Obtained during Cold and Warm Conditions. Panel shows images of the neck and upper 
thoracic region from subjects. The top row shows individual CT images, the middle row 
shows PET images, with the glucose analogue 18F-fluorodeoxyglucose (18F-FDG) as a 
tracer, during cold conditions, and the bottom row shows PET images with 18F-FDG during 
warm conditions. The image on the left side of each row represents a transaxial slice, the 
image in the middle a coronal slice, and the image on the right side a sagittal slice from the 
region of activated brown adipose tissue. The color index to the left of the PET images 
shows the level of 18F-FDG uptake, with red indicating the highest level.” [107] 
  
 ACSL1 and Brown Adipose Tissue. According to mRNA abundance, acsl1 and 
acsl5 are the highest expressed ACSL isoenzymes in rodent brown adipose tissue [83].  
Proteomic analysis of mitochondria isolated from white adipose tissue, brown adipose 
tissue, and 3T3-L1 adipocytes reveals ACSL1 protein in adipose mitochondria [40].  ACSL1 
and ACSL6 are particularly enriched in white adipose mitochondria, whereas ACSL5 is more 
abundant in mitochondria from brown adipose.  Very little research has been done to 
elucidate the roles of ACSL1 and ACSL5 in brown adipose. ACSL protein was found to be 
located on the mitochondrial outer membrane through fractionation experiments on pig BAT, 
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however, no specification of the ACSL isoenzyme could be made at the time because ACSL 
had not been cloned [109].  Total ACSL activity in BAT is unchanged when rats are exposed 
to cold (4°C) for 0.5, 1, 7, 12 or 15 days  [110].  However, the same group found a 2-fold 
increase in total ACSL activity in BAT from rats exposed to cold for 3 days or stimulated with 
a β-adrenergic agonist [111].  The reason for the discrepancy between these studies was 
not discussed.  Acsl5, but not acsl1, mRNA is increased in the BAT of cold exposed FVB-N 
mice [112].  These data implicated ACSL5 in oxidation in BAT, however, LACS5, the human 
homolog of ACSL5, is expressed in erythrocytes which do not contain intracellular 
membranes (i.e. mitochondria) and do not oxidize FA, shedding doubt on ACSL5 and its 
role in oxidation [113].  Moreover, it is well established that mouse strains such as FVB-N 
and C57Bl/6 differ in their response to cold exposure and in their regulation of genes 
involved in adaptive thermogenesis [114, 115].   
 Other models of cold intolerance. Norepinephrine signaling though the β-
adrenergic receptor is the most potent signal that activates cold-induced adaptive 
thermogenesis in BAT. This is evident from the β-adrenergic receptor knockout mice that are 
cold intolerant with core body temperature dropping below 30°C in a 4°C environment within 
2-3 hours [116].  UCP1 knockout mice body temperature also drops below 30°C in a 4°C 
environment within 4-6 hours [117].  UCP1 is the only protein known to create heat by 
proton pumping in the mitochondria of BAT, so, it is not surprising that UCP1 knockout mice 
are cold intolerant. Because of the potential role that UCP1 plays in energy homeostasis, 
the UCP1 knockout mice were expected to be obese, however, they are lean and become 
no more obese on a high-fat diet than controls [118].  Alternatively, mice that almost 
completely lack BAT (UCP-DTA) are obese but only moderately cold intolerant with their 
body temperature dropping to 35°C in a 4°C environment within 30 hours [119].  The 
discrepancy in these phenotypes has led to exploration of alternative means of 
30 
 
thermogenesis and compensatory mechanisms in UCP-DTA mice which have complex non-
UCP1-dependent phenotypes.  
Table 2.4: Mouse models of cold sensitivity 
 
Aside from the UCP1 protein itself, fatty acid oxidation is required for generation of 
protons that act as substrate for UCP1. The requirement of oxidation during cold 
thermogenesis is exemplified by the knock out mouse models of the acyl-CoA 
dehydrogenase enzymes of FA oxidation, namely, the knockout of short-chain-, medium-
chain-, long-chain-, and very long-chain acyl-CoA dehydrogenase. In all these knockout 
mice body temperature drops below 30°C in a 4°C environment within 1-4 hours with fasting 
[120-122]. These data represent the critical role that FA oxidation plays in adaptive 
thermogenesis.  
The supply of fatty acids for oxidation during adaptive thermogenesis is from 
intracellular and extracellular sources through the activation of lipolysis in both white and 
brown adipose tissue.  As such, mice that lack proteins required for lipolysis, namely, 
adipose triacylglycerol lipase (ATGL) and caveolin-1, a protein that aids lipolytic activity, are 
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cold intolerant with core body temperature dropping below 30°C in a 4°C environment within 
and 24 hours, respectively [123, 124].  It is unknown whether intracellular-derived FA stores 
are metabolized by different enzymes than extracellular-derived FA. It is possible that 
ACSL1 activates fatty acids derived from specific pools, i.e. intra-cellular versus extra-
cellular FA pools. 
  
 
 
 
 
 
 
 
CHAPTER III 
THE ROLE OF ACSL1 IN ADIPOSE TISSUE 
 
The majority of studies in 3T3-L1 adipocytes and that examined acsl1 mRNA in vivo 
conclude that the enzymatic action of ACSL1 is likely involved in the synthesis of TAG in 
white adipose.  We and others have shown that ACSL1 mRNA abundance, protein amount, 
and enzyme activity are not directly correlated and that ACSL1 does not increase TAG 
synthesis in all cell lines and tissues.  Furthermore, acsl1 mRNA is upregulated by 
transcription factors that regulate both genes of FA oxidation and genes of lipogenesis. 
These data raise doubt that ACSL1 is involved in TAG synthesis. Therefore, we have 
assessed the true role of ACSL1 in adipose by knocking it out specifically in adipose of 
mice, Acsl1A-/- mice.  Data presented in this dissertation suggest that ACSL1 is critical for 
activating FA for oxidation, not TAG synthesis.  Impaired adipose FA oxidation in the Acsl1A-
/- mice renders the mice with increased fat mass and cold intolerance.   
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Summary:  
Acyl-CoA synthetase-1 (ACSL) contributes 80% of total ACSL activity in adipose tissue and was 
believed to be essential for the synthesis of triacylglycerol. We predicted that an adipose-
specific knockout of ACSL1 (Acsl1A-/-) would be lipodystrophic, but, compared to controls, 
Acsl1A-/- mice had 30% greater fat mass when fed a low fat diet, and gained weight normally 
when fed a high fat diet. Acsl1A-/- adipocytes incorporated [14C]oleate into glycerolipids normally, 
but fatty acid oxidation rates were 50-90% lower than in control adipocytes and mitochondria. 
Acsl1A-/- mice were markedly cold intolerant, and β3-adrenergic agonists did not increase oxygen 
consumption, despite normal adrenergic signaling in brown adipose tissue. The reduced 
adipose FA oxidation and marked cold intolerance of Acsl1A-/- mice indicate that normal 
activation of FA for oxidation in adipose tissue in vivo requires ACSL1. Thus, ACSL1 has a 
specific function in directing the metabolic partitioning of fatty acids towards β-oxidation. 
Highlights 
• Adipose knockout of long-chain acyl-CoA synthetase 1 decreases ACS activity 80% 
• Mice lacking ACSL1 are cold intolerant 
• ACSL1 activates fatty acids that are directed towards β-oxidation 
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•  
 Introduction  
Dysfunctional lipid metabolism underlies the development of obesity and obesity-related 
complications such as hepatic steatosis, diabetes, and heart disease. Although the mechanisms 
that regulate the cellular uptake, activation, and metabolism of fatty acid (FA) are not fully 
understood, nearly all pathways of FA metabolism require the acyl-CoA synthetase–mediated 
conversion of FAs to acyl-CoAs (FA + CoA + ATP ? acyl-CoA + AMP + PPi). Acyl-CoAs have 
multiple fates, including use in complex lipid formation and lipid remodeling, effects on signal 
transduction, activation of transcription factors, and oxidation to provide cellular energy. Long-
chain acyl-CoAs are formed by a family of five acyl-CoA synthetases (ACSL), ACSL1, ACSL3, 
ACSL4, ACSL5, and ACSL6, and by several fatty acid transport proteins (FATP). ACSL 
isoenzymes are intrinsic membrane proteins whose active sites face the cytosol to produce 
acyl-CoAs which are either partitioned into the facing membrane monolayer where they can 
encounter downstream metabolic enzymes [19, 125], or transported to different organelles by 
the cytosolic acyl-CoA binding protein [126]. The ability of amphipathic acyl-CoAs to move freely 
within a single membrane monolayer or to be transported to distant membranes should render 
all acyl-CoAs metabolically equivalent, no matter which ACSL isoenzyme catalyzes their 
formation. Yet, gain-of-function studies suggest that each of the ACSL isoform has a distinct 
function in directing acyl-CoAs to one or more specific downstream pathways [34, 36].  
 The functions of the ACSLs are of particular interest in adipose tissue because of the 
central role that white adipose tissue (WAT) plays in energy storage and that brown adipose 
tissue (BAT) plays in energy dissipation. In WAT, Acsl1 mRNA is the most abundantly 
expressed isoform, with relatively lower expression of Acsl3, -4, and -5 [27]. Acsl1 mRNA in liver 
is upregulated by PPARα ligands [85], whereas its mRNA in WAT is increased by PPARγ 
agonists (Gerhold, 2002; Shimomura et al., 1993). In differentiating 3T3-L1 adipocytes, ACSL 
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specific activity and mRNA expression increase 100- and 160-fold, respectively [3, 4], whereas 
the expression of the other Acsl isoenzymes remains unchanged [90]. This induction of Acsl1 
expression suggested that ACSL1 is upregulated as part of the program of adipocyte 
differentiation culminating in triacylglycerol (TAG) synthesis and storage. Consistent with this 
interpretation, an expression cloning strategy designed to find cDNAs that augment FA uptake 
and incorporation into TAG cloned ACSL1 [80]. Further, overexpressed ACSL1 in 3T3-L1 
adipocytes increases FA uptake and incorporation into TAG [23, 38, 71]. In order to examine the 
putative role of ACSL1 in TAG synthesis, we created a mouse deficient in adipose ACSL1, and 
predicted that these mice would be unable to synthesize and store TAG in adipocytes. 
Surprisingly, however, the Acsl1A-/- mice had normal fat stores, but severely impaired adipose 
FA oxidation, suggesting not only that ACSL1 catalyzes the initial required step in FA oxidation, 
but also that it specifically directs FA towards mitochondrial β-oxidation.  
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Results  
Generation of mice that lack ACSL1 specifically in adipose tissue 
Mice with Loxp sequences inserted on either side of exon 2 in the Acsl1 gene [127] and 
backcrossed to the C57Bl/6 strain six times were crossed with mice in which Cre expression is 
driven by the aP2 promoter [B6.Cg-Tg (Fabp4-cre) 1Rev/J; Jackson Laboratories, Bar Harbor 
ME] to generate adipose-specific Acsl1 knockout mice (Acsl1A-/-). Littermates lacking the Cre 
gene (Acsl1flox/flox) were used as controls.  
 
ACSL1 protein was virtually absent in brown, gonadal, and inguinal adipose tissue from Acsl1A-/- 
mice (Fig. 1A). ACSL specific activity was 80% lower than in controls, confirming that ACSL1 is, 
functionally, the major ACSL in adipose tissue (Fig. 1B), with the remaining 20% of ACSL 
activity catalyzed by other ACSL isoenzymes in adipocytes and all ACS enzymes in 
stromovascular tissue [83]. Confirming the tissue-specificity of the knockdown, ACSL1 protein 
and total ACSL specific activity were unaffected in Acsl1A-/- liver (Fig. 1A, B). Real-time PCR 
showed nearly absent expression of Acsl1 mRNA in Acsl1A-/- gonadal and brown adipose tissue, 
but unchanged expression of the other four Acsl isoenzymes and a 50% reduction in Fatp1 
mRNA, a related ACS (Fig. 1C, D). Thus, other acyl-CoA synthetases did not compensate for 
the loss of ACSL1.  
 
Acsl1A-/- mice have increased fat mass and synthesize TAG normally 
Despite the 80% loss of adipose ACSL activity, Acsl1A-/- mice had increased adiposity. When 
fed a 10%-fat diet, Acsl1A-/- body weights were similar to controls (Fig. 2A), but MRI analysis 
showed that the mice had 30% more body fat (Fig. 2B). Consistent with the MRI data, gonadal 
fat depot weights were ~40% greater in mice fed chow or 10%-fat diets (Fig. 2C). Gonadal 
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adipose tissue histology, adipocyte size, GPAT specific activity, and AMPK phosphorylation 
were similar between genotypes (Fig. 2D-G). No genotype differences in liver or BAT weights 
were observed.  
 No diet-related differences were observed between genotypes in plasma glucose, FA, 
cholesterol, or insulin concentrations (Table S1). However, plasma TAG concentrations were 
17% lower in Acsl1A-/- mice. A 45%-fat diet resulted in weight gain, adiposity, and insulin 
resistance that was similar in both genotypes (Fig. 2A, Table S1). Loss of ACSL1 could 
theoretically change the cellular content and ratio of its FA substrate and acyl-CoA product, 
thereby altering the availability of ligands for PPARγ and PPARα [128, 129], however target 
genes of these transcription factors did not change significantly in Acsl1A-/- gonadal WAT (Table 
S2). 
 When fed a low-fat diet, the amount of phospholipid extracted from epididymal WAT was 
similar in both genotypes, but Acsl1A-/- WAT contained more TAG, DAG, and FA per fat pad 
(Fig. 2H). With the high-fat diet, no differences were present between control and Acsl1A-/- lipid 
classes in epididymal WAT. BAT from Acsl1A-/- and control mice fed either diet also contained 
similar amounts of all lipid classes (Fig. S1A, B). Thus, lack of ACSL1 did not impair adipose 
TAG accumulation. 
 Confirming normal TAG synthesis in both isolated white gonadal adipocytes and cultured 
primary white adipocytes from control and Acsl1A-/- mice, the rates of [1-14C]oleate incorporation 
into TAG and phospholipid were similar, indicating that the lack of ACSL1 did not impair FA 
incorporation into complex lipids (Fig. 2I,J). Thus, despite greater than 100-fold increases in 
Acsl1 mRNA and ACSL specific activity during fat cell differentiation [3, 4], TAG synthesis does 
not require FA activation by ACSL1.  We conclude that the increased fat mass did not result 
from impaired lipolysis because in 24h fasted mice and in media from white adipose tissue 
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explants with or without exposure to lipolytic stimuli (Fig. 2K-M, Table S3) FA and glycerol 
release were similar between genotypes. 
Differences in FA species content in adipose tissue. 
We did not expect to find major changes in FA species because each of the purified ACSL 
isoenzymes in vitro can activate a wide range of long-chain, saturated and unsaturated FA [90]. 
However, compared to controls, Acsl1A-/- mice fed both the low-fat and high-fat diets contained 
20-30% less 18:2n6 in TAG from brown and gonadal white adipose (Fig. S1C, D). The TAG 
fraction of BAT from Acsl1A-/- mice was composed of 15% more 16:0 than controls fed the low-
fat diet (Fig. S1E). In Acsl1A-/- BAT, the PL fraction from mice fed the high-fat diet contained 
30% more 16:0 and 15%, 22%, and 14% less 18:0, 18:2n6, and 20:4n6, respectively, than 
controls (Fig. S1F). No other differences in the major fatty acid species were observed. These 
small, but statistically significant, alterations in lipid composition of adipose tissues suggest that 
ACSL1 does contribute to the relative content of esterified FA species in neutral lipids and 
phospholipids, despite the minimal differences in FA preference observed in vitro. 
Fatty acid oxidation was impaired in white adipocytes from Acsl1A-/- mice 
Compared to mature adipocytes isolated from control mice, the rate of [1-14C]oleate 
incorporation into CO2 and acid soluble metabolites (ASM) was 50% lower in Acsl1A-/- 
adipocytes (Fig. 2N). CO2 and ASM represent complete and incomplete products of fatty acid 
oxidation; thus, the 50% reduction of FA incorporation into these oxidative products reflects 
reduced β-oxidation and suggests that impaired FA catabolism could have caused the larger 
WAT depots in the Acsl1A-/- mice.  
Decreased FA oxidation rendered Acsl1A-/- mice cold intolerant 
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FA oxidation increases markedly in BAT during cold exposure. To generate heat and maintain 
normal body temperature, ATP production is reduced when activated uncoupling protein (UCP1) 
increases the flux of protons through the electron transport chain and dissipates the 
mitochondrial proton gradient [130]. Fasted wildtype mice can maintain their body temperature 
above 35°C for as long as 24 h at 4°C [131]. In striking contrast, however, the body temperature 
of the Acsl1A-/- mice fell below 30°C within 3 h (Fig. 3A). During cold exposure, both genotypes 
shivered similarly, and gastrocnemius total ACSL activity (Fig. S4A) and Acsl1 mRNA 
abundance (data not shown) did not change in Acsl1A-/- mice. In shivering muscle, fuel 
preference and the contribution of muscle heat to total body heat remain unclear [132]; 
however, plasma FFA and VLDL were not limiting for either Acsl1A-/- skeletal muscle or BAT 
(Fig. 6C, D).   
 Direct measurements of FA oxidation rates in BAT homogenates from Acsl1A-/- mice 
showed that the rate of [1-14C]palmitate incorporation into CO2 and ASM was 36% lower than 
controls (Fig. S5C). Because label dilution occurs when fatty acid oxidation is measured in cells 
with a high lipid content, we confirmed this oxidation defect by monitoring O2 consumption in 
conscious Acsl1A-/- and control mice in Oxymax chambers. Whole body O2 consumption 
normally increases in response to adrenergic stimuli and reflects an increase in electron 
transport chain activity. Isoproterenol, a non-specific β-adrenergic receptor agonist, increased 
O2 consumption 51% in control mice, but only 18% in Acsl1A-/- mice (Fig. 3B). This blunted 
response indicates that whole body oxidation is diminished. When CL-316243, an adipose-
specific, β3-adrenergic receptor agonist [133] was injected, O2 consumption increased 30% in 
control mice, but only 2% in Acsl1A-/- mice, showing that the block in adrenergic-mediated 
oxidation was adipose-specific (Fig. 3B,S5B).  
 In mitochondria from Acsl1A-/- BAT, the production of CO2 from [1-14C]palmitate oxidation 
was reduced 62% (Fig. 3E,G), and this reduction in mitochondrial FA oxidation correlated 
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directly with the amount of mitochondrial ACS activity and ACSL1 protein present in each of 
three mitochondrial preparations (Fig. 3F,S4F,E).  In contrast, CO2 production from [1-
14C]pyruvate oxidation was similar to that of control mitochondria, showing that Acsl1A-/- BAT 
mitochondria are functional for substrates other than FA. The 31% reduction in [1-14C]palmitoyl-
CoA oxidation (Fig. 3G) suggests that FA oxidation may require the generation of acyl-CoA at 
the mitochondrial membrane, and/or that the mechanism by which ACSL1 directs its acyl-CoA 
product towards mitochondrial oxidation may be partially disrupted by homogenization.  The rate 
of oxygen consumption in control and Acsl1A-/- BAT mitochondria was similarly increased by 
UCP1-dependent pyruvate stimulation and, in both genotypes, GDP effectively reduced oxygen 
consumption by inhibiting UCP1 (Fig. S4). These data show that ACSL1 deficient BAT 
mitochondria have full UCP1 activity and that Acsl1A-/- cold intolerance is not due to impaired 
UCP1 function. Taken together, these data from live mice, BAT homogenates, and isolated 
mitochondria indicate that cold intolerance of the Acsl1A-/- mice resulted from impaired FA 
oxidation and show that ACSL1 is absolutely required for cold-adaptive thermogenesis in BAT.  
 After 4 h at 4°C, BAT from control mice depleted its lipid droplets, but lipid droplets were 
retained in Acsl1A-/- BAT (Fig. 3C). Control mice lost ~50% of BAT lipid stores after 4 h of cold 
exposure, whereas the TAG content in Acsl1A-/- BAT did not change (Fig. 3D). Liver and WAT 
histology was similar at 21oC and 4oC in both genotypes (data not shown). Although TAG 
retention in Acsl1A-/- BAT after cold exposure could be due to impaired lipolysis, the increase in 
plasma FA and glycerol in cold-exposed Acsl1A-/- mice is consistent with active TAG lipolysis in 
WAT (Fig. 6B,C), and in differentiated primary brown adipocytes from Acsl1A-/- mice, the release 
of FA into the media was greater than controls under basal conditions and similar after 
adrenergic stimuli, demonstrating that Acsl1A-/- brown adipocytes lipolyzed intracellular 
triacylglycerol normally (Fig. 3I). Surprisingly, compared to control cells, glycerol release in 
Acsl1A-/- brown adipocytes was blunted by ~50% after adrenergic stimulation (Fig. 3H). Reduced 
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release of glycerol by Acsl1A-/- brown adipocytes could result from increased conversion to 
glycerol-3-P for lipid synthesis or because the glycerol was oxidized as an alternative substrate. 
After 3 h of isoproterenol exposure, both Acsl1A-/- and control differentiated brown adipocytes 
had similar ~33% reductions in [14C]oleate-labeled TAG (Fig. 3J), indicating that both lipolysis 
and FA re-esterification after lipolysis were unaffected by ACSL1 deficiency. [1-14C]Oleate 
incorporation into ASM was 90% lower in Acsl1A-/- brown adipocytes than in controls, consistent 
with the marked decrease in FA oxidation (Fig. 3K). Thus, in cold-exposed Acsl1A-/- BAT, the 
retention of lipid droplets probably reflects an influx of FA that cannot be oxidized without 
ACSL1 and are, therefore, incorporated into neutral lipid.  
Thermogenic regulation of adrenergic and oxidative genes was normal in Acsl1A-/- mice 
β-adrenergic signaling during cold exposure induces the expression of genes that activate 
mitochondrial biogenesis, heat production, and oxidative capacity. At 4oC both control and 
Acsl1A-/- mice upregulated mRNA levels of Ucp1 and PPAR-γ coactivator-1α (Pgc1α) 2- and 30-
fold, respectively (Fig. 4A,B). These increases indicate that adrenergic-stimulated signaling was 
unimpaired in Acsl1A-/- BAT [134].  
 Compared to controls, the mRNA expression of muscle-type carnitine 
palmitoyltransferase-1 (mCpt1) was significantly higher in the Acsl1A-/- BAT at 21oC, and 
cytosolic thioesterase-1 (Cte1) was significantly higher after cold exposure, suggesting that the 
lack of ACSL1 might increase cellular FA to activate PPARα-mediated transcription (Fig. 4C). 
However, the expression of other PPARα-regulated genes, medium-chain acyl-CoA 
dehydrogenase (Mcad), acyl-CoA oxidase (Aox), and Pparα, did not differ between the 
genotypes, suggesting that the lack of ACSL1 does not affect all PPARα target genes with or 
without 4 h of cold exposure.  
 Because Acsl1A-/- BAT retained lipid droplets after cold exposure, we measured genes 
that encode lipogenic and substrate-producing proteins that would normally increase during cold 
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exposure. Acsl1A-/- BAT should have been able to lipolyze and/or endocytose circulating TAG-
rich lipoproteins and to make use of these exogenous FA sources, because the lipogenic genes 
lipoprotein lipase (Lpl) and VLDL-receptor (Vldl-r) had similar expression patterns with or 
without cold exposure in both genotypes (Fig. 4D). Similarly, 1-acylglycerol-3-phosphate O-
acyltransferase-1 (Agpat1) increased in both genotypes, as did Gpat4, a major GPAT in BAT 
[135].  These data suggest that the retained lipid droplets in Acsl1A-/- BAT were not caused by 
abnormal regulation of genes required for TAG synthesis.  
                 BAT expression of Acsl3 and Acsl4 (but not Acsl1, Acsl5, or Acsl6) was upregulated 
in both genotypes in response to cold (Fig. 4E), and long-chain acyl-CoA content in cold 
exposed Acsl1A-/- BAT did not differ from controls (Fig. 6E). These data indicate that acyl-CoAs 
synthesized by other ACSL isoenzymes were unavailable for β-oxidation and that maintenance 
of normal body temperature requires acyl-CoAs synthesized by ACSL1.  
Acyl-carnitines were reduced in Acsl1A-/- BAT  
To gain further insight into the consequences of ACSL1 deficiency, we used mass spectrometry 
to profile a targeted array of intermediary metabolites. Long-chain acyl-carnitines accumulate 
when their production by mitochondrial CPT1 exceeds their flux through β-oxidation [136]. In 
wild type mice, cold exposure lowered major long-chain acyl-carnitine species and increased β-
hydroxybutyryl-carnitine (4-OH), a strong marker of increased β-oxidation and ketone 
metabolism (Figs. 5A-C, S2B). This profile is consistent with activation of mitochondrial 
uncoupling and a shift in flux limitation from long-chain acyl-CoA dehydrogenase to short-chain 
β-hydroxy-acyl-CoA dehydrogenase. In contrast, under thermoneutral conditions, BAT 
concentrations of most long-chain acyl-carnitine species were markedly lower in Acsl1A-/- mice 
compared to controls. Taken together with our measures of FA oxidation, this finding suggests 
impaired delivery of long-chain acyl-CoAs to CPT1.  During cold exposure, although Acsl1A-/- 
BAT had increases in several long- and short-chain acyl-carnitines, these remained 
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substantially lower than in controls (Figs. 5A-C, S2B,C). BAT levels of acetyl-carnitine (C2), 
which is derived from acetyl-CoA, were similar between genotypes, suggesting that increased 
catabolism of glucose and/or amino acids in the Acsl1A-/- mice partially compensated for 
impaired FA oxidation.   
 In control mice the BAT content of most organic acids was maintained during cold 
exposure, with the exceptions of lactate and succinate which declined (Fig. 5D-F).  Compared 
to controls, lactate was lower in Acsl1A-/- mice, regardless of temperature, consistent with 
enhanced pyruvate oxidation and a shift in cellular redox state.  The lower levels of succinate in 
Acsl1A-/- BAT may reflect disinhibition of succinate dehydrogenase (complex II). Notably, BAT 
levels of several amino acid-derived CoA species (propionyl-CoA, succinyl-CoA, 3-
methylcrotonyl-CoA, isovaleryl-CoA) were elevated in Acsl1A-/- compared to control mice, 
principally during cold exposure (Fig. 5G,H). These elevations are consistent with a 
compensatory increase in protein catabolism and amino acid oxidation. Supporting this 
interpretation, the concentrations of branched chain and anaplerotic amino acids (valine, 
leucine/isoleucine, tyrosine) were elevated in the Acsl1A-/- mice, whereas alanine, the major 
gluconeogenic amino acid, was decreased (Fig. 5I,J). 
Hypoglycemia and hyperlipidemia in Acsl1A-/- mice after adrenergic stimuli 
Plasma glucose decreased in both genotypes during cold exposure, however, the plasma 
glucose concentration in Acsl1A-/- mice fell 58% more than in the controls (Fig. 6A). Similarly, 
after β-adrenergic stimulation with isoproterenol or CL-316243, Acsl1A-/- plasma glucose was 
36% or 19% lower, respectively, than controls. The larger decrements in glucose in Acsl1A-/- 
mice after cold exposure and β-adrenergic agonists, but not after 24 h of fasting (Table S3), 
suggest enhanced glucose use by Acsl1A-/- BAT.  Plasma glycerol increased similarly in both 
genotypes, both during cold exposure and after isoproterenol injection; however, in response to 
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CL-316243, circulating glycerol increased 14% in controls, but decreased 15% in Acsl1A-/- mice, 
consistent with the reduced glycerol release by Acsl1A-/- primary brown adipocytes (Fig. 3H).  
Again, the glycerol decrease in BAT may reflect its increased use as an alternate oxidative 
substrate (Fig. 6B). FA concentrations after cold exposure or CL-316243 were 30% higher in 
Acsl1A-/- mice compared to controls (Fig. 6C); this increase in plasma FA induced by β-
adrenergic stimuli, but not after 24 h of fasting, provides additional evidence for intact Acsl1A-/- 
lipolytic activity and is consistent with diminished use of FA for oxidation in BAT. In response to 
cold exposure, plasma TAG, another potential source of FA for BAT metabolism, decreased 
41% in control mice, but was unchanged in Acsl1A-/- mice despite elevated Lpl mRNA (Figs. 6D, 
4E), probably as a result of hepatic recycling of the elevated plasma FA into VLDL.  
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Discussion 
After a long-chain FA enters a cell, its metabolic fate is determined by the metabolic demands of 
the cell, the availability of other energy substrates, PPARα- and PPARγ-mediated changes in 
enzymes of complex lipid synthesis and β-oxidation [137], and the relative content of 
intracellular AMP which controls AMP-activated kinase and, thus, CPT1 [138]. Here we show 
that ACSL1 contributes critically to adipose FA metabolism by catalyzing the formation of acyl-
CoAs that are used for β-oxidation. If all acyl-CoAs were metabolically equivalent, one would 
expect that the rates of acyl-CoA incorporation into all metabolic end products would be 
diminished equally and that adipose from Acsl1A-/- mice would have impairments in both FA 
oxidation and complex lipid synthesis. However, the role of adipose ACSL1 in catalyzing the key 
initial step in FA oxidation is supported by the normal rate of FA incorporation into complex 
lipids and the 50-90% reduction in the rate of FA oxidation in white and brown adipocytes and in 
BAT mitochondria from Acsl1A-/- mice, together with the inability of Acsl1A-/- BAT to oxidize FA for 
thermogenesis. Although the content of acyl-CoA in BAT was similar in control and Acsl1A-/- 
mice, these acyl-CoAs were unavailable for β-oxidation in the absence of ACSL1. The inability 
of the other ACSL isoenzymes to direct acyl-CoAs towards β-oxidation, especially during the 
physiological stress of acute cold exposure in BAT, indicates that ACSL1 has a distinct function 
in partitioning FA, and that the other ACSL isoenzymes in adipose tissue cannot compensate for 
its absence. Our data also suggest that the importance of FA oxidation in WAT has been 
underestimated. 
 Acute cold exposure stimulates norepinephrine release, which induces adipocyte TAG 
lipolysis via β-adrenergic receptors (Fig. 7). In BAT, lipolyzed FA activates UCP1 to dissipate 
the mitochondrial proton gradient; activation of UCP1 results in energy expended in the form of 
heat rather than ATP generation. Thermogenesis is maintained primarily through FA oxidation; 
glucose cannot maintain euthermia at 4oC in knockout mice deficient in short-chain-, medium-
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chain-, long-chain-, or very-long-chain acyl-CoA dehydrogenases [139-141]. When Acsl1A-/- 
mice were exposed to a 4°C environment, their body temperature dropped below 30°C within 2 
to 5 h, despite the normal increase in BAT catecholamine-regulated genes. Because no method 
exists to distinguish between FA and acyl-CoAs as activators of UCP1 [142, 143], the actual 
activator of UCP1 could be acyl-CoA generated by ACSL1. If this were true, Acsl1A-/- mice would 
be cold intolerant because UCP1 is not activated. However, impaired acyl-CoA oxidation was 
observed directly in BAT mitochondria, brown primary adipocytes, and BAT homogenates, and 
in isolated gonadal adipocytes which do not require UCP1 activation. In addition, compared to 
control mice, the in vivo rate of oxygen consumption of Acsl1A-/- mice at 21oC was 60% lower, 
and when stimulated by isoproterenol or by an adipose-specific β3 adrenergic receptor agonist, 
was more than 90% lower, indicating reduced flux through the electron transport chain and 
reduced adipose mitochondrial oxidation. Finally, Acsl1A-/- UCP1 uncoupling was activated by 
pyruvate and inhibited by GDP, indicating normally activated UCP1 (Fig. S4) [144]. 
  The role that FA oxidation plays in WAT has not been extensively investigated [93]. 
Apart from the normal demands of cellular metabolism, adipocytes require energy both to 
synthesize FA de novo and to activate FA to acyl-CoAs for TAG synthesis. Our data show that 
the loss of ACSL1 in WAT reduced FA oxidation 50% and resulted in a 30% increase in adipose 
mass. Although it is possible that ACSL1 is not the sole isoform in WAT that can activate the FA 
that is targeted towards β-oxidation, we attribute the increased WAT mass in Acsl1A-/- mice to 
diminished use of FA for energy generation within WAT itself, because mice that cannot use 
BAT for thermogenesis are not obese unless they are kept at a thermoneutral temperature 
[145]. The potential importance of FA β-oxidation in WAT is supported by the observation that 
mitochondrial proteins increase 20- to 30-fold in WAT after treatment with a PPARγ agonist or 
during 3T3-L1 adipocyte differentiation [94, 95]. The physiological stimuli that increase the rate 
of FA oxidation in WAT are unknown, but treating 3T3-L1 cells with an adipocyte-differentiation 
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cocktail plus rosiglitazone increases the content of both mitochondrial ACSL1 protein and 
proteins required for FA oxidation, suggesting coordinated regulation [96]. 
 The AMP generated by the ACSL1 reaction may activate AMP kinase in 3T3-L1 
adipocytes stimulated with isoproterenol or forskolin [51, 146]. However, AMPK phosphorylation 
was not altered in Acsl1A-/- WAT (Fig. 2F), and acute cold exposure does not activate AMPK in 
BAT [50]. Thus AMPK activity does not mediate the cold intolerance of Acsl1A-/- mice. When 
RNAi was used to knockdown ACSL1 in 3T3-L1 adipocytes [146], the cells increased FA efflux 
during lipolysis, suggesting that ACSL1 activates and re-esterifies FA that has been lipolyzed 
from intracellular TAG. Our results suggest a different function. If reesterification were impaired 
in Acsl1A-/- adipose, one would expect that an acute cold challenge would deplete TAG stores in 
BAT and that WAT would contain less TAG. However, Acsl1A-/- mice retained their BAT lipid 
stores at 4oC, suggesting that reesterification was not diminished. Further, in Acsl1A-/- primary 
brown adipocytes, loss of [14C]-labeled FA in TAG after lipolytic stimuli was similar to controls, 
and in white adipose explants, the release of FA and glycerol was similar between genotypes 
with or without lipolytic stimuli. Although the increased release of FA from brown adipocytes 
(Fig. 3I) could suggest diminished reesterification under basal conditions, both genotypes had 
similar losses of [14C]oleate that had been incorporated into TAG and in the release of FA under 
lipolytic conditions. These data confirm normal rates of lipolysis and, together with the cold 
intolerance and increased adipose mass of the Acsl1A-/- mice, are consistent with normal FA 
reesterification. In fact, a proteomics study demonstrates marked differences in the protein 
expression of mitochondria from 3T3-L1 adipocytes and those from primary mouse adipocytes, 
so it is not surprising to find functional differences in these two cell types [40, 146].  
 Based on the dramatic increase in Acsl1 mRNA and total ACSL activity in differentiating 
3T3-L1 adipocytes [3, 4], we had predicted that adipocyte ACSL1 would catalyze the synthesis 
of acyl-CoAs destined for TAG synthesis. However, both mature and primary differentiated 
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white adipocytes from Acsl1A-/- mice incorporated [14C]oleate into TAG normally, and Acsl1A-/- fat 
depots were larger than those of controls. Further, Acsl1A-/- mice became obese and insulin 
resistant when fed a high-fat diet. Although the lack of ACSL1 in white and brown adipose tissue 
reduced ACSL specific activity by 80%, the remaining ACSL activity, derived from other ACSL 
and FATP isoenzymes, was able to synthesize acyl-CoAs directed towards normal TAG 
biosynthesis. Thus, ACSL1 is not required for TAG synthesis in adipose tissue. 
 How does ACSL1 channel acyl-CoAs towards β-oxidation? In adipocytes, subcellular 
fractionation studies identified ACSL1 on the plasma membrane, microsomes and mitochondria 
[71], on GLUT4 vesicles [75], and on lipid droplets [76]. In BAT and WAT ACSL1 protein has 
also been found in mitochondria fractions (this ms; [40]). However, even if ACSL1 were located 
solely on the mitochondrial outer membrane, its ability to channel its acyl-CoA product towards 
β-oxidation remains difficult to conceptualize. Long-chain acyl-CoAs are water-soluble, 
amphipathic molecules that can partition into membranes or bind to cytosolic carriers like acyl-
CoA binding protein. Thus, acyl-CoAs should be able to move freely within the membrane 
monolayer at their site of synthesis, and to travel between different organelles. Direct physical 
interaction of ACSL1 with other proteins, such as CPT-1, is the most likely explanation for acyl-
CoA channeling, but evidence for such interaction is lacking. 
 In summary, the loss of ACSL1 in adipose tissue produced mice with increased adiposity 
and severe cold intolerance. Adipocytes derived from Acsl1A-/- mice had normal rates of FA 
incorporation into TAG and normal loss of TAG stores after lipolysis, but had reduced rates of 
FA oxidation. Although deficient ACSL1 in liver, which expresses relatively more of the ACSL4 
and ACSL5 isoenzymes, results in only a minor defect in FA oxidation [127], we conclude that 
the function of ACSL1 in adipose tissue is to activate FA destined for β-oxidation.  
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Experimental Procedures 
Animal Treatment: Acsl1A-/- and littermate Acsl1flox/flox control mice were housed in a pathogen-
free barrier facility (12 h light/dark cycle) in accordance with the UNC IACUC, with free access 
to water and food (Prolab RMH 3000 SP76 chow). For the diet study, mice were fed a low-fat 
(10%) diet (D12450B, Research Diets) or a high-fat (45%, primarily from lard) diet (D12451) ad 
libitum from age 8 to 25 wk. Weights were measured weekly. Body fat mass was assessed by 
magnetic resonance imaging analysis (EchoMRI-100, Echo Medical Systems, LLC) in 5 mo old 
mice. For thermogenesis experiments, mice were fasted for 4 h and placed in a 4°C 
environment without food. Temperature was measured hourly with a rectal probe thermometer 
(Thermalert TH-5, physitemp). Mice were removed from the cold when core temperature 
dropped below 28°C or at 4 h. Rates of O2 consumption were determined in Oxymax chambers 
(Columbus Instruments) after mice were acclimated overnight. Data were collected from mice 
for 3 h after saline injection. After isoproterenol or CL-316243 was injected (10 mg/kg), O2 
consumption was measured for an additional 3 h, and then plasma was collected in 5% 0.5 M 
EDTA. Plasma TAG, beta-hydroxybutyrate (Stanbio), cholesterol, FFA, glucose (Wako), and 
free and total glycerol (Sigma) were measured colorimetrically. Adiponectin was measured by 
ELISA (Linco). Oral glucose tolerance tests were performed by gavaging with glucose (2.5 
mg/kg body weight) and measuring tail blood glucose at baseline, 15, 30, 60, and 120 minutes 
(One Touch Ultra glucometer, Lifescan, Inc).  
Enzyme Assays:  ACSL initial rates were measured with 50 µM [1-14C]palmitic acid, 10 mM 
ATP, and 0.25 mM CoA with total membrane fractions (0.5-4.0 µg) [147]. GPAT was measured 
with 800 µM [3H]glycerol-3-phosphate and 82.5 µM palmitoyl-CoA [148]. 
Adipocyte studies:  Adipose explants were isolated and release of FFA and glycerol was 
measured [149]. Epididymal adipocytes were isolated [150]. Rates of CO2 and ASM production 
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from [1-14C]oleate (Perkin Elmer) were measured in aliquots of the reaction mixture after 
incubating with 0.5 mL buffer containing 10 µM [1-14C]oleate for 1.5 h in a 10% adipocyte 
solution. The incubation chamber contained a center well filled with filter paper and was sealed 
with a rubber stopper. Carbon dioxide was trapped by adding 200 µl 70% perchloric acid to the 
reaction mixture and 300 µl of 1 M NaOH to the center well, and incubating the samples at RT 
for 45 min. The center well was then placed into scintillation fluid and counted. The acidified 
reaction mixture was incubated overnight at 4°C and centrifuged at 4,000 rpm for 30 min before 
aliquots of the supernatant were counted for [14C]-labeled ASM. For FA incorporation, a 10% 
adipocyte solution was incubated with 0.5 mL buffer containing 10 µM [1-14C]oleate and 90 µM 
unlabeled oleate for 2 h. Brown and white pre-adipocytes from control and Acsl1A-/- adipose 
tissue [151] were differentiated into adipocytes for 7-14 days and exposed to 500 µM oleate with 
0.6 µCi [1-14C]oleate per 60 mm dish for 3 hours.  Cells were then harvested or labeled media 
was removed, replaced with growth media for 21 hours and cells were harvested or 10 µM 
isoproterenol was added to media for an additional 3 hours followed by harvest. FA released 
into the media were measured colorimetrically (Wako) in unlabeled control plates. Total lipid 
was extracted from the cells into CHCl3 [152]. The lipid extract was dried under N2, resuspended 
in CHCl3 and chromatographed with authentic lipid standards run in parallel on 0.25-mm silica 
gel G plates in hexane:ethyl ether:acetic acid (80:20:1; v/v). The 14C-labeled lipids were 
detected and quantified with a Bioscan 200 Image System.  
Fatty acid oxidation in BAT: Freshly isolated BAT was minced and homogenized with a motor-
driven Teflon pestle and glass mortar in ice-cold buffer A (100 mM KCl, 40 mM Tris·HCl, 10 mM 
Tris base, 5 mM MgCl2·6H2O, 1 mM EDTA, and 1 mM ATP, pH 7.4) at a 20-fold dilution (wt/vol) 
or mitochondria was isolated [153], resuspended in buffer A and the rate of  [1-14C]palmitate, [1-
14C]palmitoyl-CoA, or [1-14C]pyruvate, was measured [154]. Isolated BAT mitochondria (20 µg 
protein) in buffer (70 mM sucrose, 220 mM mannitol, 10 mM KH2PO4, 2 mM MgCl2, 2 mM 
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HEPES, 1 mM EDTA, 0.1% BSA, 3 mM malate, and 1.3 µg/mL oligomycin) were loaded onto 
XF24 plates and rates of O2 consumption were measured according to the manufacturer’s 
instructions with a Seahorse X24F Analyzer (Seahorse Bioscience) during the consecutive 
addition at 4 min intervals of 5 mM pyruvate, 2 mM GDP, and 1 µM FCCP. 
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Figure 3.1. Generation of mice that lack ACSL1 specifically in adipose tissue 
A) Representative immunoblot against ACSL1 protein and B) ACSL activity in control and 
Acsl1A-/- liver, brown, gonadal, and inguinal adipose of 20 wk old mice, n=5-7. ACSL isoenzyme 
mRNA expression in C) gonadal adipose and D) brown adipose from 20 wk old control and 
Acsl1A-/- mice, n=6. Data represent mean ± SEM; *, P≤0.05 versus control.  
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Figure 3.2. Acsl1A-/- mice have increased fat mass  
A) Body weight from 6 to 24 weeks of age in mice fed LFD or HFD, n=10-15. B) Total body fat 
measured by MRI in 26 wk old control and Acsl1A-/- male mice, n=5-7. C) Fat depot weight as a 
percent of body weight (BW) in 20-26 wk old control and Acsl1A-/- male mice, n=10-15. D) 
Representative sections from control and Acsl1A-/- epididymal WAT and E) mean cells size from 
sections stained for hematoxylin and eosin, scale bars = 50 µM.  F) AMPK phosphorylation, 
relative to total AMPK, from control and Acsl1A-/- inguinal adipose, n=4-5.  G) Total GPAT 
activity in control and Acsl1A-/- gonadal adipose, n=6.  H) Lipid content of control and Acsl1A-/- 
epididymal WAT in 6 mo old male mice fed LFD or HFD diet for 4.5 mo, n=5.  [1-14C]Oleate 
incorporation into (I) glycerolipids or (N) acid soluble metabolites (ASM) and carbon dioxide 
(CO2), n=3-4, by control (C) and Acsl1A-/- (A-/-) mature epididymal adipocytes, n=6. J) [1-
14C]Oleate incorporation into (I) glycerolipids by control and Acsl1A-/- cultured primary 
adipocytes.  K) Plasma FA in control and Acsl1A-/- mice fasted for 4 or 24 hours, n=6-8. Release 
of (L) FA or (M) glycerol from control and Acsl1A-/- gonadal adipocyte explants basally or with 
10µM isoproterenol (Iso), n=8. HFD, high-fat diet; LFD, low-fat diet; TAG, triacylglycerol; DAG, 
diacylglycerol; PL, phospholipids; FA, fatty acids. Data represent mean ± SEM *, P≤0.05 versus 
control; # P≤0.05 chow or LFD versus HFD within genotype. 
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Figure 3.3. Acsl1A-/- mice are cold intolerant due to impaired FA oxidation 
A) Body temperature of fasted control and Acsl1A-/- male mice exposed to a 4°C environment for 
4 h, n=14-16. B) Control and Acsl1A-/- male mouse O2 consumption was monitored in a 
metabolic chamber for 3 h before and after injection of isoproterenol (Iso) or CL-316243 (CL) 
(10 mg/kg), n=6-8. C) Representative BAT histology stained for hematoxylin and eosin in control 
and Acsl1A-/- mice before and after cold exposure for 2-4 h when Acsl1A-/- body temperature 
reached 30°C; scale bars = 50 µm. D) TAG content of BAT from control and Acsl1A-/- mice 
fasted at 21°C or at 4°C for 4 h, n=5-6.  BAT mitochondrial (E,F) [1-14C]palmitate and (G) [1-
14C]palmitoyl-CoA and [1-14C]pyruvate oxidation into carbon dioxide (CO2) from control and 
Acsl1A-/- mice, n=3. F) Control (C) and Acsl1A-/- (A-/-) ACSL1 immunoblot and protein, and CO2 
production from [1-14C]palmitate by 3 mitochondrial preparations (A-C), relative to control. 
Control and Acsl1A-/- cultured primary brown adipocyte release of (H) glycerol and (I) FA with or 
without 10µM isoproterenol, and incorporation of [1-14C]oleate into (J) TAG and (K) ASM, n = 3. 
Data represent mean ± SEM *, P≤0.05 versus control; # P≤0.05 21°C versus 4°C within 
genotype. 
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Figure 3.4. Thermogenic regulation of genes was normal in Acsl1A-/- mice 
BAT mRNA levels were quantified by real-time PCR for genes of A,B) adrenergic regulation C) 
FA oxidation D) lipogenesis and E) acyl-CoA synthetases in BAT from male control and Acsl1A-/- 
mice without or with 4oC exposure, relative to cyclophilin A expression, n=6. Data represent 
mean ± SEM; *, P≤0.05 Acsl1A-/- versus control; # P≤0.05 21°C versus 4°C within genotype. A, 
Agpat; G, Gpat  
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Figure 3.5. Long-chain acyl-carnitines were reduced in Acsl1A-/- brown adipose tissue 
A,B,C) Free, acetyl-, and acyl-carnitine content in BAT with and without cold exposure at 4°C. 
D) Lactate and, E,F) Citric acid cycle intermediates, G,H) short-chain acyl-CoA, I) amino acids, 
and J) total amino acid content in BAT with and without 4oC exposure, n=7. DC, dicarboxylated 
acyl-carnitines; OH, hydroxylated acyl-carnitines; Asx, aspartate/asparagine; Gsx, 
glutamate/glutamine. Data represent mean ± SEM *, P≤0.05 versus control; # P≤0.05 21°C 
versus 4°C within genotype (n=6-10).  
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Figure 3.6.  Plasma metabolites and BAT acyl-CoAs in Acsl1A-/- mice after adrenergic 
stimuli. Plasma glucose (A), glycerol (B), FA (C), and TAG (D) from control and Acsl1A-/- mice 
fasted for 4 h at 21°C or 4°C, or before (T0) and 3 h after isoproterenol (Iso) or CL-316243 (CL) 
injection (10 mg/kg), n=6-8. E) Sum of long-chain acyl-carnitines (C14-C20) in control (C) and 
Acsl1A-/- (A-/-) with or without cold exposure for 2-4 h. Data represent mean ± SEM; *, P≤0.05 
versus control; # P≤0.05 21oC or T0 versus treated within genotype.  
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Figure 3.7.  BAT fatty acid metabolism in cold-exposed mice. When norepinephrine 
activates β-adrenergic receptors, activated protein kinase A (PKA) induces PGC1α in brown 
adipocytes which, together with FA, activate transcription factors that upregulate genes required 
for mitochondrial oxidative and thermogenic functions.  PKA also activates hormone sensitive 
lipase (HSL) which lipolyze triacylglycerol (TAG) in white and brown adipose cells.  FA released 
from WAT and from VLDL (via lipoprotein lipase [LPL]) enters brown adipocytes and are 
activated by ACSLs to form acyl-CoAs that can be esterified to form TAG or are oxidized. FA 
lipolyzed from TAG stores in brown adipocytes are activated by ACSL1, enter mitochondria, and 
are oxidized.  FA also activates UCP1 which uncouples the mitochondrial proton gradient, 
producing heat. 
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Supplementary Figure 3.8.  Lipid composition of adipose tissue from Acsl1A-/- mice 
A,B) Lipid content of control and Acsl1A-/- BAT in 6 mo old male mice fed a 10%-fat (LFD) or 
45%-fat (HFD) diet for 4.5 mo, n=5.  C, D) epididymal WAT and E,F) BAT lipid species content 
in TAG and PL, n=5.   Data represent mean ± SEM; groups not sharing letters are significantly 
different by 2-way ANOVA, P≤0.05.  TAG, triacylglycerol; DAG, diacylglycerol; PL, 
phospholipids; FC, cholesterol; FA, non-esterified fatty acids.   
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Supplementary Figure 3.9. Acyl-carnitines in Acsl1A-/- brown adipose tissue  
Acyl-carnitine content in BAT with and without cold exposure for 4 h at 4°C, number 
corresponds to carbon-chain length, n=6-10.  DC, dicarboxylated acyl-carnitines; OH, 
hydroxylated acyl-carnitines. Data represent the mean ± SEM; groups not sharing letters are 
significantly different by 2-way ANOVA, P≤0.05.  
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Supplementary Figure 3.10. Acyl-CoA in Acsl1A-/- brown adipose tissue  
Acyl-carnitine content in BAT with and without cold exposure for 4 h at 4°C, number 
corresponds to carbon-chain length, n=4-6.  OH, hydroxylated acyl-CoA. Data represent the 
mean ± SEM; groups not sharing letters are significantly different by 2-way ANOVA, P≤0.05. 
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Supplementary Figure 3.11.  Oxygen consumption and ACSL activity in BAT 
mitochondria and muscle 
A) Total ACSL activity in control and Acsl1A-/- gastrocnemius muscle with or without cold 
exposure, n =6. B) Absolute oxygen consumption in mice with or without CL-1316243 
(10mg/kg) stimulation, n = 6. C) [1-14C-palmitate] oxidation into carbon dioxide (CO2) from 
control and Acsl1A-/- BAT homogenates, n=5-6. Total ACSL activity (D) and ACSL1 protein (E) in 
control and Acsl1A-/- BAT mitochondria, n=3. F) Rate of oxygen consumption in control and 
Acsl1A-/- isolated brown adipose mitochondria (20 µg protein) exposed to 5 mM pyruvate (Pyr), 2 
mM GDP, and 1 µM FCCP (carbonyl cyanide P-trifluoro-methoxyphenyl-hydrazone) as 
indicated. Data represent mean ± SEM *, P≤0.05 versus control; # P≤0.05 21°C versus 4°C 
within genotype. OCR, oxygen consumption rate. 
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 Supplementary Table 1 (3.1) 
TAG synthesis was similar in control and Acsl1A-/- mice  
Plasma metabolites in 20 week old control and Acsl1A-/- male mice fasted for 4 h, n=10-12. TAG, 
triacylglycerol; FA, fatty acids; OGTT-AUC, oral glucose tolerance test-area under the curve;  
ND, not determined.  Data represent mean ± SEM; Students T-test’s: *, P≤0.05 Acsl1A-/- versus 
control within diet; # P≤0.05 low-fat vs. high-fat diet within genotype. 
 Low-Fat Diet High-Fat Diet 
 Control Acsl1A-/- Control Acsl1A-/- 
Body Weight (g) 33.1 ± 0.7 33.3 ± 0.8 37.3 ± 1.8# 36.6 ± 1.4# 
% Body Fat 12.2 ± 0.8 16.0 ± 1* 19.7 ± 3# 17.9 ± 8 
Epididymal  fat (% of BW) 1.83 ± 0.1 2.6 ± 0.2 * 3.3 ± 0.4#  3.1 ± 0.4# 
Plasma TAG (mg/dL) 30 ± 2 25 ± 2 * 33 ± 4 28 ± 1 
Plasma Cholesterol (mg/dL) 111 ± 6 118 ± 7 135 ± 12# 144 ± 6# 
Plasma FA (mEq/L) 0.24 ± 0.02 0.24 ± 0.02 0.17 ± 0.02 0.21 ± 0.05 
Plasma Glucose (mg/dL) 162 ± 5 160 ± 7 164 ± 7 170 ± 4 
OGTT-AUC (mg/dL) 3710 ± 374 2576 ± 513 4950 ± 250# 6828 ± 842# 
Plasma Insulin (µg/mL) 0.32 ± 0.03 0.57 ± 0.23 0.38 ± 0.05 0.61 ± 0.16 
Plasma Adiponectin (µg/mL) 12.8 ± 0.6 14.0 ± 0.8 ND ND 
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 Supplementary Table 2 (3.2) 
Lipogenic gene expression was similar in control and Acsl1A-/- WAT 
Gonadal adipose mRNA levels were quantified by real-time PCR in male mice fed the low-fat 
diet for 20 wk, n=6.  Data represent 2^-∆CT of Acsl1A-/- fold-change over control and normalized to 
cyclophilin A.  Data represents mean ± SEM. No significant differences were found between 
Acsl1A-/- and control values by 2-way Student’s T-test.   
Gene Fold change relative to control Function 
Vldl-r 1.63 ±0.4 FA uptake Ldl-r 1.46 ±0.4 
Caveolin-1 1.02 ±0.2 Lipolysis 
Cte1 1.13 ±0.2 
 
FA oxidation/ 
PPARα 
l-Cpt1 1.08 ±0.2 
Mcad 1.22 ±0.3 
Atp syn 1.58 ±0.6 
Pparg 1.10 ±0.3 
FA synthesis/ 
PPARγ 
Ap2 0.98 ±0.2 
Fas 1.64 ±0.4 
Cd36 1.95 ±0.9 
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Supplementary Table 3 (3.3) 
Acsl1A-/- mice respond normally to fasting  
Body weight and plasma glucose, fatty acids (FA), and β-hydroxybutyrate (β-OH) in 4 h 
and 24 h fasted control and Acsl1A-/- mice, n=5-8.  Data represent mean ± SEM; 
Students T-test’s: *, P≤0.05 Acsl1A-/- versus control at same fasting time; # P≤0.05 30 h 
versus 4 h within genotype. 
 
 
 
 
 
 
 
 
  
 
Controls Acsl1A-/- 
Hours Fasting 
4 24 4 24 
Weight (g) 23 ± 1 21 ± .5# 24 ± .6 22 ± .6# 
Glucose (mg/dL) 150 ± 4 102 ± 7# 157 ± 11 91 ± 6# 
FA (mEq/L) 0.12 ± 0.1 1.2 ± 0.1# 0.1 ± 0.1 1.3 ± 0.1# 
β-OH (mEq/L) 0.4 ± 0.1 1.7 ± 0.1# 0.4 ± 0.1 2.3 ± 0.2#* 
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Supplementary Table 4 (3.4), Primer sequences used for RT-PCR 
 
  
Gene Forward  Reverse  
Acsl1 TGGGGTGGAAATCATCAGCC CACAGCATTACACACTGTACAACGG 
Acsl3 CAATTACAGAAGTGTGGGACT CACCTTCCTCCCAGTTCTTT 
Acsl4 TGCCAAAAGTGACCAGTCCTATG TGTTACCAAACCAGTCTCGGGG 
Acsl5 TCCCAGCCCACCTCTGATGATGTG ACAAACTGTCCCGCCGAATG 
Acsl6 TGAATGCACAGCTGGGTGTA ATGTGGTTGCAGGGCAGAG 
Fatp1 CGCTTTCTGCGTATCGTCTGCAAG AAGATGCACGGGATCGTGTCT 
Ucp1 GTGAAGGTCAGAATGCAAGC AGGGCCCCCTTCATGAGGTC 
Pgc1a CAACATGCTCAAGCCAAACCAACA CGCTCAATAGTCTTGTTCTCAAATGGG 
m-cpt1 CAACTATTATGCCATGGATTTTGTGCTT CGATACATGATCATGGCGTGAACG 
Cte1 GCAGCCACCCCGAGGTAAA GCCACGGAGCCATTGATG 
Acox GGTGGACCTCTGTCTTGTTCA AAACCTTCAGGCCCAAGTGAG 
Mcad ACTTCGTGGCTTCGTCTAGA GAGCAGGTTTCAAGATCGCA 
Ppara ATGCCTTAGAACTGGATGACA GCAACTTCTCAATGTAGCCTA 
Lpl GCTGGAAAGTGCCTCCATTG CTGCTGGCGTAGCAGGAAGT 
Vldl-r TGACGCAGACTGTTCAGACC GCCGTGGATACAGCTACCAT 
Agpat1 CACCCAGGATGTGAGAGTCTG CTGACAACGTCCAGGCGAGG 
Agpat2 GCAACGACAATGGGGACCTG ACAGCATCCAGCACTTGTACC 
Gpat1 CTCGTGTGGGTGATTGTGAC AGCAAGTCCTGCGCTATCAT 
Gpat4  TGTCTGGTTTGAGCGTTCTG TTCTGGGAAGATGAGGATGG 
Cav1 CGGGAACAGGGCAACATCTA TGTGTCCCTTCTTTCTGC 
Atp Syn GTCCCGGGCTATTGCTGAGTTG TCCCCATGTGACCCGTGAAGA 
Pparg CCAGAGCATGGTGCCTTCGCT CAGCAACCATTGGGTCAGCTC 
Ap2 CAGAAGTGGGATGGAAAGTCG CGACTGACTATTGTAGTGTTTGA 
Fas TTCGGCTGCTGTTGGAAGTCAG ACCCACCCAGACGCCAGTGTTC 
Cd36 CAACCACTGTTTCTGCACTG CAGGCTTTCCTTCTTTGCAC 
CyloA AGCACTGGGGAGAAAGGATT CATGCCTTCTTTCACCTTCC 
Gapdh GGCATGGACTGTGGTCATGA ATGGGTGTGAACCACGAGAA 
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Supplementary Experimental Procedures 
RT-PCR: Tissue RNA was isolated (Qiagen RNeasy Lipid Tissues Kit), cDNA was 
synthesized (Applied Biosystems High Capacity cDNA RT Kit), and the reaction was 
performed using SYBR Green (Applied Biosystems) detection with specific primers 
(Table S4) with equal amounts of cDNA (10 ηg/reaction), and detected by a Taq-man 
thermocycler (BioRad). Results were normalized to cyclophilin A or gapdh and 
expressed as arbitrary units of 2-∆CT. 
Immunoblots: Total membrane fractions were equally loaded (70 µg) and 
electrophoresed on 10% SDS polyacrylamide gels, then transferred to PVDF membrane, 
blocked with 5% milk-TBST for 1h, incubated with primary antibody (1:1,000) anti-
ACSL1, phospho-AMPKα Thr172, or AMPKα primary antibody (Cell Signaling 
Technologies #4047, 2535, 2532 , washed, and incubated with secondary antibody 
1:10,000 (Cell Signaling Technologies, goat anti-rabbit). Protein was visualized with the 
Western Blot R-Probe Kit (Pierce).  
Histology: Tissue was fixed in 4% paraformaldehyde-PBS for 24 h, transferred to 70% 
ethanol, embedded in paraffin, serial sectioned, and stained with hematoxylin and eosin. 
Adipocyte size was quantified [149].  
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CHAPTER II (CONTINUED) 
B.5 Heart and ACSL1 Background 
 The heart is an organ responsible for supplying the body with nutrients, oxygen, 
hormones, and other circulating factors. The human heart beats an average of 72 times 
per minute and is required to sustain life.  The constant activity of the heart demands 
high levels of energy production. If the energy demands of the heart are not adequately 
supplied, due to a lack of oxygen or defects in cardiomyocyte metabolism, the heart may 
cease to perform and life cannot be sustained. Research has been focused on 
maintenance of heart function under challenged conditions, such as arrhythmia, cardiac 
hypertrophy, and cardiomyopathy, however, the metabolic underpinnings that are 
responsible for these conditions remain incompletely understood.  
 How is ACSL1 regulated in Heart? While acsl1 mRNA is the most abundantly 
expressed of all ACSL isoenzymes, all ACSL isoenzymes are expressed in adult rodent 
heart [83].  FATP1/ACSVL4 is expressed at low levels, whereas, FATP4/ACSVL5 and 
the heart-specific FATP6/ACSVL2 are the major ACSVL isoenzymes expressed in heart 
[25]. The regulation of ACSL1 has been investigated in adipose, muscle, and liver, but 
data are limited on the role and regulation of ACSL1 in the heart.  In primary 
cardiomyocytes, fatty acid exposure leads to increased intracellular lipid droplets and 
increased FA oxidation with simultaneous increases in mRNA expression of acsl1 [155]. 
In cardiomyocytes acsl1 is regulated by PPARα, a transcription factor that upregulates 
genes of fatty acid oxidation.  The promoter region of the acsl1 gene contains a PPAR 
response element (PPRE) that is similar to the PPRE of acyl-CoA oxidase, a key 
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enzyme in lipid peroxisomal oxidation [156, 157]. Acsl1 mRNA is upregulated when 
isolated cardiomyocytes are incubated with PPARα, but not PPARγ, agonists [6, 155, 
158].  Acsl1 mRNA in the heart of PPARα null mice is reduced 60%, showing that 
ACSL1 is mainly regulated by PPARα [159].  Because PPARα is a major regulator of FA 
oxidation genes such as carnitine palmitoyltransferase I and acyl-CoA oxidase, we 
postulate that ACSL1 is simultaneously upregulated by PPARα in order to provide the 
acyl-CoA substrate that these enzymes require for lipid oxidation and subsequent 
energy production. PPARα and PPARγ agonists supplemented to rat diet for 2 weeks 
increased acsl1 mRNA expression in adipose, liver, and skeletal muscle; however, the 
agonists did not elicit changes in acsl1 mRNA expression in heart [6].  In conclusion, 
ACSL1 mRNA expression is regulated in vitro by fatty acid exposure, PPARα agonists 
and insulin; however, its expression in vivo remains unchanged by fasting, high-fat 
feeding, and PPARα agonists [6].   
Table 2.5: ACSL1 regulation in Heart 
 
Acsl1 mRNA is also regulated by the estrogen-related family of transcription 
factors, (ERR) that coactivates with PGC1α and control the substrate shift from neonatal 
cardiomyocytes to adult cardiomyocytes. Knockout mouse models of two ERR 
isoenzymes (ERRα and ERRγ) result in reduced acsl1 mRNA expression coupled to 
reduced oxidative ability and ATP synthesis in the heart [160-162].  These data imply 
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that ERR is necessary for the expression of ACSL1 in heart and that without ERR the 
cardiomyocytes fail to mature into adult cardiomyocytes that use fatty acids as the 
primary substrate for ATP production.   
FA oxidation provides 60-70% of total energy for the heart. Intracellular TAG-
derived FA provide ~10% of energy requirements under normal conditions and the other 
50-60% is from extracellular circulating free FA and FA derived from lipase activity on 
circulating lipoproteins. However when the circulating fatty acid supply is limited, TAG-
derived FA can provide up to 50% of total energy requirements for the working heart 
[163].  The energy source preferred by the heart is controlled by substrate availability 
and transcriptional and hormonal regulation.  Rat neonatal cardiomyocyte exposure to 
glucose or FA leads to glycogen or TAG accumulation, respectively, indicating that 
substrate availability is the major regulator of uptake.  In vivo and in vitro, exposure to 
fatty acids, independent of glucose, leads to an increase in FA oxidation with a 
concomitant upregulation of acsl1 mRNA [155].  While the prenatal heart relies primarily 
on glucose for ATP, the adult heart relies on FA for ATP with the rates of FA oxidation 
increasing from day 0 to 60 in the rat heart [164].  Total ACSL activity is very low in the 
embryonic (E16.5) and neonatal heart but increases 90-fold and 6-fold in the adult heart, 
respectively. This transition matches the shift in substrate preference for glucose 
(prenatal heart) to fatty acids (adult heart) [5].  Furthermore, the developmental rise in 
ACSL activity from the embryonic heart to the adult heart correlates with the concomitant 
6-fold rise in the acsl1 without increases in acsl-3,-4, -5 or -6 mRNA expression [5].  
These increases in ACSL activity and acsl1 mRNA expression in heart correlate with 
increases in the heart workload, rates of ATP generation, oxidative preference for FA, 
and expression of the FA oxidative genes acyl-CoA oxidase and malonyl-CoA acyl 
dehydrogenase [5]. Together these studies imply that ACSL1 in heart is regulated by 
PPAR and ERR and that ACSL1 directs fatty acids towards oxidation in the heart.    
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The 11-fold overexpression of ACSL1 in the mouse heart is characterized by a 
lipotoxic cardiomyopathy and myocyte cell death associated with TAG and PL 
accumulation [165].  The 11-fold overexpression of ACSL1 increases fatty acid 
accumulation characterized by a 11-fold increase in myocardial TAG and 2-fold increase 
in myocardial phosphatidylcholine, implying that ACSL1 provides FA for complex lipid 
synthesis in heart.  However, because the authors did not measure rates of FA 
oxidation, FA uptake, or acyl-CoA accumulation, it is unknown if oxidation was altered by 
ACSL1 overexpression.  We hypothesize that ACSL1 provides FA for oxidative 
metabolism but does not regulate the rate of oxidation; therefore, the overexpression of 
ACSL1 in heart may increase the acyl-CoA substrate for oxidation without an increase in 
the demand for oxidation resulting in the accumulation of acyl-CoA, some of which may 
be stored as TAG and PL.   Excessive accumulation of acyl-CoA, along with other lipid 
intermediates, may activate signaling pathways and/or increase oxidative stress causing 
cell death (lipotoxicity) and excessive cell death can lead to cardiomyopathies 
characterized by cell death, fibrotic activity, and cardiac dysfunction.  It is also possible 
that the oxidative rate was increased in the ACSL1-heart specific overexpressing mice 
and that the accumulation of toxic lipid oxidation byproducts led to a state of oxidative 
stress that resulted in the death of cardiomyocytes. Without knowing the changes in 
oxidation of the ACSL1-heart overexpressing mouse it is difficult to determine the true 
role of ACSL1 in heart and the cause of the cardiomyopathy.  A similar model of 
cardiomyocyte lipotoxicity with the accumulation of TAG and PL occurs in the heart-
specific 8-fold overexpression of FATP1/ACSVL4, an ACSVL that is not highly 
expressed in heart.  Cardiac FATP1 overexpression increased rates of FA uptake 4-fold 
and rates of fatty oxidation 2-fold [166].  On the other hand, the FATP1 null mouse has 
normal heart function, thus the lack of a cardiac phenotype in the FATP1 null mice 
invalidates interpretations made about its function from the overexpression of FATP1 in 
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heart [82].   FATP6/ACSVL2 is a heart specific FATP/ACSVL, yet little is known about its 
role in the heart [167].  The overexpression of ACSL1 by 11-fold and FATP1 by 8-fold in 
the heart likely led to non-endogenous subcellular location of these membrane-
associated enzymes, to the accumulation of “lipotoxic” acyl-CoA, and limited the cellular 
regulatory mechanisms (i.e. phosphorylation, acetylation, and protein-protein interaction) 
on the excessive abundance of these proteins.  
 
B.6 Fatty Acid Oxidation in the Heart  
Because of the new-found role for ACSL1 in providing acyl-CoAs for FA 
oxidation in adipose (Aim 1 and Aim 2), the following sections will describe the 
oxidative pathway in context to the heart and how defects in oxidation affect 
cardiac outcomes. Our understanding of oxidative pathways has expanded over the 
past century since beta-oxidation was first theorized in 1904.  However, many questions 
remain regarding regulation of the oxidative pathway and the consequences of 
dysregulation.  For the oxidation of fatty acids, three different pathways are known; 
alpha-, beta-, and omega-oxidation.  β-oxidation for long-chain fatty acids occurs in the 
mitochondria and for very-long chain fatty acids occurs in peroxisomes. β-oxidation is 
the most predominant oxidative pathway in the heart, whereas the less predominate 
pathways of α-oxidation of phytanic acids and ω-oxidation of medium to very-long chain 
fatty acids occur at the endoplasmic reticulum.  For β-oxidation, cellular FA must first 
enter the mitochondria.  Entry requires the FA to be converted to an acyl-CoA by an 
acyl-CoA synthetase, after which the CoA is exchanged for a carnitine molecule by the 
enzyme carnitine-palmitoyl transferase-one (CPT I) located on the outer mitochondrial 
membrane.  CPT1 is allosterically inhibited by malonyl-CoA and is currently considered 
the major regulator of the rate of FA oxidation.  Acyl-carnitines cross mitochondrial 
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membranes via the carnitine-acyl-carnitine translocase (CACT).  Once inside the 
mitochondria, CPT II exchanges the carnitine for a CoA to re-create an acyl-CoA within 
the mitochondria. The acyl-CoA is then subject to beta-oxidation, a process that consists 
of 4 reactions constituting one cycle that removes 2 carbons from the acyl chain per 
cycle. The first reaction of the cycle is performed by an acyl-dehydrogenase which exists 
in 4 isoforms that together allow the complete metabolism of nearly all chain-length fatty 
acids. These 4 isoforms are named: short-chain, medium-chain, long-chain, and very 
long-chain acyl-CoA dehydrogenases (SCAD, MCAD, LCAD, and VLCAD, respectively).  
The 2 carbon acetyl-CoA that is removed by each cycle of beta-oxidation enters the citric 
acid cycle for complete oxidation.   
 Fatty acid oxidation in hypertrophy. Fatty acids are the major source of energy 
production for the heart [168, 169].  Fatty acid oxidation is reduced while glucose 
oxidation is increased in hypertrophic hearts. Hypertrophy of the heart occurs due to 
increased cell size of cardiomyocytes.  On one hand cardiac hypertrophy is considered 
compensatory and protective in athletes and pregnant women. Hypertrophy that occurs 
in athletes does not negatively alter heart function, structure, or metabolism. On the 
other hand cardiac hypertrophy was found to be a Framingham risk factor for heart 
failure and arrhythmia. Hypertrophy that occurs due to causes such as; hypertension, 
obesity, valuvar heart disease, and mutations in genes of contractile function; results in 
altered contractility, systolic/diastolic dysfunction, and a shift towards glycolytic 
metabolism.  In the latter case hypertrophy is accompanied by the re-induction of the 
fetal gene program. The fetal heart uses glucose as the primary oxidative substrate. It is 
unknown if the shift in oxidation, from lipolytic to glycolytic, is causal or consequence of 
ensuing cardiac hypertrophy. In the Framingham heart study, left ventricular hypertrophy 
(LVH) was identified in ~18% of the population and in ~42% of the population over the 
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age of 70 [170]. The LVH was independently associated with increasing age, blood 
pressure, obesity, valve disease, and myocardial infarction [170].  LVH in the 
Framingham population was also associated with increasing BMI, skinfold thickness, 
and blood pressure [171].  
 Impaired fatty acid oxidation: Cause or consequence of hypertrophy? It has 
remained unclear whether the shift in oxidation from lipolytic to glycolytic, is a cause or a 
consequence of hypertrophy.  The conclusion that cardiac hypertrophy can result from 
reduced FA oxidation is supported by several mouse models with genetically or 
chemically impaired FA oxidation.   
Figure 2.9. Does cardiac pathological hypertrophy occur independent of metabolic 
shift or does the metabolic shift cause hypertrophy?   
 
 Models of energy imbalance and cardiac hypertrophy. A number of studies 
have focused on mouse models of energy imbalance in the heart.  Most have induced 
hypertrophy by stress/ischemia or pressure overload and shown that the heart reverts to 
a fetal program with increased uptake and oxidation of glucose.  Under these conditions, 
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FA oxidation is down-regulated, as are the mRNA levels of PPARα and other genes 
required for FA oxidation like MCAD, MCD, mCPT1 and the peroxisomal gene AOX 
[172].  On the other hand, most animal models with deficiencies in the genes required for 
FA oxidation develop cardiac hypertrophy with a reversion of gene expression to a “fetal” 
state [173]. These genes encode for proteins involved in the conversion of acyl-CoAs to 
acyl-carnitines, transport of the acyl-carnitines into the mitochondrial matrix, and 
enzymes required for β-oxidation.  
 Impaired carnitine transporters and cardiac outcomes. The oxidation of FA 
depends on the transport of carnitine into cells by several carnitine transporters, OCTN1 
(SLC22A4), OCTN2 (SLC22A5) and OCT6 (SLC22A16) [174].  In humans, defects in 
the Na+-carnitine co-transporter (OCTN2) cause a cardiomyopathy characterized by 
cardiac lipid accumulation and hypertrophy. The cardiomyopathy improves with carnitine 
supplementation in older patients [175] .  The juvenile visceral steatosis mouse mimics 
this human defect of systemic carnitine deficiency because of a spontaneous KO of 
OCTN2, resulting in cardiac lipid accumulation and hypertrophy and a 2-fold increase in 
cardiac mitochondria [176] with preserved respiratory chain enzyme activities [177, 178].  
However, despite increased mitochondrial content, adenine nucleotides were only 60% 
of that in control hearts suggesting an energy deficit.  Treatment with L-carnitine 
improved and treatment with L-carnitine plus a PPARα agonist further improved LV 
function and the survival rate of the JVS mice, suggesting that at least part of their 
problem was a deficiency in PPARα function in addition to impaired FA oxidation [179].   
The heart expresses two CPT isoforms: L-CPT1 and M-CPT1.  Human 
deficiencies have been identified; however, patient clinical features are variable.  In rats, 
chemical inhibition of both CPT1 isoforms causes cardiomyocyte hypertrophy with a 
25% increase in heart weight [180].  A mouse KO of the L-CPT1 is not viable, and 
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although the heterozygotes had a 50% decrease in CPT1 activity in liver, they showed 
no hepatic steatosis or heart abnormality, likely due to the relatively low expression of L-
CPT1 in heart [181].  Similarly, the homozygous KO of the M-CPT1 was an embryonic 
lethal before E9.5-11.5 and the heterozygote had a 50% decrease in activity in heart, 
however the authors did not examine heart-specific changes in energy metabolism or 
histology [182].  The transport of acyl-carnitine into the mitochondrial matrix (and 
transport of carnitine out) requires CACT, and humans with CACT deficiency have early-
infant death and develop cardiorespiratory problems [183].  It was thought that an 
accumulation of “toxic” long-chain acyl-carnitines might be the major problem [183].   In 
one report of an infant who succumbed to a cardiac tachyarrhythmia had a marked 
accumulation of lipid droplets in the myocardium, liver, and kidney, and a “virtually 
complete elimination of mitochondria from cardiomyocytes” [184].  Thus a deficiency in 
CACT is lethal at least in part due to cardiac dysfunction.  CPT-II converts acyl-
carnitines in the mitochondrial matrix back to acyl-CoAs to undergo β-oxidation.  Human 
deficiency of CPT-II is autosomal recessive and results in a severe deficit of energy 
metabolism [185].  No animal models of CPT-II deficiency have been reported.  In 
conclusion, carnitine deficiency at the cellular or mitochondrial level results in, often 
lethal, cardiomyopathies characterized by cardiac lipid accumulation, mitochondrial 
biogenesis, and hypertrophy.  
 Impaired fatty acid oxidation at the mitochondria and cardiac outcomes. It 
is interesting that L-CPT1, M-CPT1, and CACT all result in lethality or early life-
threatening disease whereas a defect in one of the dehydrogenase enzymes of β-
oxidation does not.  Humans with deficiencies in medium-chain acyl-CoA 
dehydrogenase (MCAD) and long-chain acyl CoA dehydrogenase (LCAD) have reported 
dilated and hypertrophic cardiomyopathies [186].  In mouse models that lack MCAD and 
78 
 
LCAD, the heart phenotypes have not been extensively studied. VLCAD knockout mice 
are resistant to high-fat diet induced obesity [60].  The authors suggest that resistance to 
obesity in VLCAD-KO mice is due to the excess of acyl-CoAs that activate AMPK and 
increase rates of FA oxidation. In patients with VLCAD deficiencies, two clinical 
syndromes were reported, a milder form with hypoketotic hypoglycemia and a severe 
syndrome with early death and a hypertrophic cardiomyopathy [187].  VLCAD knockout 
mouse hearts have an accumulation of microvesicular lipid, marked mitochondrial 
proliferation, and cardiac hypertrophy [188].  VLCAD-KO mice had ventricular 
tachycardias and their cardiomyocytes had increased levels of cardiac ryanodine 
receptor 2, phospholamban, and calsequestrin with increased [3H]ryanodine binding in 
heart microsomes plus altered Ca2+ dynamics [189].  A mouse defective in the beta-
subunit of the mitochondria trifunctional protein (MTP or Hadhb), the enzyme that 
catalyzes the last three steps of the 4-step beta-oxidation cycle after the acyl-
dehydrogenases, had reduced MTP activity presenting with cardiac arrhythmia and 
sudden death between 9 and 16 months of age.  Histology showed multifocal cardiac 
fibrosis but lipid droplets or mitochondrial changes were not reported.  In conclusion, 
deficiencies in the one enzyme of mitochondrial fatty acid oxidation is not early lethal, 
but result in cardiomyopathies characterized with lipid accumulation and hypertrophy. 
Thus, defects in mitochondrial FA oxidation initiate the development of cardiac 
hypertrophy.  
 Impaired respiratory chain activity and cardiac outcomes. Normal function of 
the respiratory chain is critical for FA oxidation.  Humans with deficiencies in respiratory 
chain complexes show cardiac hypertrophy [190-193] or dilated cardiomyopathy [186, 
193].  After 2 weeks of age, mice with a heart-specific defect in mitochondrial 
transcription factor A (Tfam) had progressively decreasing rates in respiratory chain 
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enzyme activities and rates of mitochondrial ATP production [194].  In heart-specific 
Tfam-KO mice, mitochondrial DNA became depleted and the mice died between 10-12 
weeks of age  [172].  In Tfam-deficient hearts, mitochondrial mass increased late in the 
progression, but ATP production was not improved by the increased mitochondrial 
biogenesis.  In fact, the authors suggested that the “observed switch in metabolism is 
unlikely to benefit energy homeostasis in the respiratory chain-deficient hearts and 
therefore likely aggravates the disease. It can thus be concluded that at least some of 
the secondary gene expression alterations in mitochondrial cardiomyopathy do not 
compensate but rather directly contribute to heart failure progression” [194].  Similar 
findings are present in people with mitochondrial myopathies, usually caused by defects 
in OX/PHOS genes; and these patients present with a range of symptoms often 
including muscle weakness and multi-system degeneration [195].  Such people have 
increases in mtDNA transcripts and nuclear OXPHOS gene transcripts and a variety of 
related genes involved in energy metabolism [192].  These changes suggest that tissues 
are attempting to compensate for the OXPHOS defects by stimulating mitochondrial 
biogenesis.  Related to OX/PHOS function, a knockout of the heart/muscle isoform of 
the adenine nucleotide translocator (Ant1) resulted in cardiac hypertrophy with 
mitochondrial proliferation.  ANT transports ATP from the mitochondria into the cytosol in 
exchange for ADP [196].  In conclusion, these data suggest that defects in oxidative 
phosphorylation result in cardiac hypertrophy due to defective energy production, 
despite increased mitochondrial biogenesis.  
 FA availability for heart and cardiac outcomes. FA availability for oxidation 
influences heart energy metabolism in normal and diabetic hearts.  In this regard, the 
heart–specific deficiency of lipoprotein lipase (LPL) induced in mice at 8 weeks of age 
results in a virtually absent uptake of FA hydrolyzed from VLDL-TAG and overall FA 
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oxidation rates are reduced 50% [197].  The heart-specific LPL deficient mice develop 
cardiac hypertrophy and a 50% decline in fractional shortening.  Acute deletion of 
cardiac lipoprotein lipase forces the heart to increase glucose uptake and oxidation, 
decrease FA uptake and oxidation, and eventually leads to decreased ejection fraction 
and cardiac hypertrophy indicating that lack of exogenous FA was severely detrimental 
to heart function [197, 198].  The deficiency of CD36/FAT, a plasma membrane protein 
that enhances FA uptake into cells, reduces free FA uptake into the heart by 50% but 
does not affect FA oxidation at the mitochondria [199].  CD36 null mice have enlarged 
hearts and impaired recovery from ischemia that is rescued by the addition of medium 
chain fatty acids, suggesting that fatty acid metabolism is critical for ischemia-
reperfusion recovery [200].  These data suggest that diminished uptake of FA by the 
heart in CD36 null mice does not heavily impact heart function but diminished uptake of 
FA from circulating lipids, as in the LPL deficient hearts, leads to heart dysfunction.  
Thus, it appears that the uptake of extracellular FA is critical below a threshold.  
Table 2.6. Genetic deficiencies and resulting cardiac outcome. 
Gene Function Cardiac Outcome 
OCTN1 Carnitine transporter Hypertrophy, lipid accumulation 
CPT1-inhibitors Acyl-carnitine transferase Hypertrophy 
CACT Carnitine transporter Cardiomyopathy, lipid accumulation 
MCAD FA oxidation Hypertrophy, lipid accumulation 
VLCAD FA oxidation Hypertrophy, lipid accumulation, mitochondrial 
excess 
MTP FA oxidation Arrhythmia 
OX/PHOS Electron transport chain Hypertrophy, mitochondrial excess 
ANT1 ATP transporter Hypertrophy, mitochondrial excess 
LPL Endothelial Lipase Hypertrophy 
CD36 FA uptake/oxidation Impaired ischemia recovery 
  
 The FA entering the cardiomyocytes must be “trapped” within the cell via 
activation with a CoA or by binding to carrier proteins. For example, the heart-specific 
fatty acid binding protein, H-FABP, knockout mouse has 80% reduction in heart FA 
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uptake with a concomitant 80% increase in glucose uptake. The H-FABP knockout 
mouse has cardiac hypertrophy and exercise intolerance possibly due to reduced rates 
of FA oxidation, however, FA oxidation was not assessed  [201]. The cardiac-restricted 
knockout of PPARδ in mouse results in decreased FA oxidation and hypertrophy of the 
heart [202]. While several signaling mechanisms have been linked to the induction 
of pathological hypertrophy; the mechanisms that lead hypertrophied hearts to 
fail remain unknown.  
 Energy insufficiency in cardiac hypertrophy. The metabolic shift from FA 
oxidation towards increased glucose oxidation in the hypertrophic heart may ultimately 
result in reduced energy production.  Reductions in heart phosopho-creatine/ATP ratios 
correlate with severity of heart failure [203].  However, whether cardiac energy demands 
are adequately met by increased rates of glucose oxidation in the hypertrophy state 
remains to be established. The activity of AMPK, due to a rise in the AMP/ATP ratio, is 
associated with cardiac hypertrophy [204].  Increased AMPK activity suggests that the 
increased rates of glucose oxidation are either mediated through increased AMPK 
activity, or that glucose oxidation does not supply sufficient ATP to prevent the activation 
of AMPK.  AMPK activity has been shown to increase both FA and glucose uptake and 
oxidation; therefore it is not likely that AMPK is the mechanism by which glucose 
oxidation is preferentially increased in the hypertrophic heart. It is also unclear whether 
insufficient energy production is a causal factor in hypertrophy-related heart failure.  
However, heart failure does correlates with reductions in mitochondrial respiratory chain 
protein content and activity [205].  The mitochondrial dysfunction seen in heart failure is 
postulated to be due to oxidative stress and not due to changes in gene expression; 
however, the mechanism of increase in oxidative stress by increased glucose oxidation 
remains unclear.  Furthermore, studies show that mitochondrial function in hypertrophied 
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hearts prior to heart failure is not impaired suggesting that mitochondrial dysfunction 
occurs in late stage heart failure [206].   
 Lipid Intermediates and signaling. Ventricular hypertrophy occurs in obese 
individuals and in these patients it is associated with myocardial lipid accumulation.  
Fatty heart is correlated with congestive heart failure and diabetes and is found in some 
mouse models of cardiac hypertrophy [207].  Cellular lipids accumulate in the form of 
triacylglycerol in intracellular lipid droplets.  Triacylglycerol itself is not thought to be a 
lipotoxic molecule; however, the precursors for TAG synthesis have been shown to 
mediate cellular signaling pathways.  Lipotoxicity is a term that refers to cell death due to 
the accumulation of lipids and lipid by-products and is a postulated mechanism for 
cardiac failure.  Acyl-CoAs are the first molecule formed for the synthesis of TAG and 
the accumulation of lipids can lead to a rise in cellular acyl-CoAs, such as palmitoyl-CoA.  
Palmitoyl-CoA can condense with serine to form the molecule ceramide. Ceramide, in 
turn, may induce apoptosis by activating stress signals and/or upregulating inducible 
nitric oxide synthase.  Another lipid intermediate is lysophosphatidic acid (LPA) which is 
an intermediate of complex lipid synthesis that is a known mediator of cellular signaling.  
In cardiomyocytes, LPA increases cell size and the expression of ANF, a hypertrophy 
marker.  LPA has also been shown to stimulate the phosphorylation of Akt and the 
expression of p65 and NF-κΒ; whereas, the inhibition of PI3K, mTOR, and NF-κΒ 
prevented LPA-induced expression of ANF [208].  These data suggest that the lipid 
intermediate LPA may play a role in the signaling that mediates cardiac cell growth.  
Diacylglycerol (DAG) is another lipid intermediate known to activate protein kinase C 
(PKC) [209].  Cellular DAG levels are increased in response to signaling through the 
hypertrophic-inducing Gq protein-coupled receptor agonists angiotensin II, endothelin 1, 
and phenylephrine.  PKC regulates numerous cellular functions including cell growth and 
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differentiation and PKC plays an important role in the development of cardiac 
hypertrophy and the progression to heart failure, thus DAG may mediate PKC signaling 
and cardiac function [210-212].  Additionally, DAG can be converted to phosphatidic acid 
(PA) by one of the eleven DAG kinase isoforms.  PA has also been shown to act as a 
lipid second messenger by regulating PKC and phospholipase C isoforms that may be 
involved in mediating hypertrophic signaling [213], [214].  Thus, in models of increased 
cardiac lipid accumulation a rise in cellular lipid intermediates such as acyl-CoA, LPA, 
PA, and DAG could be expected. These lipid intermediates could thus act as ligands or 
second messengers that mediate the cellular signaling involved in the development of 
cardiac hypertrophy and heart failure.  
 Glycolytic intermediates and signaling. Glycolytic enzymes are associated 
with the sarcolemma and the sarcoplasmic reticular membranes, where the ATP 
generated by glycolysis is thought be important for supporting the activity of ion pumps 
and channels that regulate excitation-contraction coupling [215, 216].  The ATP 
generated by glycolytic metabolism may also be particularly important for maintaining 
intracellular Ca2+ homeostasis during ischemia-reperfusion potentially due to the 
anaerobic nature of glycolysis and due to the proximity of glycolytic enzymes to Ca2+ 
channels [217].   Glycolytic metabolism may play a regulatory role in Ca2+ homeostasis 
through direct interaction of glycolytic intermediates with Ca2+ channels.  The ryanodine 
receptor/Ca2+-release channel has increased activity due to exposure to glycolytic 
intermediates [218].  While direct interaction of glycolytic intermediates has not been 
shown, studies reveal that the intermediates are critical in regulating Ca2+ flux especially 
in conditions of low ATP supply potentially by serving as precursors to ATP synthesis at 
the sarcolemma [219].  These data suggest that cardiac glycolysis and glycolytic 
intermediates may serve as an energy source and regulator for Ca2+ homeostasis.   
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 Glucose stimulates S6K phosphorylation in isolated working mouse hearts, 
indicating that increased glucose catabolism activates mTOR [220]. Further, in 
cardiomyocytes that are exposed to 2-deoxyglucose, which is converted to 2-
deoxyglucose-6-phophate but not further metabolized, S6K is phosphorylated, whereas 
exposure to 3-O methylglucose, which cannot be converted to methylglucose-6-
phosphate, does not phosphorylate S6K [220]. These data suggest that an increased 
glycolytic flux stimulates mTOR and that the shift to glycolytic metabolism causes 
cardiac hypertrophy. Potentially, the increase in glycolytic activity can induce 
hypertrophy and may lead to imbalances in Ca2+ homeostasis that influence heart 
failure. 
 
Figure 2.10. Potential mechanisms linking substrate metabolism to cardiac 
hypertrophy. Cardiac hypertrophy can occur due to mTOR activation. mTOR is 
predicted to be activated by many cellular signals including insulin signaling, glycolytic 
intermediates, lipogenic intermediates, and protein kinase C. It remains unclear how a 
shift away from FA oxidation would activate mTOR.  
 
FA
Acyl-CoA
LPA
PA
DAG
AMPKPLC
PKC
Glucose
Pyruvate
Cell death
Ca+2
Ceramide
mTOR
TAG β-oxidation
ATP
G-6-P
FA Glucose
S6K
Cell growth
Mitochondrial biogenesis
Fetal genes
PDK1
Akt
BCAA
Insulin
P
P
P
P
 
 
 
 
 
 
 
 
CHAPTER IV 
THE ROLE OF ACSL1 IN CARDIAC METABOLISM AND FUNCTION 
 
 The aim 1 and 2 manuscript focused on the role of ACSL1 in adipocyte 
metabolism of adipose-specific ACSL1 knockout mice, Acsl1A-/-.   ACSL1 is the major 
ACSL isoenzyme expressed in adipose tissue where the primary fate of FA is storage as 
TAG, but ACSL1 is also the major ACSL isoenzyme in heart where the primary fate of 
FA is oxidation. The next chapter focuses on the cardiac-related phenotype of a multi-
tissue tamoxifen-induced ACSL1 knock out mouse, Acsl1T-/-.  The data that follows also 
suggests that ACSL1 activates FA for oxidation in heart. These studies show that the 
reduction in FA oxidation causes cardiac hypertrophy through the activation of mTOR.  
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Mouse cardiac acyl-CoA synthetase-1 deficiency impairs fatty acid oxidation and induces 
hypertrophy and mitochondrial biogenesis. 
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Abstract 
Acyl-CoA synthetase isoform-1 (ACSL1) catalyzes the synthesis of acyl-CoA from long 
chain fatty acids and contributes the majority of long-chain acyl-CoA synthetase activity in 
the heart.  To understand its functional role in heart, we studied mice lacking ACSL1 under 
temporal control (Acsl1T-/-).  Compared to littermate controls, heart ventricular ACSL activity 
was reduced more than 90%, acyl-CoA content was 65% lower, and long-chain acyl-
carnitine content was 80-90% lower.  The rate of [14C]palmitate oxidation in heart 
homogenate and mitochondria was 90% lower than in controls, and maximal [14C]pyruvate 
and [14C]glucose oxidation were each 20% higher.  Compared to controls, Acsl1T-/- hearts 
were hypertrophied, and the mitochondrial area was 54% greater than controls with twice as 
much mitochondrial DNA.  The phosphorylation of S6 kinase, a target of mTOR kinase, 
increased 5-fold in Acsl1T-/- hearts, and the mRNA abundance of Pgc1α and Errα, increased 
by 100% and 41%, respectively; these S6K targets induced mitochondrial biogenesis.  Our 
data suggest that ACSL1 is required to synthesize the acyl-CoAs that are oxidized in the 
heart, and that without ACSL1, diminished FA oxidation and compensatory catabolism of 
glucose and amino acids leads to mTOR activation, cardiac hypertrophy, and mitochondrial 
biogenesis without lipid accumulation or immediate cardiac dysfunction. 
 
Keywords: oxidation, cardiac hypertrophy, acyl-CoA, mitochondrial biogenesis, mTOR 
Non-standard Abbreviations and Acronyms: ACSL, long-chain acyl-CoA synthetase; ASM, 
acid soluble metabolites; FA, fatty acid; PC, phosphatidylcholine; PL, phospholipid; TAG, 
triacylglycerol; mTOR, mammalian target of rapamycin. 
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Introduction 
Under fasting conditions 60 to 90% of heart ATP is provided by the mitochondrial oxidation 
of long-chain fatty acids (FA) [53, 221, 222].  Reduced cardiac FA oxidation and increased 
glucose utilization are a proposed consequence of pathological left ventricular hypertrophy 
(LVH) [223, 224].  However, when genes that encode enzymes of FA oxidation are knocked 
out in mice, LVH develops [225-228].  Thus, it remains unclear whether the shift in substrate 
use is a cause or consequence of cardiac hypertrophy and whether the increased use of 
glucose interferes with cardiac function. 
 ACSL isoenzymes convert FA to acyl-CoA in an ATP-dependent manner, 
simultaneously activating and trapping FA within cells [229].  Activation to acyl-CoA is 
required before FA can be either oxidized to provide ATP or esterified to synthesize 
triacylglycerol (TAG) or membrane phospholipids (PL).  The activation of FA is catalyzed by 
one of a family of 5 long-chain acyl-CoA synthetases (ACSL), ACSL1, ACSL3, ACSL4, 
ACSL5, and ACSL6, which differ in substrate preference, enzyme kinetics, subcellular 
location, and tissue-specific expression [24].  Because amphipathic acyl-CoAs can move 
freely within a membrane monolayer or be transported to distant membranes, all acyl-CoAs 
should, theoretically, be metabolically equivalent, no matter which ACSL isoenzyme 
catalyzes their formation and no matter which subcellular organelle is the site of their 
synthesis.  Yet, both loss-of-function and gain-of-function studies suggest that each ACSL 
isoenzyme has a distinct function in directing acyl-CoAs to one or more specific downstream 
pathways [16, 34, 36]. 
 Although FA provide the major substrate for oxidation in heart, it is unknown whether 
ACSL activity affects FA oxidation rates or whether a particular ACSL isoenzyme activates 
FA destined for oxidation.  Total ACSL activity of mouse embryonic (E16.5) heart increases 
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14-fold during the week after birth and 90-fold by adulthood [5].  This dramatic increase in 
ACSL activity parallels the transition of the developing heart’s substrate preference from 
glucose prenatally to FA after birth.  In mice, this transition is accompanied by a 6-fold 
increase in Acsl1 mRNA abundance and a >90% decrease in the mRNA abundance of 
Acsl3, the predominant Acsl1 in fetal heart [5].  In rats the increase in ACSL activity and 
Acsl1 mRNA expression parallels the postnatal heart’s increased workload, rate of ATP 
generation, oxidative preference for FA, and expression of FA oxidative genes [230].  
Together, these data suggested that ACSL1 might be the major activator of the FA that are 
oxidized in postnatal cardiac tissue.   
 In order to understand the relationship between cardiac substrate use and 
hypertrophy, we created a mouse model that lacks acyl-CoA synthetase-1 (ACSL1) in 
multiple tissues, including heart.  We reasoned that the absence of ACSL1 would enable us 
to learn whether a block in FA activation prevents potential lipotoxicity and abnormal heart 
function, and to determine the mechanism by which a shift in substrate use from FA to 
glucose causes cardiac hypertrophy.   
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Results 
Cardiac ACSL activity and acyl-CoA content are reduced in mice that lack ACSL1 
Mice with Loxp sequences inserted on either side of exon 2 in the Acsl1 gene were 
backcrossed to the C57Bl/J6 strain six times [78], and then interbred with mice in which Cre 
expression, driven by chicken β-actin and cytomegalovirus enhancers, can be induced by 
tamoxifen (B6.Cg-Tg(CAG-cre/Esr1)5Amc/J; Jackson Labs, Bar Harbor, MA) to generate 
tamoxifen-inducible multi-tissue Acsl1 knockout mice (Acsl1T-/-).  Tamoxifen was injected i.p. 
(3.5 mg/kg body wt) for 4 consecutive days when mice were 6-8 weeks old.  Control 
littermates, which were also injected with tamoxifen, lacked the Cre gene (Acsl1flox/flox).   
 Compared to liver, kidney and adipose, the largest and most persistent reduction in 
total ACSL enzyme activity and ACSL1 protein was observed in Acsl1T-/- hearts (Figure 1A, 
B, S1A, B).  Ten weeks after tamoxifen was injected, total ACSL activity in heart ventricles 
was 97% lower than controls (Figure 1A).  The ACSL activity that remained in tissues was 
probably due to other ACSL isoenzymes, to residual ACSL1 activity in cells that had not 
been exposed to tamoxifen, or in liver, to hepatocytes that metabolize tamoxifen.  The 
appearance, histology, and weights of the liver and adipose tissue did not differ between 
genotypes (Table 2; data not shown).  Two weeks after the tamoxifen injection, heart Acsl1 
mRNA was nearly absent but 40% of ACSL1 protein remained (Figure 1B), suggesting that 
the half-life of ACSL1 may be as long as two weeks.  By ten weeks after tamoxifen, virtually 
no ACSL1 protein was present.   Other differences between the two time points included 
37% lower Acsl1T-/- TAG and 2.5-fold higher FA concentrations in plasma, compared to 
controls at two weeks, but not at ten weeks after tamoxifen.  In Acsl1T-/- hearts, loss of 
ACSL1 reduced the total pool of long-chain acyl-CoAs by 65% (Figure 1D), with 67-75% 
reductions in 16:0-, 16:1-, 18:1-, 18:2-, and 18:3-CoA species and a 26% reduction in 18:0-
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CoA (Figure 1E).  Expressed as a percentage of total acyl-CoA content, 18:0-CoA was 
twice as high in Acsl1T-/- hearts as in controls, and all other species except 16:0 were 
reduced ~20% (Figure S1C).  Thus, aside from the relative increase in 18:0-CoA, lack of 
ACSL1 did not markedly change the FA composition of the acyl-CoA pool.  These data 
indicate that ACSL1 is the major activator of long-chain FA in the heart, and that the 
knockdown of Acsl1 was virtually complete and persistent in cardiac tissue for as long as 10 
weeks.  Despite the 65% reduction in long-chain acyl-CoA content in Acsl1T-/- hearts, total 
cardiac TAG content did not change, suggesting that ACSL1 does not limit the acyl-CoA 
pool used for the synthesis of TAG (Figure 1F).  
ACSL1 is required for heart FA oxidation 
To determine whether ACSL1 provides acyl-CoAs for FA oxidation, we assessed the rates 
of [1-14C]palmitate incorporation into CO2 and ASM, which are measures of complete and 
incomplete oxidation, respectively.  Compared to controls, the rate of maximal FA oxidation 
in Acsl1T-/- heart homogenates was 95% lower (Figure 2A).  Thus, the absence of ACSL1 
nearly abolished FA oxidative capacity.  In contrast, in Acsl1T-/- liver, in which ACSL1 protein 
and activity remained similar to that of controls (Figure S1A,B), the rate of [1-14C]palmitate 
oxidation was unchanged (Figure 2A).  The oxidation rates for the ACSL1 product [1-
14C]palmitoyl-CoA  were similar between genotypes (Figure 2B), indicating that CPT1-
mediated transport of acyl-CoA into the mitochondria and its subsequent oxidation to CO2 
was unimpaired and that the severe block in FA oxidation in Acsl1T-/- hearts was due to the 
lack of FA activation.  
 
 The 95% lower rates of FA oxidative capacity in Acsl1T-/- heart homogenates strongly 
suggested that ACSL1 activates the pool of FA that is directed towards mitochondrial 
oxidation.  This interpretation is further supported by the presence of residual ACSL1 in 
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purified heart mitochondria two weeks after tamoxifen was injected (Figure 2C).  At that 
time, when ~40% of ACSL1 protein still remained, [1-14C]palmitate oxidation in Acsl1T-/- heart 
mitochondria was 40% lower than in controls (Figure S1D); however, 10 weeks after 
tamoxifen, when ACSL1 protein was absent, [1-14C]palmitate oxidation was 90% lower than 
in controls (Figure 2D).  These data showing that the rate of FA oxidative capacity and the 
amount of ACSL1 protein decreased in parallel, support the idea that ACSL1 is required to 
activate cardiac FA before they can be oxidized.  
 
 Cellular acyl-carnitines are markers of metabolite flux through degradative and 
oxidative pathways [136].  In Acsl1T-/- cardiac tissue, total free carnitine was 77% higher than 
in control hearts, indicating that carnitine was not limiting (Figure 2E), whereas acetyl-
carnitine was 51% lower, consistent with reduced mitochondrial acetyl-CoA levels (Figure 
2F).  Confirming the impaired FA oxidation, nearly all medium-chain (8 to 12 carbons) acyl-
carnitine species in Acsl1T-/- hearts were 60-80% lower than in controls (Figure 2G), and 
long-chain acyl-carnitines were 80-90% lower (Figure 2H).  Total cholesteryl ester and 
diacylglycerol were reduced ~20% in Acsl1T-/- hearts, but total PL and TAG were unaffected 
(Figure S2A,B,C).  Because the content of PL and TAG was normal in Acsl1T-/- hearts, but 
the abundance of nearly all acyl-carnitine species was reduced ~90%, it appears that 
ACSL1 activity does not affect the synthesis of acyl-CoAs used in the pathways of PL and 
TAG synthesis, but, instead, specifically provides the acyl-CoAs required for FA oxidation.  
  
Pathological cardiac hypertrophy and mitochondrial biogenesis in the Acsl1T-/- mice 
Compared to controls, the weights of Acsl1T-/- female and male hearts as a percent of body 
weight were 23% and 17% greater, respectively (Figure 3A).  Cardiomyocyte area was 27% 
larger than controls (Figure 3B), and ventricular walls appeared thickened (Figure 3C). 
Echocardiography confirmed that Acsl1T-/- ventricular walls were 10-41% thicker than 
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controls (Table 1) with a 34% heavier left ventricular mass (Figure 3D).  Analysis also 
showed that the Acsl1T-/- left ventricular inner diameter was ~30% smaller than controls, 
suggesting concentric ventricular hypertrophy (Table 1).  Despite LVH, the percent fractional 
shortening and ejection fraction were similar to controls, indicating that cardiac function 
remained normal for at least 2 months after the ablation of Acsl1 (Figure 3E,F and Table 1). 
 Upregulation of fetal genes occurs with pathological hypertrophy [231], thus, the 4- to 
5-fold higher mRNA expression of the fetal genes, α-skeletal actin and brain natriuretic 
peptide, together with the 6-fold upregulation of Acsl3, the major Acsl mRNA expressed in 
fetal heart [5] (Figure 1C), is compatible with  pathological hypertrophy (Figure 3G).  
Fibrosis was not present (data not shown).  Thus, lack of ACSL1 for ten weeks severely 
impaired FA oxidation and induced ventricular hypertrophy with upregulation of fetal genes 
but without cardiac dysfunction or failure.  
 Electron microscopy showed that the mitochondrial area in Acsl1T-/- ventricles was 
54% greater than in controls (Figure 4A,B).  Confirming the enhanced mitochondrial 
biogenesis in Acsl1T-/- ventricles, the mitochondrial DNA abundance for NADH 
dehydrogenase subunit 1, cytochrome B, and cytochrome C oxidase 1 were at least 2-fold 
higher than controls (Figure 4C).  Mitochondrial biogenesis is driven by several transcription 
factors, including PGC1α and ERRα [232].  In Acsl1T-/- ventricles the mRNA abundance of 
Pgc1α and Errα was 100% and 41% greater, respectively, than in controls (Figure 4D).  
Because FA oxidation was severely impaired, we suspected that an energy deficit might 
exist that would activate the energy-sensing enzyme, AMP-activated kinase (AMPK), which 
can upregulate Pgc1α.  However, compared to controls, AMPK phosphorylation (Thr172), 
was ~40% lower in Acsl1T-/- ventricles (Figure 4E). Myocardial ATP and AMP content did 
not differ between genotypes (Figure S2D), suggesting that glucose oxidation had 
increased sufficiently to maintain the cellular ATP/AMP ratio.  Because long-chain acyl-CoAs 
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can indirectly reduce AMPK activation by allosterically interacting with LKB1/AMPKK, the 
decrease in AMPK phosphorylation may have resulted from the reduction in ventricular acyl-
CoA content [61]. 
Increased glucose use in Acsl1T-/- hearts 
Because the capacity of Acsl1T-/- hearts to oxidize FA was markedly impaired, yet cellular 
ATP content was preserved, we questioned whether the oxidative capacity for non-FA 
substrates had increased to compensate.  In Acsl1T-/- heart homogenates, the maximal rate 
of [U-14C]glucose incorporation into [14C]CO2 was 20% higher than in controls (Figure 5A), 
and in Acsl1T-/- ventricular mitochondria, the oxidation of [1-14C]pyruvate to [14C]CO2 was 
17% higher (Figure 5B).  Consistent with increased utilization of glucose, blood glucose in 
Acsl1T-/- plasma was 17% lower than in controls (Table 2). These findings suggested an 
increase in pyruvate dehydrogenase activity compatible with the increase in mitochondrial 
abundance.  In addition, propionyl- and methyl-malonyl/succinyl-carnitines were 71% and 
174% higher in Acsl1T-/- hearts (Figure 5C).  These carnitine species are metabolites of 
glucose and of branched-chain and ketogenic amino acids, suggesting that oxidation of 
these alternate substrates had increased in Acsl1T-/- hearts.  Confirming that protein 
catabolism provided an alternative fuel source, the total amino acid content in Acsl1T-/- 
hearts was 32% higher than in controls (Figure 5D).  This increase in amino acid content 
was reflected by increases in nearly every amino acid species (Figure 5E,F).  Together, 
these data strongly support the conclusion that reduced FA oxidation in Acsl1T-/- hearts leads 
to compensatory increases in glycolysis and protein catabolism.   
mTOR stimulates hypertrophy and mitochondrial biogenesis in Acsl1T-/- hearts  
The mammalian target of rapamycin, mTOR kinase, activates pathways that increase both 
cell growth and mitochondrial biogenesis [233, 234].  mTOR kinase activation is required for 
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both thyroid hormone-induced and spontaneous hypertensive rat cardiac hypertrophy [235, 
236].  To determine whether mTOR was linked to the hypertrophy and mitochondrial 
biogenesis observed in Acsl1T-/- hearts, we quantified phosphorylation of the mTOR target, 
p70-S6 kinase (S6K).  Compared to controls, S6K phosphorylation at Thr389 was 5-fold 
greater in Acsl1T-/- hearts (Figure 5G).  These data strongly suggest that the cardiac 
hypertrophy in Acsl1T-/- mice was mediated by activation of the mTOR pathway.  Possible 
causes of enhanced mTOR signaling include elevations in amino acid availability [237], 
enhanced glycolytic flux [238], elevated plasma insulin [239], and hypertension [240].  
mTOR activation in Acsl1T-/- hearts probably resulted from a combination of several of these 
factors, including the 32% higher amino acid content (Figure 5D) and the  increase in 
glucose oxidation.  In addition, diminished AMPK activity, as measured by the ~40% 
reduction in Acsl1T-/- heart AMPK phosphorylation (Figure 4E), would relieve the inhibition of 
mTOR by AMPK [241].  Other activators of mTOR signaling were not present; neither 
plasma insulin nor the area under the curve during an insulin tolerance test differed between 
genotypes (Table 2), and hypertension was not present (Table 2).  In summary, these data 
suggest that increased amino acid availability, decreased AMPK activity, and increased 
glycolytic flux activated mTOR in Acsl1T-/- hearts, and that enhanced mTOR activity resulted 
in mitochondrial biogenesis and cardiac hypertrophy.  
  PPARα transcription factor activity in nuclear extracts from control and Acsl1T-/- 
hearts was not different between genotypes (Figure S2E), but several PPARα/δ target 
genes were markedly upregulated in Acsl1T-/- hearts, including muscle carnitine 
palmitoyltransferase 1, cytosolic thioesterase 1, and Acsl3 [242]  (Figure 5 H, I and 1C).  
The increased mRNA abundance of mitochondrial β-oxidation genes could reflect either 
increased mitochondrial content in Acsl1T-/- hearts or the activation of PPARδ by mTOR 
[243].   
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Altered FA composition of Acsl1T-/- cardiac lipids 
Despite the 90% loss of ACSL activity, Acsl1T-/- and control hearts contained similar amounts 
of TAG and PL (Figure 1F, Figure S2A,B,C).  If all acyl-CoAs were metabolically 
equivalent, the composition of complex lipids would reflect changes in the acyl-CoA pool.  
However, despite the fact that the Acsl1T-/- hearts contained twice as much 18:0-CoA as 
controls (as a percentage of total long-chain acyl-CoAs) (Figure S1C), the amount of 18:0 
did not change in the TAG, PE, and PS fractions of Acsl1T-/- hearts and was significantly 
lower in the CL and PC fractions (Figure S3A-J).  Acsl1T-/- 18:1-CoA content was ~60% 
lower than in controls and, as a percent of total long-chain acyl-CoAs, was 10-20% lower 
(Figure 1E, Figure S1C), however, the total content of 18:1 was not altered in the TAG, PE, 
and PS fractions, and was increased in the CL and PC fractions.  As a percent of total 
esterified FA, 18:1 was increased in TAG, PE, CL, and PC, but not in PS (Figure S3A-J).  
These data indicate that the FA composition of TAG and PL in Acsl1T-/- heart did not reflect 
the changes in the acyl-CoA pool and suggest that other ACSL isoenzymes contributed the 
acyl-CoAs that were esterified in pathways of glycerollipid synthesis.  
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Discussion    
The primary finding of this study is that ACSL1 provides the FA used for cardiac oxidation, 
and that in the absence of ACSL1, the heart compensates by increasing the oxidation of 
glucose and amino acids.  Normally, FA provide 60 to 90% of the heart’s energy 
requirements, and glucose and lactate oxidation provide the remaining ATP [221, 222].  The 
use of these three energy sources is controlled by substrate availability, physiological 
conditions, and transcriptional and hormonal regulation.  Our data suggest that, in addition, 
the activity of the ACSL1 isoform controls the use of FA as an oxidative substrate.  
 
 Whether a shift from lipolytic to glycolytic oxidation is a cause or a consequence of 
cardiac hypertrophy has remained unclear.  Data from human deficiencies in FA oxidation 
and rodent models with genetically or chemically impaired FA oxidative capacity support the 
interpretation that reduced FA oxidation causes cardiac hypertrophy.  For example, in 
humans, defects in the Na+-carnitine co-transporter (OCTN2) cause a cardiomyopathy 
characterized by cardiac lipid accumulation and hypertrophy [244].  Similarly, the juvenile 
visceral steatosis mouse mimics human systemic carnitine deficiency because it has a 
spontaneous deficiency of OCTN2 that results in cardiac lipid accumulation and hypertrophy 
and a 2-fold increase in cardiac mitochondrial area [225].  Similarly, inhibition of CPT1 and 
acyl-carnitine synthesis in rats leads to cardiac hypertrophy [226], and mice deficient in long-
chain acyl-CoA dehydrogenase (LCAD) [227] or very-long-chain acyl-CoA dehydrogenase 
(VLCAD) [228] also develop cardiac hypertrophy, increased mitochondrial biogenesis, and 
TAG accumulation.  In VLCAD deficient mice, AMPK is activated and whole body fat 
oxidation is increased [60]. 
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 When ACSL1 is overexpressed 12-fold in mouse heart, left ventricular mass doubles 
by 3 weeks of age, and heart failure, characterized by a 50% reduction in percent fractional 
shortening, occurs by 4 weeks of age [245].  Rates of FA oxidation were not assessed in 
these hearts, but heart TAG and phosphatidylcholine content was 12-fold and 1.5-fold 
higher, respectively, than in controls.  These data suggest that when ACSL1 is markedly 
overexpressed, the acyl-CoAs produced are used to synthesize TAG and PL.  In this model, 
ACSL1 overexpression probably trapped high amounts of acyl-CoA within cardiomyocytes, 
without a concomitant increase in demand for oxidation.  Thus, similar to VLCAD and LCAD 
null mice, in which mitochondrial FA oxidation is partially prevented [227, 228], excess and 
potentially toxic acyl-CoAs are esterified to form TAG.  In contrast to these models, lack of 
ACSL1 prevents FA activation, thereby both blocking FA metabolism and preventing FA 
from being trapped as acyl-CoA within cells.  The reduction in ACSL activity allows non-
activated FA to leave cells, thereby decreasing the apparent rate of FA uptake and amount 
of FA retained [35].  The Acsl1T-/- mice have severely impaired cardiac FA oxidation that 
results in hypertrophy, but without TAG accumulation.  
 The fact that cardiac content of PL and TAG was unchanged in Acsl1T-/- hearts 
despite a 97% reduction in ACSL activity, suggests that ACSL1 does not substantially 
contribute to the synthesis of acyl-CoAs that are incorporated into glycerolipids.  If the 
metabolic fate of a cellular acyl-CoA were non-specific, then a 65% decrease in long-chain 
acyl-CoA content should diminish both oxidation and TAG synthesis equally.  The normal 
content of TAG, the 80-90% reduction in long-chain acyl-carnitines, and the 90% decrease 
in palmitate oxidative capacity support the conclusion that ACSL1 channels FA specifically 
towards oxidation, and that acyl-CoAs synthesized by other ACSL isoenzymes are used for 
complex lipid synthesis, but not for oxidation. 
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 A major regulator of cell size is the kinase mTOR which activates S6K to initiate 
transcriptional activity that induces cell growth [246].  Activated mTOR is present in several 
models of cardiac hypertrophy and is likely to be an important signal in the pathway that 
mediates hypertrophy.  For example, S6K phosphorylation is increased in the hypertrophic 
hearts of spontaneous hypertensive rats (SHR), and treatment with the mTOR inhibitor 
rapamycin attenuates the hypertrophy without altering the hypertension [240].  Similarly, 
rapamycin inhibits thyroid hormone-induced S6K phosphorylation and cardiac hypertrophy 
[236].  Exercise-induced cardiac hypertrophy in mice also increases S6K phosphorylation 
[247], whereas mouse hearts lacking acetyl-CoA carboxylase 2 (ACC2) have reduced S6K 
phosphorylation and smaller hearts  [248].  These data strongly suggest that mTOR 
activation mediates cell growth in several models of cardiac hypertrophy and that when 
mTOR is inhibited, the hypertrophy reverses or diminishes.   
 Several mechanisms could enhance mTOR activation in Acsl1T-/- hearts, including 
elevated amino acid content and diminished AMPK activity.  AMPK phosphorylates the 
tumor suppressor complex that coverts GTP-Rheb to GDP-Rheb and inactivates mTOR 
[241].  Thus, a lower content of activated AMPK would potentially relieve this inhibition to 
allow greater mTOR activity.  A third mechanism for activating mTOR is observed in isolated 
working mouse hearts, in which the metabolism of glucose has increased [238].  In these 
hearts, the initial phosphorylation of glucose appears to be critical for S6K phosphorylation; 
S6K phosphorylation occurred after exposing cardiomyocytes to 2-deoxyglucose, which can 
be phosphorylated, but not after exposure to 3-O methylglucose, which cannot.  Our data 
suggest that the shift from FA to glucose oxidation, the consequent increase in glycolytic 
flux, the increase in amino acid availability, and the reduction in AMPK phosphorylation all 
contributed to mTOR activation in Acsl1T-/- hearts.  mTOR then increased the mRNA 
expression of Pgc1α and Errα, resulting in mitochondrial biogenesis [249]. 
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 Because the ACSL reaction converts ATP to AMP, it has been proposed that ACSL-
generated AMP is a major activator of AMPK during lipolysis in 3T3-L1 adipocytes [51].  
AMPK is not activated when ACSL1 is overexpressed in mouse hearts [250].  In Acsl1T-/- 
hearts, AMP content was not diminished, yet AMPK phosphorylation was 40% lower than in 
controls, diminishing AMPK activation (Figure 4E).  In Acsl1T-/- heart mitochondria, the 
oxidation of palmitate, but not palmitoyl-CoA, was impaired, indicating that ACSL1 was 
required to activate FA for oxidation and that CPT1 activity for acyl-CoA was normal.  Thus, 
the block in FA occurred because ACSL1 did not provide an acyl-CoA substrate.   
 
 In summary, the loss of ACSL1 in mouse heart results in severely impaired FA 
oxidation, a compensatory increase in glucose oxidation, and cardiac hypertrophy without 
systolic dysfunction or lipid accumulation.  The 5-fold increase in S6K phosphorylation 
suggests that the activation of the mTOR pathway initiates the observed cardiac 
hypertrophy and mitochondrial biogenesis in Acsl1T-/- hearts.  In support of the role of ACSL1 
in activating FA for oxidation, mice with an adipose-specific knockout of ACSL1 had reduced 
FA oxidation rates in white and brown adipocytes and were severely cold intolerant [251].  
Like ACSL1 in adipose, it appears that ACSL1 functions in cardiac tissue to activate FA 
destined for β-oxidation.  In this model, the shift in substrate use from FA to glucose causes 
the ensuing cardiac hypertrophy, although cardiac function was not impaired during the time 
period studied. 
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Methods:  
Animal Treatment: All protocols were approved by the University of North Carolina 
Institutional Animal Care and Use Committee.  Mice were housed in a pathogen-free barrier 
facility (12 h light/dark cycle) with free access to water and food (Prolab RMH 3000 SP76 
chow).  When the mice were 6-8 weeks old, tamoxifen (Sigma, St. Louis MO) (75 mg/kg 
BW), dissolved in corn oil (20 mg/ml), was injected i.p. for 4 consecutive days into both 
Acsl1T-/- and littermate Acsl1flox/flox control mice.  Tissues were removed and snap frozen in 
liquid nitrogen.  To isolate mitochondria, hearts were removed, rinsed in PBS, minced and 
homogenized with 10 up-and-down strokes, using a motor-driven Teflon pestle and glass 
mortar in ice-cold buffer (0.2 mM EDTA, 0.25 M sucrose, 10 mM Tris HCl, pH7.8, protease 
inhibitor (Roche, Florence, SC)).  Homogenates were centrifuged at 1,000 x g for 10 min at 
4°C, the supernatant was spun at 12,000 x g for 15 min at 4°C, and the resulting pellet was 
washed once and resuspended in oxidation buffer.  Protein content was determined by the 
BCA assay (Pierce, Rockford, IL) with BSA as the standard.  Plasma was collected from 
mice in 5% 0.5 M EDTA.  Plasma TAG, β-hydroxybutyrate (Stanbio, Boerne, TX), 
cholesterol, FFA, glucose (Wako, Richmond, VA), and free and total glycerol (Sigma) were 
measured with colorimetric assays.  Insulin tolerance tests were performed by i.p. injection 
with insulin (0.5 U/kg body wt) and tail blood glucose was measured at baseline, 15, 30, 60, 
and 120 min using a One Touch Ultra glucometer (Lifescan, Inc., Milpitas, CA).  Blood 
pressure was measured by CODA High-Throughput Non-Invasive Tail Blood Pressure 
System (Kent Scientific, Torrington, CT).   
ACSL assay:  ACSL initial rates were measured with 50 µM [1-14C]palmitic acid (Perkin 
Elmer, Waltham, MA), 10 mM ATP, and 0.25 mM CoA in total membrane fractions (0.5-4.0 
µg) or in ventricular mitochondria [147]. 
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RT-PCR: Total RNA was isolated from ventricles (RNeasy Fibrous Tissues Kit, Qiagen, 
Alameda, CA), and cDNA was synthesized (Applied Biosystems High Capacity cDNA RT 
Kit). Total DNA was isolated using the QIAmp DNA Micro Kit (Qiagen).  DNA or cDNA was 
amplified by real-time PCR using SYBR Green (Applied Biosystems, Foster City, CA) 
detection with primers specific to the gene of interest.  Results were normalized to the 
housekeeping gene Gapdh for mRNA and H19 for DNA and expressed as arbitrary units of 
2-∆∆CT relative to the control group.   
Immunoblots: Total protein lysates were isolated in lysis buffer (20 mM Tris base, 1% Triton-
X-100, 50 mM NaCl, 250 mM sucrose, 50 mM NaF, 5 mM Na2P2O7, plus protease inhibitor 
(#11836153 Roche. Florence, SC)).  Total membrane fractions were isolated in Medium I 
(10 mM Tris, pH7.4, 1 mM EDTA, 0.25 M sucrose, 1 mM dithiothreitol).  Equal amounts of 
protein (40-60 µg) were loaded and resolved on 10% SDS polyacrylamide gels and 
transferred to nitrocellulose membranes.  Blots were probed with antibodies against ACSL1 
(#4047, Cell Signaling, Danvers, MA), P-AMPK (#2535), and P-p70 S6K (#9234) and were 
then stripped and reprobed with either total AMPKα (#2532) or p70 S6K (9202).  Purity of 
mitochondrial fractions was verified by immunoblot with antibodies against the mitochondrial 
protein VDAC (Abcam, Cambridge MA, ab16816) and the ER protein calnexin (Abcam, 
ab13504).   
Histology: Hearts were gravity perfused and fixed for 24 h in 4% paraformaldehyde-PBS and 
transferred to 70% ethanol.  Fixed tissues were embedded in paraffin, serial sectioned, and 
stained with hematoxylin and eosin or Masson's trichrome.  For lectin staining, 
paraformaldehyde-fixed cardiac tissue was deparaffinized, hydrated, and incubated with 
Triticum vulgaris lectin TRITC conjugate (Sigma).  Sections were subsequently examined by 
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fluorescence microscopy.  For electron micrograph analysis, animals were euthanized and 
the hearts perfused with a freshly made solution containing 2% paraformaldehyde and 2.5% 
glutaraldehyde in 0.15 M sodium phosphate buffer, pH 7.4.  Cardiac tissue was imaged 
using a LEO EM910 transmission electron microscope at 80kV (LEO Electron Microscopy, 
Thornwood, NY) and photographed using a Gatan Bioscan Digital Camera (Gatan, Inc., 
Pleasanton, CA).  Mitochondrial area and myocyte size were quantified using NIH ImageJ 
Software. 
.Echocardiograms:  Mouse echocardiograms were performed on unanaesthetized mice with 
the VisualSonics Vevo 770 (Toronto, Ontario, Canada) ultrasound biomicroscopy system.  
M-mode images of the left ventricle were analyzed using VisualSonics software.    
Fatty acid oxidation: Freshly isolated ventricles and liver were minced and homogenized 
with 10 up-and-down strokes using a motor-driven Teflon pestle and glass mortar in ice-cold 
buffer (100 mM KCl, 40 mM Tris·HCl, 10 mM Tris base, 5 mM MgCl2·6H2O, 1 mM EDTA, 
and 1 mM ATP (pH = 7.4)) at a 20-fold dilution (wt/vol) [154].  Oxidation was measured in a 
200 µl reaction mixture containing 100 mM sucrose, 10 mM Tris·HCl, 10 mM KPO4, 100 mM 
KCl, 1 mM MgCl2·6H2O, 1 mM L-carnitine, 0.1 mM malate, 2 mM ATP, 0.05 mM coenzyme 
A, and 1 mM dithiothreitol (pH = 7.4) with either:  8 µM [1-14C]palmitate (0.1 µCi/reaction) 
and 100 µM sodium palmitate complexed to BSA; 16 µM [1-14C]pyruvate (0.1 µCi/reaction) 
and 200 µM pyruvate; 4 µM [1-14C]palmitoyl-CoA (0.04 µCi/reaction) and 50 µM palmitoyl-
CoA or 8 µM [U-14C]glucose (0.1 µCi/reaction) and 200 µM glucose.  Oxidation studies 
measured the production of 14C-labeled carbon dioxide (CO2) and acid soluble metabolites 
(ASM) for 30 min without substrate competition in a two-well oxidation system: one well 
contained the reaction mixture with the tissue homogenate and the adjoining well contained 
1N NaOH.  The reaction was terminated by adding 70% perchloric acid to the assay well 
and then incubated for one h to drive the CO2 into the NaOH.  Radioactivity of ASM in the 
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supernatant of the reaction mixture and CO2 was determined by liquid scintillation.  Fatty 
acid oxidation was quantified using the following formula: ([(dpm-BL)/SA] / [g of tissue wet wt 
x time (min) of reaction incubation]),where BL is the dpm of blank wells and SA is the FA 
specific radioactivity.  
 Tissue lipid and nucleotide content: Acyl-carnitines were quantified by liquid 
chromatography and tandem mass spectrometry [252].  Complex lipid content was 
analyzed by Lipomics Technologies, Inc (West Sacramento, CA) [253].  Acyl-CoA and 
diacylglycerol composition and content were assessed from whole heart extracted with 
internal standards [254].  After separation, purification, and elution, lipid metabolite extracts 
were separated by high performance liquid chromatography, and individual and total lipid 
species were analyzed by liquid chromatography/tandem mass spectrometry [254].  Frozen 
heart was homogenized in 0.4 M perchlorate and neutralized in 4M K2CO3 as described 
[255].  Nucleotides were separated by HPLC [256] using a Varian Prostar solvent delivery 
system (PS-210 Varian, Palo Alta, CA) and a Luna 5u C18 100A column (Phenomenex, 
Torrance, CA). Peaks were detected using a Gilson 118 UV detector (Middleton, WI).  
PPARα activity: Nuclear fractions were isolated from fresh hearts (Nuclear Extraction Kit, 
Cayman Chemicals, Ann Arbor, MI) and used with the PPARα Complete Transcription 
Factor Assay Kit (Cayman Chemicals, Ann Arbor, MI) according to the manufacturer’s 
protocol.  
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Figure 1 (4.1). ACSL activity and acyl-CoA content are reduced in mice that temporally 
lack ACSL1. 
Total ACSL activity (A) and ACSL1 protein (B) in control and Acsl1T-/- ventricles 2 and 10 wk 
after tamoxifen, n=5-7. C) Acsl isoenzyme mRNA abundance in ventricles 2 and 10 wk after 
tamoxifen in control and Acsl1T-/- mice, n=6.  Heart total (D) and individual long-chain acyl-
CoA content (E) in control and Acsl1T-/- mice 10 weeks after tamoxifen, n=7-8.  F) Heart TAG 
content in control and Acsl1T-/- mice 10 weeks after tamoxifen, n=7-8.  Data represent mean 
± SEM; *, P≤0.05 versus control; #, P≤0.05 2 wk versus 10 wk after tamoxifen within 
genotype.  
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Figure 2 (4.2). Acsl1T-/- hearts have impaired FA oxidation  
A) [1-14C]Palmitate oxidation to CO2 and acid soluble metabolites (ASM) in heart and liver 
homogenates and B) heart [1-14C]palmitoyl-CoA oxidation into CO2 from control (C) and 
Acsl1T-/- (T-/-) mice, n=5-6.  C) Representative immunoblots against ACSL1, VDAC, and 
calnexin in control and Acsl1T-/- mitochondrial fractions 2 and 10 weeks after tamoxifen. D) 
[1-14C]Palmitate oxidation to CO2 and ASM from control (C) and Acsl1T-/- (T-/-) ventricular 
mitochondria, n=5-6.  E) Free, F) acetyl-, G) medium-chain, and H) long-chain acyl-
carnitines in control and Acsl1T-/- hearts, n=5-7.  Data represent mean ± SEM; *, P≤0.05 
versus control. 
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Figure 3 (4.3). Acsl1T-/- mice develop cardiac hypertrophy  
A) Wet weight of control and Acsl1T-/- female and male hearts expressed as a percent of 
body weight, n=10-20.  B) Quantification of cardiomyocyte area from lectin-stained control 
and Acsl1T-/- male hearts, n=3.  C) Representative H&E stained control and Acsl1T-/- hearts.  
D) Echocardiography calculation of left ventricular (LV) mass over body mass from male 
control and Acsl1T-/- mice, n=8-10.  E) Representative echocardiogram M-mode images and 
F) percent fractional shortening (%FS) in control and Acsl1T-/- male mice, n=8-10.  G) mRNA 
abundance of fetal gene markers, α-skeletal actin (αSkAc) and brain natriuretic peptide 
(Bnp) in control and Acsl1T-/- hearts, n=6.  Data represent mean ± SEM; *, P≤0.05 versus 
control. 
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Figure 4 (4.4). Mitochondrial excess in Acsl1T-/- hearts   
A) Representative electron microscopy images (8000X, scale bar = 2µm) and B) 
quantification of mitochondrial area from control and Acsl1T-/- male 10 wk ventricles, n=3.  C) 
Quantification of the mitochondrial DNA genes, cytochrome C oxidase 1 (Co1), cytochrome 
B (Cytb), and NADH dehydrogenase subunit 1 (Nd1) relative to nuclear DNA in male and 
female control and Acsl1T-/- 10 wk ventricles, n=6.  D) mRNA abundance of Pgc1α and Errα 
in control and Acsl1T-/- ventricles 2 wk after tamoxifen, n=6.  E) Quantification of AMPK 
phosphorylation at Thr172 over total AMPK in control and Acsl1T-/- 10 wk ventricles, n=5-7.  
Data represent mean ± SEM; *, P≤0.05 versus control. 
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Figure 5 (4.5). Glucose oxidation, amino acid catabolism, and S6 kinase activation are 
increased in Acsl1T-/- hearts 
A) [U-14C]Glucose oxidation to CO2 in heart homogenates from control and Acsl1T-/- mice, 
n=5-6. B) [1-14C]Pyruvate to CO2 in heart mitochondria from control and Acsl1T-/- mice, n=3-
4. C) Short-chain acyl-carnitines in control and Acsl1T-/- hearts, n=5-7.  D) Total amino acids 
and E,F) individual amino acids in control and Acsl1T-/- hearts, n=5-7.  G) Representative 
immunoblots and quantification of p70S6K phosphorylation at Thr389 per total p70S6K in 
control and Acsl1T-/- ventricles, n=8-10.  H,I) mRNA abundance of Cte1, mCpt1, Mcad, 
Cd36, Fas, Atps, and Pparα in control and Acsl1T-/- ventricles, n=6.  Data represent mean ± 
SEM; *, P≤0.05 versus control. 
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Figure 6 (4.6). Overview of metabolic disturbance and pathway activation in the 
Acsl1T-/- heart. 
The loss of ACSL1 prevents uptake and activation of FA for FA oxidation, but not for TAG 
and PL synthesis.  The inability of Acsl1T-/- heart to oxidized FA is compensated for by 
increased glucose and amino acid catabolism.  The shift in oxidative metabolism results in 
the activation of the mTOR pathway that causes mitochondrial biogenesis and hypertrophy 
in Acsl1T-/- heart.  
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Table I. Echocardiogram diameter and functional characteristics 
Transthoracic echocardiogram imaging was performed on conscious control and Acsl1T-/- 
male mice 10 weeks after tamoxifen.  M-mode images were analyzed, n=6-8.  Data 
represent mean ± SEM *, P≤0.05 versus control.  IVS, interventricular septum; LVID, left 
ventricular inner diameter; LVPW, left ventricular posterior wall; %EF, percent ejection 
fraction; LV, left ventricular; d, diastole; s, systole.  
 
 Control Acsl1T-/- 
IVS,d 0.98 ± .02 1.29 ± .02* 
LVID,d 2.88 ± .06 2.47* ± .06* 
LVPW,d 0.86 ± .01 1.23* ± .02 
IVS,s 1.67 ± .03 1.89* ± .04 
LVID,s 1.31 ± .04 1.08* ± .03 
LVPW,s 1.48 ± .03 1.80* ± .04 
% EF 86.6 ± .50 88.3 ± .51 
LV Mass (mg) 86.5 ± 3.57 115.4* ± 4.24 
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Table 2.  Body weight, adipose weight, plasma metabolites, and blood pressure in 
male mice  
Male control and Acsl1T-/- mice 2 and 10 weeks after tamoxifen body and adipose weight, 
plasma metabolites, and area under the curve in response to insulin tolerance tests, n=15-8. 
Data represent mean ± SEM; *, P≤0.05 versus control; †, P≤0.05 2 week versus 10 week 
within genotype.   G-WAT, gonadal white adipose tissue; TAG, plasma triacylglycerol; FA, 
plasma fatty acids; ITT, insulin tolerance test; AUC, area under the curve.   
 
 2 weeks 10 weeks 
 Control Acsl1T-/- Control Acsl1T-/- 
Body Weight 25.5 ± 1.5 23.3 ± 1.7 31.4† ± 0.8 30.1† ± 0.4 
G-WAT (% of BW) 0.87 ± 0.1 0.92 ± 0.1 1.7† ± 0.2 1.8† ± 0.2 
TAG (mg/dL) 47.2 ± 3 29.7 ± 2.0* 36.7† ± 5 33.8 ± 2 
FA (mmol/L) 0.08 ± .03 0.28 ± .04* 0.08 ± .01 0.09† ± .01 
Glucose (mg/dL) 136 ± 8 131 ± 9 164 ± 3.6 136* ± 5.3 
Insulin (ng/mL  -  -  2.73 ± 0.8 1.67 ± .2 
ITT (AUC)  -   -  4981 ± 298 4828 ± 357 
Systolic (mm Hg)  -   -  155 ± 4.0 158 ± 3.4 
Diastolic  (mm Hg)  -   -  120 ± 4.3 125 ± 3.6 
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Supplementary Figure 1 (4.7). ACSL activity and ACSL1 protein loss in  Acsl1T-/- liver, 
kidney, and adipose tissue and Acsl1T-/- heart acyl-CoA composition and loss of FA 
oxidation over time. 
A) Total ACSL activity in control and Acsl1T-/- 2 and 10 wk after tamoxifen and B) 
representative immunoblot against ACSL1 protein in liver, kidney, gonadal adipose (WAT), 
and brown adipose (BAT), 10 wk after tamoxifen, n=5-7.  C) Heart long-chain acyl-CoA 
content as a relative percentage in control and Acsl1T-/- mice 10 weeks after tamoxifen, n=7-
8.  D) [1-14C]Palmitate oxidation to CO2 and ASM from control (C) and Acsl1T-/- (T-/-) 
ventricular mitochondria 2 and 10 wk after tamoxifen, n=5-6.  Data represent mean ± SEM; 
*, P≤0.05 versus control.  
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Supplementary Figure 2 (4.8). Heart lipid content, fibrosis, and PPARα transcriptional 
activity are normal in Acsl1T-/-mice. 
A,B,C) Lipid content of control and Acsl1T-/- male heart 10 wk after tamoxifen, n=8.  
D)Myocardial ATP and AMP content determined by HPLC in control and Acsl1T-/- hearts.  E) 
PPARα transcription factor activity in nuclear extracts from control and Acsl1T-/- heart, n=6-8. 
Data represent mean ± SEM; *, P≤0.05 versus control.  TAG, triacylglycerol; CL, cardiolipin; 
CE cholesterol ester; DAG, diacylglycerol; PC, phosphatidylcholine; PE, 
phosphatidylethanolamine. 
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Supplementary Figure 3 (4.9). Lipid composition of heart from Acsl1T-/- mice 
Heart long-chain FA species content as percent of total FA and in total nmol in the TAG 
(A,B), CL (C,D), PC (E,F), PE (G,H), and PS (I,J) fractions from control and Acsl1T-/- hearts, 
n=8Data represent mean ± SEM; *, P≤0.05 versus control.  TAG, triacylglycerol; CL, 
cardiolipin; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PS, 
phosphatidylserine.  
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CHAPTER V 
THE LACK OF ACSL1 SPECIFICALLY IN CARDIOMYOCYTES  
 
 The previous manuscript described the cardiac phenotype of a “total” body ACSL1 
knock out in which the lack of ACSL1 in peripheral tissues and in non-cardiomyocyte cells 
within the heart may have influenced circulating metabolites and the ensuing cardiac 
phenotype. To confirm that lack of ACSL1 specifically in cardiomyocytes results in impaired 
cardiac FA oxidization and leads to hypertrophy, we generated a tamoxifen-inducible 
ventricular cardiomyocyte-specific ACSL1 knockout mouse, Acsl1H-/-.  The cardiac 
hypertrophy and severe defect in FA oxidation persisted in the Acsl1H-/- mouse, suggesting 
that ACSL1, specifically in cardiomyocytes, is required for FA oxidation and that without 
ACSL1, hypertrophy ensues. Thus, the goal of Aim3D has been completed.  However, to 
further explore the role of ACSL1 in cardiomyocytes, we will characterize the  response of 
Acsl1H-/- mice to various challenges, including high-fat diet-induced cardiac TAG-
accumulation and insulin resistance, recovery from ischemic injury, oxidation of FA and 
glucose in isolated working heart, gene expression by microarray, and the rates of FA and 
glucose uptake. While the proposed Aim has been completed, the chapter that follows is a 
manuscript in preparation because the physiological experiments proposed above are 
ongoing.   
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Lack of ACSL1-mediated FA oxidation impairs recovery from ischemia and prevents high-fat 
diet induced cardiac steatosis  
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Abstract: 
Long chain acyl-CoA synthetases (ACSL) catalyze the conversion of long chain fatty acids 
into their acyl-CoA derivatives.  Although ACSL1 is the most abundant of the five ACSL 
isoenzymes in the heart, its role in cardiac FA metabolism remains unclear. In mice with a 
heart-specific loss of ACSL1 under temporal control (Acsl1H-/-), heart total long-chain acyl-
CoA synthetase activity was reduced more than 90%, compared to littermate controls.  
ACSL1 deficiency reduced the content of acyl-CoA by 30% and palmitate and oleate 
oxidation was ~90% lower than in control hearts.  Acsl1H-/- hearts developed hypertrophy, 
evidenced by increased heart weight and left ventricular wall diameter.  The lack of ACSL1 
increased cell death 24 hours after cardiac ischemia.  Acsl1H-/- mice, compared to controls, 
were resistant to high-fat diet induced weight gain and the accumulation of cardiac TAG. 
These data suggest that cardiac ACSL1 catalyzes the initial step for FA retention and 
activation specifically for FA oxidation and that without ACSL1, diminished FA oxidative 
capacity leads to cardiac hypertrophy, increased cell death after ischemia and resistance to 
high-fat diet induced TAG accumulation.  
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Introduction: 
The current epidemic of obesity is characterized by imbalances in lipid storage and lipid 
oxidation for energy that can lead to diseases such as diabetes and cardiovascular disease.  
In the heart, long-chain fatty acids (FA) of 14-20 carbons are the major substrates for energy 
production [168, 169].  The complete oxidation of fatty acids and glucose via mitochondrial 
oxidative phosphorylation accounts for greater than 90% of heart ATP production [257].  
When cardiac FA oxidative metabolism is impaired genetically, pathological cardiac 
hypertrophy develops [173]. Pathological hypertrophy is defined by increased cardiomyocyte 
size accompanied by alterations in cell function and cell metabolism.  Hypertrophy may 
initially be a positive adaptation to a disease state, but with time, may result in a decline in 
cardiac function. In the Framingham heart study, left ventricular hypertrophy (LVH) was 
identified in ~18% of the total population and in ~42% of the population over the age of 70 
[170, 171]. LVH is independently associated with increasing age, blood pressure, obesity, 
valve disease, and myocardial infarction [171].  
 Ventricular hypertrophy occurs in obese individuals and in these patients it is 
associated with myocardial lipid accumulation [258].  Fatty heart is correlated with 
congestive heart failure and diabetes and is found in some mouse models of cardiac 
hypertrophy [207].  Cellular lipids accumulate in the form of triacylglycerol in intracellular lipid 
droplets.  Triacylglycerol itself is not thought to be a lipotoxic molecule; however, the 
precursors for TAG synthesis have been shown to mediate cellular signaling pathways that 
can induce cell death [259].  Lipotoxicity is a term that refers to cell death due to the 
accumulation of lipids and lipid by-products and is a postulated mechanism for cardiac 
failure.  Acyl-CoAs are the first molecule formed for the synthesis of TAG and the 
accumulation of lipids can lead to a rise in cellular acyl-CoAs.  In models of increased 
cardiac lipid accumulation a rise in cellular lipid intermediates such as acyl-CoA, LPA, PA, 
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and DAG could be expected. These lipid intermediates could act as ligands or second 
messengers that mediate the cellular signaling involved in the development of cardiac cell 
death.  
 Injury sustained after an ischemic event postulated to be caused by the rapid 
reversion back to aerobic mitochondrial metabolism leading to increased oxidative stress 
and mitochondrial Ca+2 flux that leads to cell death by increasing the membrane permeability 
transition [260].  Inhibiting mitochondrial oxidation improves the acute recovery of isolated 
perfused hearts and cardiomyocytes [260]. However, long-term (24 hour) recovery after 
ischemia is improved by PPARα agonists and impaired in PPARα cardiac deficient mice 
[261, 262]. These data suggest that acute recovery from ischemia is improved by a slower 
transition to mitochondrial oxidative metabolism, but that the long-term recovery after 
ischemia-reperfusion is improved by mitochondrial oxidative metabolism.  
 ACSL isoenzymes convert FA to acyl-CoA in an ATP-dependent manner, 
simultaneously activating and trapping the FA within the cell. The conversion of FA to acyl-
CoA is postulated to regulate the rate of cellular FA uptake by a process described as 
vectoral acylation [35, 73, 229, 263]. Activation to acyl-CoA is also required before FA can 
be oxidized to provide ATP or esterified for energy storage as TAG or for the synthesis of 
membrane phospholipids. The activation of FA is catalyzed by one of a family of 5 long-
chain acyl-CoA synthetases (ACSL), ACSL1, ACSL3, ACSL4, ACSL5, and ACSL6, which 
differ in substrate preference, enzyme kinetics, subcellular location, and tissue-specific 
expression [24]. Because, theoretically, amphipathic acyl-CoAs can move freely within a 
membrane monolayer or be transported to distant membranes, all acyl-CoAs should be 
metabolically equivalent, no matter which ACSL isoenzyme catalyzes their formation and no 
matter which subcellular organelle forms the site of their synthesis. Yet, both loss-of-function 
and gain-of-function studies suggest that each of ACSL isoenzyme may have a distinct 
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function in directing acyl-CoAs to one or more specific downstream pathways and in 
regulating rates of FA uptake [34, 36].   
 FA are the major substrate for energy production preferred by the adult heart.  The 
low total ACSL activity of embryonic (E16.5) heart increases 14-fold in the week after birth 
and is 90-fold higher in the adult heart together with increases in Acsl1 mRNA [5]. The 
increase in ACSL activity and Acsl1 mRNA expression parallels the heart’s increased 
workload, rate of ATP generation, oxidative preference for FA, and expression of FA 
oxidative genes.  We previously reported that ACSL1 is critical for FA oxidative metabolism 
in the heart of a multi-tissue ACSL1 knockout mouse, the Acsl1T-/- mouse [264]. Here we 
report severe decreases in FA oxidation in the tamoxifen-inducible ventricular 
cardiomyocyte-specific Acsl1 knockout mouse, Acsl1H-/-. The lack of ACSL1 specifically in 
ventricular cardiomyocytes impairs FA oxidation and recovery from ischemia, and it protects 
from high-fat diet-induced TAG accumulation.  
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Results:  
Generation of Acsl1H-/- mice  
Mice with Loxp sequences inserted on either side of exon 2 in the Acsl1 gene9 were 
backcrossed to the C57Bl/J6 strain six times and then interbred with mice in which Cre 
expression is driven by α-myosin heavy chain promoter is induced by tamoxifen (B6.Cg-
Tg(Myh6-cre/Esr1)1Jmk/J, Jackson Labs)  to generate tamoxifen-inducible heart-specific 
Acsl1 knockout mice (Acsl1H-/-).  Tamoxifen was injected i.p. (3.5 mg/kg body wt) for 4 
consecutive days when mice were 6-8 weeks old.  Control littermates, which were also 
injected with tamoxifen, lacked the Cre gene (Acsl1flox/flox). Data were collected 2 and 10 
weeks after tamoxifen was injected.  
The α-MHC promoter is expressed in ventricular but not atrial cardiomyocytes. 
Consequently, Acsl1H-/- heart atrial ACSL activity was similar to controls whereas Acsl1H-/- 
heart ventricle ACSL activity was 90% lower (Fig 1A).  Real-time PCR showed nearly 
absent expression of Acsl1 mRNA in Acsl1H-/- ventricles, and 50% lower in Acsl5 mRNA 
expression (Fig 1B).  ACSL1 protein was absent in Acsl1H-/- ventricles, but was similar to 
controls in liver and skeletal muscle (Fig 1C).  In Acsl1H-/- hearts, loss of ACSL1 reduced the 
total long-chain acyl-CoA pool by 30%, with 30-43% reductions in 16:0-, 16:1-, 18:1-, 18:2-, 
and 18:3-CoA species and no change in 18:0-CoA (Fig. 1D,E).  Expressed as a percentage 
of total acyl-CoA content, only 18:3 was significantly reduced and was 12% less than 
controls, thus, the total acyl-CoA pool was reduce but the FA composition of the acyl-CoA 
pool is not changed by the lack of ACSL1. These data suggest that ACSL1 is the major 
activator of long-chain FA in the heart but that other ACS enzymes provide up to 70% of the 
long-chain acyl-CoA pool.  
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ACSL1 is required for heart FA oxidation 
To determine whether ACSL1 provided acyl-CoAs for FA oxidation, the rates of [1-
14C]palmitate incorporation into CO2 and ASM, which are measures of complete and 
incomplete oxidation, respectively, were measured in  heart homogenates from Acsl1H-/- and 
control mice. Compared to controls at 10 weeks after tamoxifen, the rate of FA oxidation in 
Acsl1H-/- heart homogenates was 92% lower (Fig. 2A). Thus, the lack of ACSL1 nearly 
abolished FA oxidation. [1-14C]Pyruvate incorporation into CO2 in Acsl1H-/- heart 
homogenates was similar to controls, showing that mitochondrial oxidation was normal for 
this non-FA substrate (Fig 2B). These data show that FA oxidation was severely impaired in 
hearts that lacked ACSL1.  
 
Cardiac hypertrophy of Acsl1H-/- hearts 
As a percent of body weight, the wet weights of Acsl1H-/- male and female hearts were 25% 
and 20% greater, respectively, than controls (Fig 3A).  The left ventricular (LV) masses 
calculated from echocardiograph M-mode images were 34% heavier (Fig 3B).  M-mode 
imaging showed the diameters of the Acsl1H-/- LV posterior wall (LVPW,d) and the 
interventricular septum (IVS,d) in diastole were 32% wider than controls, the LV inner 
diameter (LVID) was 13% smaller in Acsl1H-/- hearts, and the LV volume was 32% lower 
(Table 1).  The percent fractional shortening and the ejection fraction of the Acsl1H-/- hearts 
were similar to measurements in controls, indicating that cardiac function remained normal 
despite ventricular hypertrophy (Table 1). Histological analysis of Acsl1H-/- hearts showed 
minimal fibrosis (data not shown). I the Acsl1H-/- hearts, the higher mRNA expression of the 
fetal gene markers, α-skeletal actin and brain natriuretic peptide, suggests that the 
hypertrophy was pathological (Fig 3D).  The mitochondrial area, appearance, and 
mitochondrial DNA abundance were similar between genotypes (Fig 3E,F,G). Thus, lack of 
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ACSL1 impaired FA oxidation and induced ventricular hypertrophy without cardiac 
dysfunction or failure.  
 
 
Acsl1H-/- mice are resistant to high-fat diet induce obesity  
Female Acsl1H-/- mice were fed a 60%-high fat diet for 10 weeks to determine if whether 
ACSL1 is required for high-fat diet-induced accumulation of cardiac TAG and insulin 
resistance. Acsl1H-/- mice fed the high-fat diet ad libitum, gained 3 g less than controls (25.7 
g versus 22.7 g) (Fig. 4A).  Acsl1H-/- mice fed the high-fat diet, compared to littermate 
controls, accumulated less adipose mass. Gonadal and inguinal adipose depots were 36% 
and 20% less, respectively (Fig. 4B,C). Food intake, whole-body energy expenditure, and 
ambulatory movement across three planes were similar between genotypes (Fig. S1A-D).  
Despite the reduced accumulation of adipose mass in the high-fat diet fed Acsl1H-/- mice, 
after 8 weeks on the high-fat diet, compared to littermates on the control diet, the area under 
the curve for a glucose tolerance test was ~77% greater in both genotypes (Fig. 4D).  
Plasma TAG and FA were not different between genotypes on either diet; however, high-fat 
diet feeding raised plasma cholesterol ~18% in both genotypes (Table 1). Acsl1H-/- blood 
glucose was ~19% lower than controls fed either diet (Table 1). Control cardiac TAG 
increased 24% with high-fat diet feeding, whereas no change in cardiac TAG was observed 
in the Acsl1H-/- mice (Fig 4E).  Despite the lack of TAG accumulation in Acsl1H-/- hearts, the 
heart weight was 25% greater than controls fed either diet. Acsl1H-/- heart weight was 28% 
and 41% greater when normalized to body weight on the low-fat and high-fat diets, 
respectively (Fig 4F).  
 
Increased ischemia-induced cell death in the Acsl1H-/- hearts 
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To test the role of ACSL1 in recovery from ischemia-reperfusion injury, control and Acsl1H-/- 
left anterior descending arteries were occluded for 30 minutes followed by reperfusion. Cell 
death was assessed by triphenyltetrazolium chloride staining in hearts 24-hours later. Both 
the control and Acsl1H-/- mice had similar areas at risk (AAR) from the ischemia event, 
however, in control hearts, 30% of the AAR was infarct (dead) whereas in Acsl1H-/- hearts, 
45% was infarct (Fig. 5A).  The 150% greater area infarct in Acsl1H-/- heart suggests that 
ACSL1 is critical for full recovery from ischemia. These data suggest that ACSL1 and the 
ability of the heart to oxidize FA are beneficial for the long-term recovery of cardiac tissue 
after an ischemia-reperfusion study.  
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Discussion 
 The primary finding of this study is that ACSL1 is required for FA oxidation by 
cardiomyocytes.  The knockout of ACSL1 reduced the cardiac content of long-chain acyl-
CoA by 30%.  If the metabolic fate of a cellular acyl-CoA were non-specific, one would 
expect to find diminished availability of acyl-CoAs for both the oxidation and the synthesis of 
complex lipids. However, the normal content of glycerolipids, and the 80-90% reduction in 
palmitate oxidation support the conclusion that ACSL1 channels FA specifically towards 
oxidation, and that acyl-CoAs synthesized by other ACSL isoenzymes were available and 
sufficient for complex lipid synthesis, but not for oxidation.  
 
 The effects of a multi-tissue tamoxifen inducible ACSL1 knockout mouse, Acsl1T-/-, 
on heart function and metabolism have been investigated.  The Acsl1T-/- hearts have 
severely impaired FA oxidation, mitochondrial biogenesis, and develop left ventricular (LV) 
hypertrophy.  However, the lack of ACSL1 in peripheral tissues and in non-cardiomyocyte 
cells within the heart may have influenced circulating metabolites and the ensuing cardiac 
phenotype. To confirm that lack of ACSL1 specifically in ventricular cardiomyocytes caused 
defects in FA oxidation and cardiac hypertrophy similar to that observed in the Acsl1T-/- 
hearts, we generated a tamoxifen-inducible ventricular cardiomyocyte-specific ACSL1 
knockout mouse, Acsl1H-/-.  Total ACSL activity in the Acsl1T-/- heart was reduced 97% and 
reduced 90% in the Acsl1H-/- suggesting that at least 90% of total ventricular ACSL activity is 
catalyzed by ACSL1 specifically in cardiomyocytes.  The rate of [1-14C]palmitate oxidation 
was reduced ~90% in both Acsl1T-/- and Acsl1H-/- heart homogenates, confirming that ACSL1 
specifically and uniquely directs FA towards oxidation in cardiac tissue.  Although, both the 
Acsl1H-/-  and Acsl1T-/- hearts had 90% or greater loss in total ACSL activity, the long-chain 
acyl-CoA content was reduced 65% in Acsl1T-/- but only 30% in Acsl1H-/-, suggesting that 
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ACSL1 expressed in non-cardiomyocytes and in Acsl1H-/- atria contribute to ~30% of cardiac 
acyl-CoA content.   
 Both Acsl1T-/- and Acsl1H-/- mice have enlarged hearts, compared to controls, with LV 
that are 20-35% heavier, have 10-40% increased LV wall diameter, and are dilated due to 
~30% smaller LV inner diameter.  The ejection fraction and fractional shortening are similar 
to controls, thus neither Acsl1T-/- nor Acsl1H-/- mice show systolic dysfunction.  The Acsl1T-/- 
hearts upregulated of several fetal genes, including α-skeletal actin, Acsl3, and brain 
natrietic peptide, suggesting that the cardiac hypertrophy was pathological; however, the 
Acsl1H-/- hearts upregulated α-skeletal actin only casting doubt on the pathological nature of 
hypertrophy in Acsl1H-/- heart.  Cardiac gene expression for several PPARα/δ regulated 
genes also deviated between the models.  Specifically, carnitine-palmitoyl transferase 1 and 
medium-chain acyl-CoA dehydrogenase were upregulated in Acsl1T-/- hearts, whereas 
medium-chain acyl-CoA dehydrogenase and Pparα  were downregulated in Acsl1H-/- hearts. 
These data suggest that the upregulation of PPAR regulated genes in Acsl1T-/- hearts is not 
due to the lack of ACSL1 in cardiomyocytes, but that the peripheral effect of multi-tissue 
ACSL1 knockout influences cardiac PPAR regulation.  Conversely, the PPARα target, 
cytosolic thioesterase 1 (Cte1) is ~6-fold upregulation in both Acsl1T-/- and Acsl1H-/- hearts. 
Cte1 is also upregulated in brown adipose tissue of the adipose-specific knockout, Acsl1A-/-, 
and in the liver of the liver-specific ACSL1 knockout, Acsl1L-/-, thus the lack of ACSL1 in 
multiple cell types leads to the upregulation of Cte1.  It remains unclear why CTE1 would be 
upregulated in the absence of ACSL1 particularly because CTE1 catalyzed the reverse 
reaction (acyl-CoA ? FA) of ACSL1.  Microarray analysis was performed on Acsl1H-/- and 
control hearts 2 and 10 weeks after tamoxifen to gain better insight into the temporal 
alterations in gene expression that occur when ACSL1 is lost specifically in cardiomyocytes.  
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 Another discrepancy between the Acsl1T-/- and Acsl1H-/- hearts is the mitochondrial 
excess found in the Acsl1T-/- but not in Acsl1H-/- heart.  The mitochondrial area measured 
from TEM images in Acsl1T-/- hearts, compared to controls, showed a 54% increase in 
mitochondria, and the ratio of mitochondria-specific DNA to nuclear DNA was 2-fold greater.  
In Acsl1H-/- hearts, mitochondrial area was 35% greater than controls, although this was not 
statistically significant at p=0.055, and the ratio of mitochondrial DNA to nuclear DNA was 
similar between Acsl1H-/- and controls. These data suggest that factors other than the lack of 
ACSL1 in cardiomyocytes drove mitochondrial biogenesis in Acsl1T-/- hearts.  In summary, 
the data show that ACSL1 activates FA specifically for oxidation in cardiomyocytes and the 
shift away from FA oxidation leads to cardiac hypertrophy.  
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Methods:  
Animal Treatment: Acsl1H-/- and littermate Acsl1flox/flox control mice were housed in a 
pathogen-free barrier facility (12 h light/dark cycle) in accordance with the UNC IACUC, with 
free access to water and food (Prolab RMH 3000 SP76 chow). When the mice were 6-8 
weeks old, tamoxifen (3 mg /40 g body wt), dissolved in corn oil (20 mg/ml), was injected i.p. 
for 4 consecutive days.  For the high-fat diet study, mice were given a control low-fat diet, 
D12450B, or a 60%-high-fat diet, D12492 (Research Diets Inc.) ad libitum beginning three 
days after the final tamoxifen injection. Tissues were removed and snap frozen in liquid N2. 
Protein content was determined by the BCA assay (Pierce) with bovine serum albumin as 
the standard. Plasma was collected from mice in 5% 0.5 M EDTA.  Plasma TAG, β-
hydroxybutyrate (Stanbio), cholesterol, fatty acid, glucose (Wako), and free and total 
glycerol (Sigma) were measured with colorimetric assays.  Insulin tolerance tests were 
performed by i.p. injection with insulin (5 U/kg body wt) and tail blood glucose was 
measured at baseline, 15, 30, 60, and 120 min using a One Touch Ultra glucometer 
(Lifescan, Inc). Rates of O2 consumption were determined in Oxymax chambers (Columbus 
Instruments) after mice were acclimated overnight. Data were averaged from two day and 
two night cycles per mouse. 
ACSL assay:  ACSL initial rates were measured with 50 µM [1-14C]palmitic acid, 10 mM 
ATP, and 0.25 mM CoA in total membrane fractions (0.5-4.0 µg) or in ventricular 
mitochondria [147]24. 
RT-PCR: Total RNA was isolated from ventricles (Qiagen RNeasy Fibrous Tissues Kit), and 
cDNA was synthesized (Applied Biosystems High Capacity cDNA RT Kit), or total DNA was 
isolated (QIAmp DNA Micro Kit, Quiagen), and the reaction was performed using SYBR 
Green (Applied Biosystems) detection with primers specific to the gene of interest with equal 
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amounts of cDNA (10 ηg/reaction), and detected using a Taq-man thermocycler (BioRad).  
Results were normalized to the housekeeping gene Gapdh and expressed as arbitrary units 
of 2-∆CT.   
Immunoblots: Protein isolated in lysis buffer (20 mM Tris base, 1% Triton-X-100, 50 mM 
NaCl, 250 mM sucrose, 50 mM NaF, 5 mM Na2P2O7, plus protease inhibitor (#11836153 
Roche)) or total membrane fractions isolated in Medium I (10 mM Tris, pH7.4, 1 mM EDTA, 
0.25 M sucrose, 1 mM dithiothreitol) were equally loaded (40-60 µg) and electrophoresed on 
10% SDS polyacrylamide gels, then transferred to PVDF membrane, blocked with 5% milk-
TBST-1% or 5% BSA-TBST-1% for 1 h, incubated with anti-ACSL1 primary antibody (Cell 
Signaling Technologies, ACSL1 Antibody #4047) overnight at 4°C, washed, and incubated 
with secondary antibody for 1 h at room temperature (Cell Signaling Technologies, goat anti-
rabbit).  Protein was visualized with the Western Blot R-Probe Kit (Pierce).  
Histology: Hearts were gravity perfused and fixed for 24 h in 4% paraformaldehyde-PBS, 
then transferred to 70% ethanol.  Tissue was then embedded in paraffin, serial sectioned, 
and stained with hematoxylin and eosin or Masson's trichrome.  For electron micrograph 
analysis, animals were euthanized and the hearts perfused with a freshly made solution 
containing 2% paraformaldehyde and 2.5% glutaraldehyde in 0.15 M sodium phosphate 
buffer, pH 7.4. Cardiac tissue was imaged using a LEO EM910 transmission electron 
microscope at 80kV (LEO Electron Microscopy, Thornwood, NY) and photographed using a 
Gatan Bioscan Digital Camera (Gatan, Inc., Pleasanton, CA). Quantification was performed 
using Image J Software.  
Echocardiograms:  Mouse echocardiograms were performed on unanaesthetized mice with 
the Visual Sonics Vevo 770 ultrasound biomicroscopy system.  M-mode images of the left 
ventricle were analyzed using Visual Sonics software.    
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Left Anterior Descending Coronary Artery (LAD) Ligation. Mice were anesthetized with 
isoflorane. An endotracheal tube was inserted and connected to a Harvard rodent volume-
cycled ventilator. The chest cavity was opened by a 0.5 cm incision of the left third 
intercostal space.  Ligation was performed with a suture passed with a tapered needle 
underneath the LAD artery about 1mm lower than the tip of the left auricle. The artery was 
compressed by tightening the ligature, producing myocardial blanching and 
electrocardiographic (ECG) S-T segment elevation. After occlusion for 30 minutes, blood 
flow was restored by removing the ligature.  Mice were anesthetized and killed 24 hours 
after ligation. Evans blue was perfused through non-ischemic heart, removed, and cut into 
sections. The sections were stained with triphenyltetrazolium chloride and fixed in 4% 
paraformaldehyde.  Sections were photographed and the area at risk and area ischemic 
were calculated using image J software, NIH. 
Fatty acid oxidation: Freshly isolated ventricles were minced, then homogenized with 10 up-
and-down strokes, using a motor-driven Teflon pestle and glass mortar in ice-cold buffer 
(100 mM KCl, 40 mM Tris·HCl, 10 mM Tris base, 5 mM MgCl2·6H2O, 1 mM EDTA, and 1 
mM ATP (pH = 7.4)) at a 20-fold dilution (wt/vol) [265].  Oxidation was measured in a 200 µl 
reaction mixture containing 100 mM sucrose, 10 mM Tris·HCl, 10 mM KPO4, 100 mM KCl, 1 
mM MgCl2·6H2O, 1 mM L-carnitine, 0.1 mM malate, 2 mM ATP, 0.05 mM coenzyme A, and 
1 mM dithiothreitol (pH = 7.4) with either 8 µM [1-14C]palmitate and 100 µM sodium palmitate 
complexed to BSA or with 16 µM [1-14C]pyruvate and 200 µM pyruvate.  Oxidation studies 
measured the production of 14C-CO2 and acid soluble metabolites (ASM) for 30 min in a two-
well oxidation system. One well contained the reaction mixture and tissue homogenate and 
the adjoining well contained 1N NaOH. The reaction was terminated by adding 70% 
perchloric acid to the assay well, and cells were incubated for one h to drive the CO2 into the 
NaOH.   Radioactivity of ASM in centrifuged fractions and CO2 was determined by liquid 
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scintillation counting using 4 ml of Ecolite (Molecular Products).  Fatty acid oxidation was 
quantified using the following formula: ([(dpm-BL)/SA] ÷ [g of tissue wet wt/well x min of 
reaction incubation]) x 60 min/h, where BL is the dpm of blank wells and SA is the FA 
specific radioactivity [265].  
  
Tissue Lipid: Acyl-carnitines were quantified by liquid chromatography and tandem mass 
spectrometry [252].  Acyl-CoA and DAG composition and content were assessed from whole 
heart homogenized with appropriate internal standards in specific organic reagents [254]. 
After separation, purification, and elution, lipid metabolite extracts were separated by high 
performance liquid chromatography, and individual and total lipid species were analyzed by 
liquid chromatography/tandem mass spectrometry.  
 
  
 
 
134 
 
Figures:   
Figure 1 (5.1). Generation of mice that temporally lack ACSL1 specifically in ventricles  
A) Total ACSL activity with [1-14C]palmitate in control and Acsl1H-/- atria and ventricles 10 wk 
after tamoxifen, n=5-7. B) Representative immunoblot against ACSL1 protein in heart, liver, 
and gastrocnemius (gastroc) muscle 10 weeks after tamoxifen. C) Acsl isoenzyme mRNA 
abundance in heart 10 wk after tamoxifen in control and Acsl1H-/- mice, n=6.  Heart total (D) 
and long-chain acyl-CoA content (E) in control and Acsl1H-/- mice 10 weeks after tamoxifen, 
n=7-8. Data represent mean ± SEM; *, P≤0.05 versus control.  
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Figure 2.(5.2). Acsl1H-/- hearts have impaired FA oxidation  
A) [1-14C]Palmitate and B) [1-14C]Oleate oxidation in CO2 and acid soluble metabolites 
(ASM) in heart homogenates from control and Acsl1H-/- mice, n=5-6. C) [1-14C]Pyruvate 
oxidation in CO2 in heart homogenates from control and Acsl1H-/- mice, n=5-6. Data 
represent mean ± SEM; *, P≤0.05 versus control. 
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Figure 3 (5.3). Acsl1H-/- mice develop cardiac hypertrophy  
A) Wet weight of control and Acsl1H-/- male and female hearts expressed as a percent of 
body weight, n=10-20. B) Echocardiography calculation of left ventricular (LV) mass in 
control and Acsl1H-/- male mice, n=8-10. C) Representative H&E stained control and Acsl1H-/- 
hearts. D) mRNA abundance of fetal gene markers, a-skeletal actin (αSka) and brain 
natriuretic peptide (Bnp) control and Acsl1H-/- hearts, n=6. E) Representative electron 
microscopy images and F) quantification of mitochondrial area from control and Acsl1H-/- 
ventricles, n=3. G) Quantification of the mitochondrial DNA genes, NADH dehydrogenase 
subunit 1 (Nd1), cytochrome B (cytb), and cytochrome C oxidase 1 (Co1) relative to nuclear 
DNA in control and Acsl1H-/- 10 week ventricles, n=6.  Data represent mean ± SEM *, P≤0.05 
versus control. 
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Figure 5 (5.4).  Acsl1H-/- mice are resistant to high-fat diet induced obesity and cardiac 
TAG accumulation   
A) Body weight over 10 weeks on low-fat diet or 60%-high-fat diet in control and Acsl1H-/- 
mice, n=10-15. B) Inguinal and C) gonadal adipose depot mass in control and Acsl1H-/- mice 
after 10 weeks on the diet, n=10-15. D) Blood glucose and E) area under the curve (AUC) 
during a glucose tolerance test in control and Acsl1H-/- mice after 8 weeks on the diet, n=10-
15. F) Heart weight and G) heart TAG content in control and Acsl1H-/- mice after 10 weeks 
on the diet, n=8-15. Data represent mean ± SEM *, P≤0.05 versus control. 
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Figure 5 (5.5). Improved acute but impaired long-term recovery from ischemia in 
Acsl1H-/- heart 
A) Quantification of area at risk (AAR) and area of infarct (AI) in control and Acsl1H-/- hearts 
24 h after a 30 min of ischemia, n=6-8. B) Representative images of hearts stained with 
Evans blue and triphenyltetrazolium chloride 24 h after 30 min of ischemia. Data represent 
means ± SEM *, P≤0.05 versus control. 
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Table 1 (5.I). Echocardiogram diameter and functional characteristics in Acsl1H-/- 
Transthoracic echocardiogram imaging was performed on conscious control and Acsl1H-/- 
male mice 2 and 10 weeks after tamoxifen. M-mode images were analyzed, n=6-8. Data 
represent mean ± SEM *, P≤0.05 versus control. 
 
 
Control 
2 wks 
Acsl1H-/- 
2 wks 
Control 
10 wks 
Acsl1H-/- 
10 wks 
IVS,d 0.96 ± 0.02 1.02 ± 0.02 0.99 ± 0.02 1.3 ± 0.05* 
LVID,d 3.0 ± 0.13 2.9 ± 0.04 3.13 ± 0.19 2.7 ± 0.11* 
LVPW,d 0.97 ± 0.01 0.97 ± 0.01 0.93 ± 0.01 1.2 ± 0.04* 
IVS,s 1.69 ± 0.06 1.64 ± 0.05 1.68 ± 0.05 1.9 ± 0.05* 
LVID,s 1.34 ± 0.08 1.33 ± 0.03 1.43 ± 0.09 1.2 ± 0.03* 
LVPW,s 1.53 ± 0.05 1.44 ± 0.05 1.53 ± 0.04 1.66 ± 0.03* 
% EF 87 ± 0.9 86.1 ± 0.5 86 ± 0.7 86 ± 1.1 
% FS 55 ± 1.0 54 ± 0.7 54 ± 0.9 54 ± 1.4 
LV Mass, mg 96 ± 6.7 97 ± 3 104 ± 9 129 ± 4.7* 
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Table 2 (5.2). Plasma metabolites in control and Acsl1H-/- mice fed control and high-fat 
diet. 
Female control and Acsl1H-/- plasma glucose, fatty acid (FA), cholesterol, glycerol, and 
triacylglycerol (TAG) 4 hour fasted values after 10 weeks on the diets, n=8-12. Data 
represent mean ± SEM *, P≤0.05 genotype effect within diet; #, P≤0.05 diet effect within 
genotype. 
 Control LFD Acsl1
H-/- LFD Control HFD Acsl1H-/- HFD
Glucose (mg/dL) 160 ± 7 132 ± 5* 163 ± 10 129 ± 4* 
FA (mEq/L) 0.23 ± .04 0.23 ± .04 0.28 ± .04 0.28 ± .05
Cholesterol (mg/dL) 81 ± 2 84 ± 5 96 ± 4# 100 ± 3# 
Glycerol (mg/dL) 1.2 ± .2 1.3 ± .2 1.4 ± .2 1.1 ± .2 
TAG (mg/dL) 39 ± 4 35 ± 5 31 ± 4 39 ± 5 
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Figure S1 (5.6). Normal RER, food intake and activity in Acsl1H-/- mice 
Female control and Acsl1H-/- mice, on the high-fat or low-fat diet for 9 weeks, A,B) 
respiratory exchange ratio, C) activity and D) food intake across three planes were 
measured in the CLAMS system. Data represent mean ± SEM *, P≤0.05 genotype effect 
within diet; #, P≤0.05 diet effect within genotype. 
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CHAPTER VI 
SYNTHESIS 
 
Overview of research findings 
 The major finding of this dissertation is that ACSL1 is the ACSL isoenzyme that 
channels FA towards oxidative metabolism in adipose tissue and heart.  These findings are 
the result of investigating the metabolism and overt phenotypes in mouse models that lack 
ACSL1 in specific tissues.  ACSL1 was previously thought to provide acyl-CoA for the 
synthesis of TAG in adipose tissue, and its role in cardiac metabolism remained unclear. 
This dissertation provides evidence for the new-found role that ACSL1 plays as the first 
enzyme for the FA oxidative pathway.  These data also suggest that ACSL1 is critical for 
regulation of whole body adipose mass, thermogenesis, and cardiac metabolism and 
growth.  
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DIRECTIONS FOR FUTURE RESEARCH 
 
How does FA channeling occur via acyl-CoA synthetases? 
ACSL1 protein-protein interaction 
 This dissertation work has elucidated a function for ACSL1 in specifically channeling 
FA toward oxidation in several tissues. However, it remains unclear exactly how the ACSL1 
enzyme could be shuttling its product towards a single metabolic pathway.  The acyl-CoA 
produced by the ACS reaction has both hydrophobic and hydrophilic properties that should 
allow it to move freely within membranes and/or bind to proteins such as acyl-CoA binding 
proteins; thus all acyl-CoAs should theoretically be free to enter any downstream metabolic 
pathway. We predict that the different ACSL isoenzymes have interact with other proteins, 
thereby placing the acyl-CoA in direct contact with proteins that take it to specific metabolic 
pathways. For example, we hypothesize that in muscle tissues, ACSL1 is likely to interact 
with proteins such as M-CPT1 that would use the acyl-CoA as substrate to form an acyl-
carnitine that would be transported into the mitochondria for the oxidative metabolism. The 
proteins that ACSL1 and other ACSLs interact with are likely to vary by tissue and cell type. 
Experiments are required to identify the specific protein-protein interactions of ACSL1 in 
different tissues and cell types and under different hormonal and physiological conditions.   
 Members of the Coleman Lab, specifically Dr. Jennifer Frahm and Dr. Lei Li, have 
recently generated data using mass spectrometry technologies that show ACSL1 interacting 
with several mitochondrial oxidative proteins.  More studies are required to explore how the 
protein-protein interactions of ACSL1 facilitate channeling, control enzyme activity, and 
regulate metabolic flux. These studies would include identifying the protein-interacting 
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domains of ACSL1, mutating or truncating theses domains, and assessing enzyme activity 
and rates of FA oxidation in the mutants.  
ACSL subcellular location 
 The subcellular location of the ACSL isoenzymes likely facilitates the proteins’ role in 
cellular metabolism. For example an acyl-CoA formed at the mitochondria would 
preferentially be oxidized, whereas an acyl-CoA formed at the ER would be used for 
complex lipid synthesis.  Although the ACSL1 protein is found in specific cell fractions in 
various tissue (see background), fractionation methods are often flawed because of the 
difficulty in obtaining highly pure fractions. Confocal microscopy of endogenous protein is a 
more reliable method to identify subcellular location, however, confocal microscopy for 
ACSL isoenzymes has not been conducted due to the poor quality and specificity of the 
endogenous ACSL isoenzymes-specific antibodies.  Future studies should include the 
design and synthesis of highly-specific antibodies to all the endogenous ACSL isoenzymes, 
followed by confocal microscopy studies to identify the isoenzymes’ subcellular locations in 
multiple tissues and cell lines.  Confocal microscopy can also be used to study the 
movement of ACSL isoenzymes from one organelle to another.   
 
What is the role of ACSL1 in the ER?  
 While isolating mitochondria from heart for the oxidation studies, I observed ACSL1 
protein in both the mitochondrial and the microsomal fractions. Although my microsomal 
fractions were not devoid of mitochondrial proteins, it is likely that some ACSL1 protein 
resides in the non-mitochondrial organelles. Confocal microscopy, with a good endogenous 
ACSL1 antibody, is required to identify ACSL1 cellular localization. However, if ACSL1 is 
expressed at the ER, what is the role of ER ACSL1, and are the rates of TAG synthesis 
and/or omega oxidation reduced in Acsl1T-/- and Acsl1H-/- hearts?   
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 The rate of labeled FA incorporation into cardiac TAG could be measured in several 
systems. First, HL-1 cardiomyocyte-like cells with ACSL1 knocked down could be used to 
study rates of TAG synthesis.  However, HL-1 cells may not exactly mimic the metabolism of 
a contracting mouse heart, and these cells are difficult to transfect with siRNA (against 
Acsl1). Secondly, isolated primary cardiomyocytes from control and Acsl1H-/-mice could be 
used to study rates of TAG synthesis. However, primary cardiomyocyte isolation is 
technically difficult, and these cells can only be obtained from the glucose-oxidizing fetal 
heart.  A third system would be to isolate whole working heart in the Langendorff perfusion 
apparatus to study rates of FA oxidation and TAG synthesis. Working heart is the preferred 
method, due to the intactness of the heart; however, our lab does not have the equipment 
necessary to perform these studies. We are collaborating with Dr. Mark Jeffrey at UT-
Southwestern who will study the rates of fatty acid and glucose oxidation in whole working 
hearts in the Langendorff apparatus. These studies of oxidative, but not anabolic 
metabolism of 13C-labeled glucose and FA are on-going in control and Acsl1H-/- isolated 
working hearts. Lastly, to measure rates of TAG synthesis in the heart we plan to 
intravenously inject labeled FA and collect heart to extract lipids and quantify the amount of 
labeled FA that was incorporated into lipids.  The latter experiments will be performed with 
the assistance of Dr. Terry Combs and Trisha Grevengoed.  
 If ACSL1 does not affect rates of TAG synthesis, why is it present at the ER? As 
discussed previously, ACSL1 could facilitate the oxidation of FA through the ER omega-
oxidation pathway.  The product of omega oxidation is a dicarboxylic acid, a molecule 
identified by mass spectrometry as an indicator of the flux of FA through the omega 
oxidation pathway. If the amount of dicarboxylic FA were reduced similar to the reduction in 
acyl-carnitines, it would suggest that ACSL1 also regulates FA oxidation at the ER.  ER-
localized ACSL1 may also be a “reserve” site if, with stimuli, ACSL1 would move to the 
mitochondria to facilitate FA oxidative metabolism.  
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ACSL1 protein regulatory mechanisms 
 Until now, the regulation of ACSL isoenzymes has been inferred from mRNA 
expression.  However, the activity and function of ACSL isoenzymes is likely to be regulated 
post-translationally, by acetylation, phosphorylation, protein-protein interactions, and 
intracellular location. The mechanisms that would activate or inhibit ACSL1 in vivo are 
unknown. Recent mass spectrometry data from the Coleman lab shows that ACSL1 is 
phosphorylated and acetylated at multiple sites.  These phosphorylation and acetylation 
sites may regulate enzyme activity, perhaps in response to various hormonal or other 
signaling stimuli. Research is ongoing in the Coleman lab to determine how mutations that 
mimic or inhibit the phosphorylation and acetylation affect ACSL1 activity. The data 
generated will be critical for understanding the regulatory mechanisms on ACSL1 protein.   
 
Why do brown adipocytes that lack ACSL1 release less glycerol?  
 While performing labeling and lipolytic experiments in control and Acsl1A-/- brown 
adipocyte cells, we observed approximately 50% less glycerol released under lipolytic 
conditions. The appropriate experiment to determine why glycerol released is blunted in the 
knock out cells would be to use labeled glycerol and trace its metabolism with and without 
lipolytic stimuli. We hypothesize that due to reduced rates of FA oxidation in the Acsl1A-/- 
cells, the glycerol may either be oxidized to compensate or be used to form complex lipids 
from FA taken up by the cell but not oxidized.   
 
De novo synthesis in ACSL1 knockout tissues 
          TAG content in WAT and in cold-exposed BAT is greater in the Acsl1A-/- mice; 
however, I did not measure the rates of FA synthesis in these tissues. Overexpression of 
GLUT4 in mouse tissues activates CHREBP that upregulates de novo FA synthesis genes.  
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It is possible that glucose uptake and oxidation are increased in ACSL1 knock out tissues to 
compensate for impaired FA oxidative metabolism, and that the glucose intermediates that 
act as signals to activate CHREBP in GLUT4-overexpressing tissues are present in ACSL1 
knock out tissues.  We have not investigated mTOR activation in white adipose in the 
Acsl1A-/- mice. The increased flux of glucose oxidative metabolism in ACSL1 knockout tissue 
may activate mTOR, as it appears to do in the heart (see pg 97 and 112). Adipose activation 
of mTOR is linked to ChREBP activation and upregulation of de novo FA synthesis genes. If 
rates of FA synthesis are increased in the Acsl1A-/- adipose, this could be the cause of 
increased white adipose mass.  Opposing this idea is the finding that the mRNA abundance 
of fatty acid synthetase is not increased in Acsl1A-/- gonadal adipose.  To confirm that FA 
synthesis is not increased, the incorporation of radiolabeled acetate or glucose into lipid can 
be measured in control and ACSL1 knockout primary isolated adipocytes and primary pre-
adipocytes, as well as in working heart, and/or cardiomyocytes that express or lack ACSL1.  
 
Acsl1A-/- macrophage affects 
 Although the FABP4 promoter used to express Cre recombinase in the Acsl1A-/- mice 
is known to be expressed in macrophages, we have yet to measure the change in ACSL1 
protein, activity, or mRNA in Acsl1A-/- macrophages. Dr. Karin Bornfeldt used our Acsl1 
floxed mice to create a macrophage-specific Acsl1 knockout (Acsl1MACKO). Although her data 
have not yet been published, Dr. Bornfeldt and her colleagues found that compared to 
controls, Acsl1MACKO bone-marrow derived macrophages have a reduced inflammatory 
response to M1 (LPS and IFN-γ) activation. However, no differences in circulating 
inflammatory molecules were observed in Acsl1MACKO mice. The Acsl1MACKO thioglycollate-
elicited macrophages, compared to controls, had reduced rates of oleate incorporation into 
TAG and CE; however, Acsl1MACKO macrophages had normal TAG and CE content. The only 
phenotype observed of Acsl1MACKO macrophages in vivo was reduced atherosclerotic plaque 
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formation when Acsl1MACKO bone marrow was transplanted into Ldlr-/- mice infected with the 
islet-killing and diabetic-inducing lymphocytic choriomeningitis virus (LCMV). Thus, type-1 
diabetic LDLR-/- mice with Acsl1MACKO macrophages were resistant to atherosclerosis.  
However, LDLR-/- mice expressing Acsl1MACKO macrophages in the non-diabetic state did not 
have resistance to atherosclerotic plaque formation. These findings suggest that 
macrophages deficient in Acsl1 in the Acsl1A-/- mice do not modulate the observed 
phenotype of increased fat mass, cold intolerance, and impaired mitochondrial FA oxidation.  
 
Acsl1A-/- rate of adipocyte differentiation 
 The Acsl1A-/- mice have increased fat mass, but we failed to show increased 
adipocyte cell size by histology. Thus, the question remains concerning how the rate of 
adipocyte differentiation is affected in Acsl1A-/- mice. My experience with primary pre-
adipocyte cultures, suggests that animal-to-animal and isolation-to-isolation variation is too 
great to reliably measure differences in adipocyte differentiation.  To study the rates of 
adipocyte differentiation, I would propose to isolate pre-adipocytes from mice with floxed 
Acsl1 and expressing the ubiquitous tamoxifen-inducible Cre Recombinase , then expose 
the cells, from the same mouse, to media with vehicle or tamoxifen (to induce the knockout) 
and measure the rates of differentiation. 
 
 mTOR and ACSL1, what is the link and what does it mean?  
                  Data presented in this dissertation suggests that the kinase, mTOR, is activated 
in Acsl1 knockout hearts. mTOR has been highlighted as a major signaling molecule in the 
pathogenesis of cardiac hypertrophy and mitochondrial excess. The question remains, is 
mTOR activation the mechanism through which hypertrophy and mitochondrial biogenesis 
occurs? In other words, would rapamycin treatment attenuate or reverse the hypertrophy 
and the high mitochondrial content observed in ACSL1 knockout mice?  
 
 
149 
 
 
How is mTOR stimulated in ACSL1-knockout heart? 
                Another question remains, what are the stimuli that activates mTOR in the ACSL1 
knockout mice? Known stimulators of mTOR in heart include: insulin signaling, IGF 
signaling, glycolytic metabolites (particularly glucose-6-phosphate), inhibited AMPK activity, 
PKC, PLC, and the MAPK/ERK pathway (phenylephrine induced).  Cardiac mTOR is 
activated by several known stimulators of cardiac hypertrophy, including angiotensin II, 
pressure overload, hypertension, thyroid hormone, and phenylephrine.  Thus, mTOR seems 
the likely mechanism through which hypertrophy is induced in these models. However, each 
of the models activates a different pathway upstream of mTOR; thus, the stimulators of 
mTOR vary depending on the model.  It remains to be elucidated which of the known stimuli 
activates mTOR in the ACSL1 knockout mice and why that stimulus is present.  
              In adipocyte lipolysis stimulated by isoproterenol, the AMP generated from the 
ACSL1 enzymatic reaction has been implicated in activating AMPK [266].  Further research 
is required to assess cellular AMP levels and the activation of AMPK in ACSL1 knockout 
tissues. AMPK phosphorylation was decreased in Acsl1T-/- hearts but preliminary 
experiments show that total cardiac AMP and ATP levels are not different between 
genotypes.   
 
 
150 
 
 
Figure 6.1. Potential links between ACSL1 knockout and mTOR activation. 
The lack of ACSL1 reduces the conversion of long-chain FA to acyl-CoA by ~90% and reduces the 
oxidation of FA by ~90% in Acsl1H-/- and Acsl1T-/- hearts. Both Acsl1H-/- and Acsl1T-/- hearts become 
enlarged, but the two transgenic hearts have unique gene expression profiles and mitochondrial 
content. Acsl1H-/- and Acsl1T-/- both have reduced DAG, and DAG can activate mTOR through PKC. 
However, because DAG is reduced in the Acsl1H-/- and Acsl1T-/- hearts, PKC activation by DAG is not 
likely to be the mechanism that activates mTOR.  AMPK can inhibit mTOR activity; however, because 
AMPK phosphorylation is increased in Acsl1H-/- but decreased in Acsl1T-/- hearts, AMPK activation and 
relief of mTOR inhibition is probably not the mechanism that allows cell growth in the Acsl1H-/- hearts. 
In both transgenic models the reduction in cardiac FA oxidation is compensated for by increased 
glucose uptake and oxidation. Glucose intermediates can activate mTOR in cardiomyocytes, thus an 
increase in glycolytic metabolism may mediate mTOR-driven cardiac hypertrophy.  
 
Continuation of Acsl1H-/- studies:  
The objective to confirm the impaired FA oxidation and hypertrophy in the heart of a heart-
specific ACSL1 knockout mouse has been completed. Our original intention was to include 
FA oxidation measurements in heart homogenates and the cardiac phenotyping data from 
the Acsl1H-/- mice with the manuscript on the Acsl1T-/- mice.   However, rather than combining 
this data into one manuscript, we have opted to perform additional studies on the Acsl1H-/- 
mice to further determine how the lack of ACSL1 affects heart metabolism and function.  
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The following list briefly describes the additional questions being asked, the methods used 
to answer these questions, and progress made towards the completion of the experiment:  
Are Acsl1H-/- mice resistant to high-fat diet induced obesity? 
Method: Acsl1H-/- and control mice have been placed on a 60%-high-fat diet for 10 
weeks. Cardiac TAG content and insulin-stimulated signaling will be determined.  We 
expect to find that TAG does not accumulate in the Acsl1H-/- mice because the lack of 
ACSL1 reduces uptake and retention of FA.  
Progress: See manuscript 3. Diet studies have been performed and data collection for 
heart insulin signaling is underway. We hypothesize that Acsl1H-/- mice will be resistant to 
high-fat diet-induced TAG accumulation in the heart, because ACSL1 reduces the rate of 
FA uptake, retention of the excess dietary FA, see next question.  
Does ACSL1 affect the rate of FA uptake by the heart? 
Method: Radiolabeled bromo-palmitate, 2-deoxy-glucose, and palmitate will be injected 
into control and Acsl1H-/- mice intravenously. Hearts and plasma will be extracted 30 
minutes later and the total radioactivity in the heart will be counted.  For the labeled FA 
substrates, total lipid will be extracted and by chromatographed to quantify label 
incorporated into complex lipids. My expectation is that uptake and retention of the 
bromolyated FA will be reduced in the Acsl1H-/- heart because the rate of FA conversion 
to an acyl-CoA, and thus trapping within the cell, will be reduced.  The rate of FA 
incorporation into complex lipids will be normal in the Acsl1H-/- heart because ACSL1 
channels FA towards oxidation, not towards lipid synthesis.  Glucose uptake will be 
increased in the Acsl1H-/- hearts because the oxidation of glucose is increased to 
compensate for the reduced FA oxidative capacity.  
Progress: In the planning stage  
How does the lack of ACSL1 change transcriptional activity?  
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Method: Control and Acsl1H-/- ventricle mRNA will be analyzed by microarray studies. 
These data will be mostly exploratory, but we expect that we will see changes because 
we have QRT-PCR data that show Acsl1H-/- ventricles upregulate the fetal gene program 
and down-regulate several PPAR-regulated genes.  
Progress: Microarrays have been run in collaboration with Dr. Cam Patterson. Analysis 
is underway.  
How are the rates of FA and glucose oxidation changed in Acsl1H-/- whole heart?  
Method: use of the “gold standard” Langendorff perfusions to measure the rate of FA 
and glucose oxidation in whole working hearts of control and Acsl1H-/- mice.  
Progress: Mice were shipped to UT Southwestern and the Langendorff perfusions have 
been performed with 13C-labeled substrate. The tissue is awaiting mass spectrometry 
analysis and data analysis will follow. This has been performed in collaboration with Dr. 
Mark Jeffrey We expect to see reduced oxidation of the FA substrate and increased 
oxidation of the glucose substrate in Acsl1H-/- hearts to corroborate data we have 
generated in cardiac homogenate and mitochondrial preparations.  
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Public Health Significance  
FA metabolism plays a central role in obesity and obesity-related complications. 
Understanding the metabolisms that underlie disease will aid in treating disease. Because 
ACSL1 had previously been postulated to activate FA for lipid synthesis in adipose tissue, 
drugs to inhibit ACSL1 to reduce obesity had been considered. However, the data presented 
in this dissertation provide novel evidence that ACSL1 activates FA destined for oxidation. 
Thus, a drug that activates ACSL1 has the potential to increase caloric expenditure through 
thermogenesis and the catabolism of fat. Data presented in this dissertation show that 
ACSL1 is critical for FA oxidation. The knockout of adipose ACSL1 in mouse results in 
increased adipose mass, and the knockout of cardiac ACSL1 results in cardiac hypertrophy. 
Thus, SNPs in ACSL1 may be correlated with obesity and idiopathic hypertrophies in human 
populations.  
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